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ABSTRACT 
 The work described in this thesis has studied the role of CD151 in modulating 
the form and function of its integrin partners, α3β1 and α6β1/β4. Stable depletion of 
CD151 in MDA-MB-231 (MDA-231), a metastatic breast cancer cell line, changed the 
glycosylation profile of the α3β1 integrin but did not affect modification of α6 
integrins. Further analysis showed that CD151 influences α3β1 integrin’s 
glycosylation as early as the very first mannose trimming within the ER. Generation 
and analyses of MDA-231 cell lines expressing various CD151 mutants indicated that 
tight interaction, recruitment into TERM and glycosylation of CD151 are all required 
for CD151 to influence the glycosylation of α3β1 integrin. Depletion of CD151 
reduced the level of α1,2-linked fucose and β1-4 branching of GlcNAc presented on 
the integrin, as detected by lectin blot assay. 
 Sucrose density gradient (SDG) experiments showed that glycosylation-, 
palmitoylation- and QRD (mutation introduced to CD151 which inhibits tight 
association between CD151 and α3β1 integrin) mutants of CD151 were all capable of 
recruiting α3β1 integrin into the light fractions. These data demonstrate that CD151’s 
role in glycosylation of α3β1 integrin is independent from its ability to recruit the 
integrins into the light fractions of the SDG. Contrary to the published data, we 
found that CD151 was able to recruit α3β1 integrin into the light fractions as part of a 
microdomain (QRD mutant) as well as a separate entity (palmitoylation mutant).  
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 Other tetraspanins, such as CD9, CD63 and CD81 showed similar yet distinct 
roles played by these tetraspanins during glycosylation.  For example, CD9 depletion 
altered the glycosylation of α3 integrin subunit and increase the general level of cell 
surface α2,6-linked sialic acid presentation by 100%. All four tetraspanins altered the 
cell surface glycotope profile upon depletion.   
 Analysis of α6 integrin subunit, showed no difference to its glycosylation 
profile upon CD151 depletion. In fact, during the course of our investigation, we 
demonstrated a hierarchical preference for CD151 to form tight associations with 
α3β1 over α6β1 and α6β4 integrins in MDA-231 cell line. Analysis of α6 integrin 
subunits from all four tetraspanin depleted cell lines revealed a difference in another 
type of post translation modification of the α6 integrin subunit which resulted 
cleavage of the integrin; whereby the head region of the α6 subunit is proteolytically 
cleaved at the cell surface by urokinase plasminogen activator resulting in a ligand 
binding deficient variant, α6p (Davis et al., 2001). Depletion of CD151 increased the 
level of α6p while depletion of CD9 and CD81 decrease its level in MDA-231 cells.   
 Functionally, depletion of CD151 in MDA-231 decreased their ability to 
migrate towards Lm332 in Boyden chamber migration assays by ~90%. 
Reconstitution of MDA-231 CD151(-) cells with wild type CD151, but not 
glycosylation-deficient CD151 restored their migration potential. During 30 minute 
adhesion assay, no difference was observed in their ability to adhere to Lm332 or 
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fibronectin. Finally, their interaction with endothelial cells was compared by 
performing transendothelial migration assays and transient attachment assays. 
Depletion of CD151 had no effect on their ability to migrate across the endothelial 
monolayer. However, transient adhesion assay showed a batch specific influence. 
MDA-231 CD151(+) attached more readily than CD151(-) cells in some HUVEC 
batches while the opposite, or no difference was observed in others. These results are 
discussed from the point of CD151 mediated α3β1 glycosylation and α6β1/β4 
cleavage. 
 Characterisation of tetraspanins by EndoH and PNGase digestion suggested 
mono-N-glycosylated CD9 and CD151 to be modified by phosphomannosylation and 
complex N-glycan respectively. Tri-N-glycosylated CD63 and CD82 molecules 
showed some resistance to both glycosidases, suggesting that they may carry both 
phosphomannosyl and complex glycan modification. Castanospermine inhibition of 
the glycosylation pathway markedly reduced the level of several integrins including 
α3β1 and α6β1/β4 which suggests a novel use for this compound for therapeutic 
purposes.  
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God does not play dice. 
Albert Einstein 
 
 
… not only that God does play dice, 
..He sometimes confuses us by throwing them where they can't be seen. 
Stephen Hawking 
 
 
Nothing in glycobiology makes sense, except in the light of evolution. 
 
Ajit Varki 
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1. INTRODUCTION 
1.1 Tetraspanin Superfamily 
 Tetraspanins are type III transmembrane proteins found in all metazoans. To 
date, a total of 33 mammalian tetraspanins genes have been characterised. Members 
of this family have distinguishing characteristics which set them apart from other 
proteins with four transmembrane regions and tetraspanin-like proteins found in 
fungi and plants (Huang et al.,  2005; Garcia-Espana et al.,  2008). Meandering across 
the membrane 4 times, they consist of a short cytoplasmic amino-terminal tail, 
followed by a small extracellular loop (SEL), a small intracellular loop, a large 
extracellular loop (LEL) and finally ending with a cytoplasmic carboxy-terminal tail. 
These diminutive proteins range in length from 204 to 355 amino acids and protrude 
3.5 to 5 nm from the membrane. The SEL and LEL consist of a stretch of 13-30 and 69-
150 amino acids respectively. The LEL is subdivided into two domains, consisting of 
a conserved and a hypervariable region (Figure 1.1). Members of this family also 
carry an obligatory cysteine-cysteine-glycine (CCG) motif on the LEL and an 
additional two to eight cysteine residues in the LEL. Disulphide bond formation 
between the cysteines within the CCG motif and other cysteine residues in the LEL 
confers a structural heterogeneity to these proteins (Charrin et al.,  2009). 
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Figure 1.1: A cartoon and 3D structure depicting the structural features of 
tetraspanin. 
(i) Cytoplasmic amino terminal (N), short extracellular loop (EC1), intracellular loop, 
large extracellular loop (EC2) and cytoplasmic carboxy terminal (C). EC2 is divided 
into constant region (beige shade) containing a helix stretches (A,B and E) and 
hypervariable region (blue shade) containing conserved ‘CCG’ motif and cysteine (C) 
residues (yellow shade). Many tetraspanins carry additional cysteine (C) residues 
(green) in EC2. Membrane proximal cysteine residues are usually palmitoylated 
(image taken from Hemler, 2005). (ii) A predicted 3D structure of tetraspanin CD81 
as described by (Seigneuret, 2006) viewed at opposing angles. The blue and red 
ribbon represents transmembrane domains and small extracytoplasmic loop. The 
green ribbon labelled A, B and E represents the conserved regions while the pink 
region (C and D) represents hypervariable region within the LEL. The yellow bridges 
in the LEL and red asterisk in the cytoplasmic face represent disulphide bonds and 
palmitoylation sites (image taken from Charrin et al., 2009). 
 
The majority of animal cells contain several different tetraspanins and their 
distribution varies from cell to cell. For example, CD81 is widely expressed while 
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CD151 has a more restricted distribution; being expressed on nearly all epithelial, 
endothelial, fibroblastic and neuronal cells. A select few exhibit a very limited 
expression. Peripherin/RDS, for example, is only expressed in the rod outer segments 
in the retina (Kohl et al.,  1998; Hemler, 2005). 
Glycosylation and palmitoylation are the two most common post-translational 
modifications of these molecules. Most tetraspanins are glycosylated on their large 
extracellular loop, except for CD9 which carries a potential glycosylation motif on its 
small extracellular loop. Palmitoylation, on the other hand, occurs at the membrane 
proximal cysteine residue of the cytoplasmic leaflet, and contributes to the most 
important characteristic of the tetraspanin proteins - the ability to form lateral 
interactions with each other as well as other membrane proteins. In fact, only CD82, 
CD81, CD9 and UPKIA have so far been identified to have ligand binding capacity 
(Pileri et al.,  1998; Ellerman et al.,  2003; Bandyopadhyay et al.,  2006). Site-directed 
mutagenesis of all membrane proximal cysteine residues on CD9 and CD151 
disrupted their palmitoylation which adversely affected their ability to form 
secondary lateral interaction (Charrin et al.,  2002; Yang et al.,  2002; Berditchevski et 
al.,  2002). Through their lateral interactions, tetraspanins facilitate molecular 
crowding and the formation of large multimeric complexes on the plasma 
membrane. This enriched platform of tetraspanins and their interacting partners on 
the membrane is known as the tetraspanin enriched microdomain (TERM) (Figure 
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1.2). The formation of TERMs coordinates various cellular functions such as cell 
adhesion, migration, membrane fusion, inter- and intracellular signaling as well as 
endocytosis. Composition of the TERM varies according to cell type and the 
associated function. Within TERM, the interaction amongst component molecules 
can be characterised as primary, secondary and tertiary interactions. These multiple 
layers of interactions are categorised by their resistance to dissociation when 
extracted with various detergents at different stringency. 
Detergents are amphiphatic molecules with polar ‘head’ and non-polar ‘tail’ 
structure. Their unique characteristic is usually employed to manipulate the 
hydrophobic-hydrophilic interactions which exist in the biological systems such as 
the lipid bilayer organisation of cell membranes. The ability of various detergents to 
disrupt protein-protein, lipid-lipid and protein-lipid interactions is determined by 
the composition of its hydrophobic component. Triton X-100, for example, has short 
bulky hydrophobic chain capable of penetrating through the lipid bilayer and 
depletes the inner leaflet of the bilayer. However, they are unable to penetrate into 
the water-soluble components of the membrane and as a result, are unable to disrupt 
hydrophilic protein-protein interaction. Accordingly, resistance to disruption under 
1% TritonX-100 conditions usually denotes a primary (or a direct protein-protein) 
interaction. The long monolayer spanning hydrophobic tail of Brij 96 on the other 
hand, is less disruptive on the lipid bilayer. Membrane solubilisation under 1% Brij 
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96 or 1% Brij 97 has been shown to discriminate tetraspanin-tetraspanin interactions 
which are lost in 1% Triton X-100 condition (Chen et al.,  2009; Charrin et al., 2009). 
Resistance to the milder detergent, which has been attributed to the presence of 
gangliosides (Ono et al.,  2001) and a partial lipid raft like property observed within 
these domains (Yashiro-Ohtani et al.,  2000; Claas et al.,  2001), usually reflects a 
secondary or tertiary partnership within a TERM (Figure 1.2). 
 
Figure 1.2: Diagram representing different levels of interaction within the 
tetraspanin enriched microdomain.  
CD151 forms primary interaction with integrins  and ; secondary 
interaction with CD9 and CD81 and tertiary interaction with EWI-2 protein. 
[Adapted from (Yauch et al.,  1998; Sterk et al.,  2002a; Charrin et al.,  2003a)] 
 
Stoichiometric primary interactions have been identified between several 
tetraspanins and their partners which has functional repercussions. For instance, the 
partnering of uroplakin IA with uroplakinII (UPII) and uroplakin IB with 
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uroplakinIII (UPIII) are fundamental for urothelial plaque formation (Kong et al.,  
2004).  CD9’s association with membrane-anchored heparin-binding EGF-like growth 
factor precursor (proHB-EGF) has been shown to increase the effectiveness of proHB-
EGF’s juxtacrine growth factor activity (Iwamoto et al.,  1994; Higashiyama et al.,  
1995). Primary interaction between CD81 and another membrane protein, CD19, is 
important for lowering the threshold for receptor activation in B cells (Maecker and 
Levy, 1997; Miyazaki et al.,  1997; Tsitsikov et al.,  1997).  Alliance of CD63 with H,K-
ATPase beta-subunit proton pumps have been reported to facilitate its internalisation 
and trafficking to late endosome-lysosmal compartment by sequential association 
with adaptor proteins µ2 and µ3 in gastric parietal cells (Duffield et al.,  2003).   
Furthermore, CD9 and CD81 partner with members of the Ig domain 
containing cell surface protein, EWI-2 and EWI-F (Stipp et al.,  2001a; Stipp et al.,  
2001b). In a study to understand the implication of EWI-F (CD9P-1) association with 
CD9 and CD81, CD9P-1 was overexpressed in a model cell line, HEK293.  
Overexpression of CD9P-1 increased  integrin mediated motility of HEK293 cells 
on collagen I, while their motility on fibronectin was decreased. The opposite was 
observed upon CD9 or CD81 overexpression. Based on these findings it was 
proposed that CD9 and/or CD81 ratio to CD9P-1 determines the cellular response to 
collagen and fibronectin associated motility (Chambrion and Le, 2010).  
Among all the known ‘tetraspanin-partner’ associations, CD151’s 
stoichiometric association with integrin is possibly one of the most widely 
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studied interactions on account of its physiological and pathological significance 
(Yauch et al., 1998). Tight association between CD151 and laminin binding integrins 
play an important role in proper hemidesmosome and basement membrane 
assembly, wound healing, leukocyte cell extravasation and tumour cell metastasis, 
among others (Sterk et al.,  2000; Kazarov et al.,  2002; Kohno et al.,  2002; Sawada et 
al.,  2003; Barreiro et al.,  2005; Chometon et al.,  2006; Cowin et al.,  2006; Sachs et al.,  
2006; Caplan et al.,  2007; Baleato et al.,  2008; Chien et al.,  2008; Geary et al.,  2008; 
Sadej et al.,  2009; Ang et al.,  2010; Novitskaya et al.,  2010; Shi et al.,  2010).  
 
1.1.1 Tetraspanin CD151 
The tetraspanin CD151 is also known as GP27, MER2, PETA-3, RAPH, SFA1, 
and TSPAN24. The topology and defining characteristics of CD151 are illustrated in 
Figure 1.3. CD151 was first described as a novel 27kDa platelet surface glycoprotein 
by Leonie K. Ashman and collegues. A monoclonal antibody (14A2.H1) recognising 
this protein bound to platelets and other haematopoetic cells such as 
megakaryocytes, monocytes, epithelial cells in the tonsillar crypts and endothelial 
cells. However, lymphocytes, lymphoid cell lines, neutrophils and haematopoetic 
progenitor cells tested negative against this antibody (Ashman et al.,  1991). A 
subsequent molecular study categorised this protein as a member of the tetraspanin 
family (Fitter et al.,  1995). Pretreating endothelial cells with antibodies directed 
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against CD151, CD81 or  integrin, retarded migration of individual cells in wound 
healing assay. Fluorescence microscopy analysis of these cells revealed localisation of 
CD151 at cell-cell junction where other members of the tetraspanin family such as, 
CD9 and CD81 and integrin  localised (Yanez-Mo et al.,  1998). Around the same 
time, the presence of a stoichiometric association between CD151 and α3β1 was 
reported and this association was proposed to regulate neutrophil cell migration by 
recruiting a distinct family of membrane associated phosphatidylinositol 4-kinase 
into their fold (Yauch et al., 1998). It was later shown that CD151 form a highly 
stoichiometric association with integrin both in vivo and in vitro while CD9 and 
CD81 are recruited into the TERM as secondary partners (Charrin et al., 2002). 
Mutational analysis narrowed down a triamino sequence, glutamine-arginine-
aspartic acid or QRD sequence in the large extracellular loop of CD151 as the crucial 
site for both  and  to form tight interaction with CD151(Kazarov et al., 
2002). Subsequent studies have identified several roles for CD151 in potentiating 
mediated cell migration; CD151 was shown to stabilise the active conformation 
of the integrin (Nishiuchi et al.,  2005), facilitate its endocytosis(Winterwood et al.,  
2006) as well as alter the glycosylation profile of the integrin (Baldwin et al., 2008).  
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Figure 1.3: A diagram representing the tetraspanin CD151.  
The defining characteristics of CD151 are described in the legend. 
 
 
In contradiction, ablation of CD151 has been reported to have a pro-migratory 
effect (Johnson et al.,  2009). In an elegantly composed study, Johnson et al. showed 
that silencing of CD151 in A431, an epidermal carcinoma cell line, enhanced 
collective migration of tumour cells during wound healing assay. E-cadherin 
mediated cell-cell junction formation was destabilised in these CD151 silenced cells. 
However, no difference was observed in the level of E-cadherin associated 
components (β-catenin, α-catenin, p120ctn, α-actinin and plakoglobin) that co-
precipitated with E-cadherin in CD151(+) and CD151(-) cells. Junction formation was 
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restored upon re-expression of wildtype CD151, but not by a CD151 variable region 
chimera. Further analysis, to explain the increased collective migration revealed that 
this was not due to E-cadherin dislocation, but was a result of actin displacement 
from cell-cell junctions that was triggered by excessive RhoA activation. This study 
highlighted the opposing influences of CD151 on  integrin function and the need 
to interpret  role during metastasis in collective association with CD151. 
 
1.2 Integrin Superfamily 
The term ‘integrin’ was first coined by R.O.Hynes to describe a family of 
structurally related dimer molecules that ‘integrated’ the extracellular matrix to the 
intracellular cytoskeleton and coordinate various cellular functions (Hynes, 1987). 
This family of functionally conserved adhesion receptors is expressed in all 
metazoan. They consist of non-covalently paired  and  subunit dimers (Figure 1.4). 
There are 24 known mammalian integrin heterodimers from a limited combination of 
18  subunits and 8 subunits. Some  subunits, for example , pair with only one 
 subunit, to form . The subunit on the other hand, associates with 
several  subunits to form several paired combinations such as α1β1, α2β1, α3β1, 
α4β1, α5β1, α6β1, α7β1, α8β1, α9β1, α10β1, α11β1 and αvβ1. The subunits consist of 
large N-terminal extracellular domains (~800 amino acids), ~ 20 amino acid 
transmembrane alpha helix and a short cytoplasmic tail of around 13-70 amino acids 
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with the exception of  which has a large cytoplasmic tail (~1000 amino acids). The 
first three dimensional structure of the integrin extracellular domain was described 
for v  integrin (Xiong et al.,  2001).  
 
Figure 1.4:  Integrin architecture.  
A general representation of α (shaded green) and β (shaded magenta) integrin 
subunit in open conformation. Fifty percent of  subunits contain  I domain 
(shaded yellow) 
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The general structure of integrin’s extracellular region depicts a large head on 
two legs. The ‘head’ of the  subunit contains a conserved FG-GAP repeats that form 
a seven-bladed  propeller structure and three tandem repeats of calcium binding 
domain. While the  subunit contains a von-Willebrand factor A-domain, also known 
as A-domain. Studies on  showed that the proper conformation of the calcium 
binding domain is important for maturation and cell surface expression of b  
complex (Gidwitz et al.,  2004). The  subunit ‘leg’ consists of a ‘thigh’ and two ‘calf’ 
domains with a highly flexible knee or ‘genu’ region between the thigh and the calf. 
In v and some other subunits, the membrane proximal calf region has a furin 
cleavage site and is post-translationally cleaved, resulting in heavy and light chain 
fragments which are held together by a disulphide bridge. Through what’s possibly 
an early evolutionary bifurcation, half of the known  subunits, 1, 2, , M, 
L, X, D and E, carry a 200aa inserted domain (I-domain) which is homologus to 
von-Willebrand factor A-domain (Hughes, 1992) within the FG-GAP repeats. The  
subunit ‘leg’ consists of the hybrid domain, the plexin–semaphorin–integrin (PSI) 
domain, four epidermal growth factor-like repeats and a membrane flanking 
cystatin-like fold.  
The transmembrane regions of both the subunits span across the membrane at 
different angles. Structural and mutational studies on αIIbβ3 predicted the α subunit 
transmembrane domain to consist of a short α helix perpendicular to the lipid bilayer 
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while the β subunit’s α helix tilts at a 25O angle. At this angle, the subunits are 
maintained at the low affinity state by electrostatic interaction between Arg995 (in 
αIIb) and Asp723 (in β3) and clasp formation at the inner and outer membrane 
border. Disruption to the tilt/length of the transmembrane angle results in integrin 
activation (Armulik et al.,  1999; Partridge et al.,  2005; Shattil et al.,  2010).  
The cytoplasmic region of the subunit carries a conserved GFFKR motif 
that’s partially embedded into the membrane. This motif is important for the inner 
membrane clasp formation that maintains the resting state of the integrin. The 
cytoplasmic region of  subunits contain two conserved NPXY motif. Binding of 
cytoskeletal/cytoplasmic proteins talin (Tadokoro et al.,  2003) or kindlin (Montanez 
et al.,  2008; Ma et al.,  2008; Moser et al.,  2008) to the first and second NPXY motif, 
respectively, is a prerequisite for integrin activation. Integrin activation can be 
further modulated by competitive binding of filamin (Garcia-Alvarez et al.,  2003; 
Kiema et al.,  2006), Dok1 (Wegener et al.,  2007) and ICAP1 (Millon-Fremillon et al.,  
2008) which blocks talin binding as well as strategic phosphorylation of threonine 
and tyrosine residues (Takala et al.,  2008; Oxley et al.,  2008). Devoid of a kinase 
domain, these allosteric molecules go through conformational changes in response to 
environmental cues and subsequently, orchestrate bidirectional signaling across the 
membrane (Hynes 1987; Arnaout et al.,  2005; Humphries et al.,  2006). While cell 
surface expression and clustering contributes to it, conformational change remains 
the crucial factor in regulating integrin function. 
14 
 
Integrins exist in three functional states: high, intermediate and low affinity. 
Structural studies on these receptors attribute the low affinity form to the bent state 
and the high affinity form to extended state of the extracellular domain (Figure 1.5) 
(Takagi and Springer, 2002; Takagi et al.,  2002; Beglova et al.,  2002). 
                                                     
 
Figure 1.5 Low affinity and high affinity conformation of integrin subunits. 
(A) Inactive integrin dimer adopts a compact and bent conformation. (B) The 
extended conformation is assumed upon activation by talin (yellow) binding of at the 
cytoplasmic tail (inside out signalling) or ligation of molecule (red) at the ligand 
binding site at the extracellular domain (outside in signalling) 
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The mechanism of how integrins change from a low to a high affinity state is 
not fully understood, however, two models have been proposed. Both models agree 
that a conformational change in the head domain is required for ligand binding. 
However, the ‘switchblade’ model proposes that ligand binding occurs only in the 
extended form (Luo et al.,  2007) while the ‘deadbolt’ model maintains that the 
integrin extension occurs upon ligand binding (Xiong et al.,  2003). While the 
‘switchblade’ model is more widely accepted, there is also ample evidence from 
crystallised and transmission electron microscope images of v  integrin to confirm 
ligand binding in the bent conformation (Xiong et al., 2001; Adair et al.,  2005). 
Integrins set the ‘cellular mood’ by constantly interrogating and responding to 
environmental cues (Miranti and Brugge, 2002; Berrier and Yamada, 2007). In fact, a 
cell’s survival depends on the integrins’ ability to interact with the extracellular 
matrix (ECM). Presence of unligated integrins on adherent cells, can induce 
apoptosis through caspase 8 activation  (Stupack et al.,  2001). Initial ligation of 
integrins to their ligands is thought to be of foremost importance in inducing 
clustering. The number, size and distribution of integrin complexes are determined 
by the physical and chemical properties of the ECM and are especially sensitive to 
ligand spacing (Arnold et al.,  2004; Cavalcanti-Adam et al.,  2007) and to rigidity of 
the matrix (Pelham, Jr. and Wang, 1997; Paszek et al.,  2005).  
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Classification of integrins is rather complicated since they are capable of 
binding multiple ligands with different affinities. Furthermore, most extracellular 
matrices have more than one type of ligand binding domain (Plow et al.,  2000). 
Initially, integrins were broadly divided into two subfamilies based on the presence 
of a 200 amino acid I element in the  subunit which shares a sequence homology to 
von-Willebrand factor A-domain. A more representative classification was later 
introduced based on their preferred ligand: the RGD motif, LDV motif, 
laminin/collagen binding A-domain  integrins and laminin binding non A-domain 
integrins (Humphries et al., 2006) and is summarised in Figure 1.6. 
Figure 1.6 Integrin-ligand classification.  
Integrins are classified from their best known ligands: RGD motif, LDV motif, non-I 
domain containing laminin receptors and I-domain containing collagen/laminin 
receptors. I domain containing α subunits are in red. Purple line represents integrins 
dimers found in immune cells are.  (Humphries et al., 2006; Luo et al., 2007) 
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1.2.1 Integrin  
 A polypeptide corresponding to human integrin subunit was first 
described while screening for monoclonal antibodies raised against human bladder 
cancer cell surface antigen. It was also shown to be highly expressed in many tumor 
cell lines (Fradet et al.,  1984). This cell surface glycoprotein was initially assigned to 
the very late antigen (VLA) group of proteins and named as VLA-3. Similar to the 
previously described VLA-1 and VLA-2, VLA-3 formed a heterodimer with the VLA-
subunit which later came to be known as 1 integrin subunit (Hemler et al.,  
1987). The two variants that have been reported for 3 subunit, namely isomer 3A 
and isomer 3B, differ in the splicing of the light chain and have distinct tissue 
distribution (de Melker et al.,  1997). Within the extracellular region, there are 14 
potential N-linked glycosylation sites, 11 in the heavy chain and 3 within the light 
chain (data from www.uniprot.org). At least 7 disulphide bonding patterns have 
been mapped to this region. Three furin cleavage sites are mapped within the 
disulphide bridge between amino acids 846 to 890 (Figure 1.7) (Krokhin et al.,  2003). 
During heterodimer assembly which occurs in the rough endoplasmic 
reticulum,  integrin only pairs with integrin subunit for integrin dimer 
formation. The β1 subunit has 14 potential glycosylation sites and 28 putative 
disulphide bonding motifs (data from www.uniprot.org). There are 5 known splice 
variants of the β1 subunit, all of which occurs at the cytoplasmic tail. The difference 
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in splice variance does not have any effect on the ligand binding which occurs in the 
extracellular domain, but triggers different signaling pathways in the cytoplasmic 
end which leads to different cellular responses (Armulik, 2002). Structural analysis 
predicts the head region of the dimer forming a ligand binding pocket that interacts 
with Laminin332 in a divalent ion (Mn2+) dependent manner. 
 
Figure 1.7 Diagram showing a linear model for integrin subunits.  
(A) Representation of I-domain containing  subunit. (B) The non I-domain 
containing 3 integrin subunit domains. Putative post translation modification sites 
on the extracellular domain are highlighted: glycosylation (red bars), disulphide 
bond (black connectors) and furin cleavage site (blue arrows). (C) 1 integrin subunit 
domains. Glycosylation sites are marked with red bars. Disulphide bonds are not 
shown.PM: plasma membrane. The domains are not drawn to scale and the 
glycosylation sites are an approximation. 
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1.3 Laminin 332 
The basement membrane that lines the epithelial layer is a crucial component 
in maintaining the integrity of this tissue. It provides a platform for epithelial cells to 
anchor to while going through cell division, differentiation and during migration.  It 
also influences cell behaviour by signaling for specific cellular responses such as 
proliferation and apoptosis.  
 The basement membrane consists of a mix of several biologically active 
components including laminins, collagenIV, heparan sulphate proteoglycans and 
nidogen. Laminins are the most abundant glycoproteins in the basement membrane 
and are also where they are most widely found. Laminins consist of heterotrimer α, β 
and γ chains and their nomenclature reflects their chain designation: ie., Laminin111 
consist of α1β1γ1 chains while Laminin211 is composed of α2β1γ1 chains (Aumailley 
et al.,  2005). They are composed of a central 400 kD α chain which contains varying 
numbers of globular regions, and 200 kD β and γ subunits that wrap around the α 
chain to form a crucifix shape. This large molecule contains many domains that 
interact with various cell surfaces and secreted molecules as depicted in Figure 1.8. 
The α3β1 integrin is a laminin binding receptor with clear preference towards 
Laminin 332 and Laminin 511 (Nishiuchi et al.,  2003; Nishiuchi et al.,  2006). Using 
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recombinant proteins, the  integrin binding site in Laminin332 has been located 
to the large globular domain 3 (LG3) on the α chain (Shang et al.,  2001).  
 
Figure 1.8: The structure of laminin trimer.  
(A) Laminins form a crucifix structure consisting of α, β and γ subunit with an 
average length of 100nm. The α chain (red) has three globular domains in the head 
region and five globular domains consisting of epidermal growth factor (EGF) 
repeats in the tail. The β (yellow) and γ (blue) chains coil around the  chain and 
form the ‘trunk’. (B) Laminin 332 is a truncated form of the typical laminin structure. 
It is devoid of the globular domain in the head region, and has single globular 
domain on the  and  chains. Laminin 332 can be cleaved by various proteases 
(MMP,BMP and plasmin) exposing this region for potential ligand binding. 
 
The basement membrane was initially thought to play an important role in 
restraining in situ carcinomas from spreading to the surrounding area. A breach of 
this border, attributed to the proteolytic degradation by enzymes secreted by tumour 
cells, defines invasive carcinoma (Liotta et al.,  1977; Jones and DeClerck, 1980; Hu et 
al.,  2008). While this observation is a widely accepted model, later studies have also 
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shown that carcinomas secrete their own brand of basement membranes which is 
utilised as a substrate in promoting proliferation and metastasis (Frenette et al.,  1988; 
Frenette et al.,  1989; Hao et al.,  1996; Katayama et al.,  2003). Transition from a 
benign to a metastatic tumour is preceded by several events. One of the major 
changes that mark this transition is altered glycosylation of cell surface receptors and 
the secreted extracellular matrix components. Coupled with the tumour-associated 
proteolytic enzymes secreted by carcinomas, this alteration has a profound effect on 
invasion and metastasis (Oz et al.,  1989; Singh et al.,  2004). 
 
1.4 Glycosylation 
The majority of proteins go through at least one or more post-translational 
modifications in their lifetime. These modifications include covalent attachment of 
small molecules (phosphorylation and sulphation) or larger preassembled structures 
(palmitoylation, glycosylation and ubiquitination) to specific amino acid or motifs on 
the protein backbone. Among membrane associated proteins, glycosylation 
represents the most common type of modification. Glycosylation is a co- and post-
translational modification event which is controlled both genetically and 
epigenetically. Protein glycosylation itself exists in various forms depending on the 
nature of the preassembled oligosaccharide structure and the amino acid residue it is 
attached to on the polypeptide backbone. Following these prerequisites, glycol-
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peptide linkages consist of 5 types of N-glycosyl, 27 O-glycosyl, 4 Phospho-glycosyl, 
one C-mannosyl and one glypiation type of linkages. Of all the different types of 
sugar-amino acid bond, the -glucosylamine linkage of N-acetylglucosamine 
(GlcNAc) to asparagine (N) is the most common type of oligosaccharide 
modification. During this type of glycosylation, a homogeneous preassembled high 
mannose oligosaccharide structure is attached to the asparagine residue of a triamino 
motif, Asn-X-Ser/Thr, where X represents any amino acid except proline. 
Consequently, this type of glycosylation is also known as asparagine-linked 
glycosylation (ALG) or N-linked glycosylation (NLG). Approximately, ~70% of all 
glycosylated proteins are asparagine-linked glycosylated (Spiro, 2002). Since ALG 
occurs within the ER and the Golgi apparatus, the glycosylated portion of 
glycoproteins are found either within the secretory pathway or exposed to the 
extracellular face of the cell. However, some Ser/Thr linked O-linked glycoproteins 
have been reported to have nuclear and cytoplasmic distribution (Hart, 1997). Due to 
the inherent variation accrued in glycan structures during maturation, glycosylation 
proves the simplest way for diversification to modify cellular behaviour. 
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1.4.1 The N-linked Glycosylation (NLG) Pathway 
1.4.1.1   Assembly of dolichol oligosaccharide precursor 
 While the NLG pathway itself starts in the lumen of ER, the components 
required for this process are synthesised and transported from the cytosol into the 
lumen. Monosaccharides, obtained as nutrients or as a degradation product, are 
activated to form UDP-monosaccharides, GDP-monosaccharides or CMP-sialyl 
sugars and transported across the ER and Golgi membranes via specific barrel 
shaped sugar nucleotide transporters (SNT). Most SNTs are localised to the Golgi but 
some are also found in the ER. The assembly of triantennary tetradecasaccharide 
dolichol biphosphate glycolipid, Glc3Man9GlcNAc2-PP-dolichol, which is a universal 
precursor for eukaryote ALG is also initialised at the cytoplasmic face and flipped 
across to mature in the lumenal compartment of the ER as illustrated in Figure 1.9. 
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Figure 1.9 Assembly of dolichol oligosaccharide precursor at the cytoplasmic and 
lumenal surface of the ER membrane. 
Two N-Acetylglucosamine residues (pentagon shaded blue) are attached to the 
membrane embedded dolichol biphosphate chain followed by the addition of five 
mannose residues (circles shaded yellow) at the cytoplasmic face of the ER. M5-DLO 
flippase then flicks to re-orientate this structure into the ER lumen where four more 
mannose residues are added to form a high mannose structure. Eventually, three 
glucose residues are added to the first branch and the glucosylated high mannose 
precursor is now ready to be transferred to a peptide backbone by the oligosaccharyl 
transfer complex. 
 
The enzyme M5-DLO (5 mannose containing dolichol oligosaccharide) 
flippase has been identified to be responsible for this function after comparing the 
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flipping potential of several glycolipids ranging from M3-DLO to M9-DLO (Sanyal et 
al.,  2008; Sanyal and Menon, 2009). The name M5-DLO flippase was selected to 
reflect the glycolipid candidate that flipped across the membrane most rapidly, 
Man5GlcNAc2-PP-dolichol or M5-DLO. The maturation of the precursor continues 
within the ER lumen in the presence of Man-P-dolichol, Glc-P-dolichol and 
glycosyltransferases until the final precursor, Glc3Man9GlcNAc2-PP-dolichol, is 
assembled and is ready to be transferred onto a polypeptide. A representation of the 
final oligosaccharide assembly and the type of linkages between the 
monosaccharides is detailed in Figure 1.10(A-E).  
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Figure 1.10 Structure of N-linked oligosaccharide.  
(A) The high mannose precursor consists of three glucose residues (triangles shaded 
red), nine mannose residues (circles shaded yellow) and two N-Acetylglucosamine 
(GlcNAc) residues (pentagon shaded blue) linked to the dolichol lipid via two 
phosphate residues (P). (B) A Haworth projection represents a 3D structure of cyclic 
monosaccharides where thicker lines indicate atoms closer to the observer. Numbers 
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1-6 represent the six carbon atoms of the hexose molecule. The ‘α’ designation 
indicates the hydroxyl group on the first carbon (C-1) and hydroxymethyl group 
attached to the fifth carbon (C-5) are on the opposite sides of the ring’s plane, while 
‘β’ is designated when they are on the same side of the plane. (C) The example of a 
β1-4 linkage depicted here represents the glycosidic linkage between two GlcNAc 
residues, linking C-1 of a newly attached monosaccharide to the C-4 of the GlcNAc 
on the growing chain. (D) A representation of the α1-6 linkage where a glycosidic 
bond is formed between C-1 of the donor (left) and C-6 of the acceptor (right) 
mannose residue. (E) A chemical structure representing the mature precursor 
(Glc3Man9GlcNAc2) covalently attached to the asparagine residue of protein 
backbone. The various linkages are underlined in red. This image was reproduced 
from (Weerapana and Imperiali, 2006) with slight modifications. 
 
 
1.4.1.2   Glycoprotein synthesis – chaperones and checkpoints 
 Nascent proteins destined for the secretory pathway are tagged with a 
signaling peptide sequence at the amino terminal end. This model, suggesting that 
the attachment of ribosome to the ER is directed by a signal at the amino terminus 
end of the polypeptide, was first proposed by David Sabatini and Gunter Blobel in 
1971. Their hypothesis was based on the difference they found in the protein size 
when secreted proteins such as immunoglobulin were translated in vitro in the 
presence or absence of microsomes (Sabatini and Blobel, 1970; Blobel and Sabatini, 
1970). A RNA-multiprotein complex called signal recognition particle (SRP) 
recognises and binds to both the signal peptide sequence and the ribosome in the 
cytosol, temporarily halting the translation process. In the mammalian system, SRP 
guides the whole complex toward the rough endoplasmic reticulum (RER) 
28 
 
membrane where it anchors to SRP receptor protein. Binding of SRP to its receptor 
releases both the ribosome and the signal peptide from this complex, immediately 
restoring the translation process. The signal peptide from the growing polypeptide 
sequence is directed into the RER membrane through a multiprotein complex that 
forms a channel through the membrane called SEC61. The signal peptide is then 
cleaved by signal peptides located within the RER lumen. Once the translation is 
completed, the protein is released into the RER lumen. However, not all polypeptides 
are cleaved to remove the signal peptide sequence. And depending on where the 
signal peptide(s) and hydrophobic stretches are located, various types of 
transmembrane proteins are generated, ie.type 1, type 2 and multipass (Figure 1.11).  
ER chaperone proteins recognise and bind to the nascent polypeptide as it 
emerges through the SEC61 translocon. If an ALG site is detected within the first 50 
amino acid sequence, the emerging polypeptide associates with calnexin, a 
membrane bound ER lectin that recognises oligosaccharides or bulky hydrophilic 
patches. Otherwise, it associates with a chaperone from the Hsp70 family called BiP, 
which associates directly to the polypeptide. Crowding of calnexin, BiP and another 
soluble ER lectin called calreticulin towards the nascently synthesised polypeptide 
protects it by inhibiting aggregation and allowing the time required for proper 
folding of N-linked glycoproteins (Molinari and Helenius, 2000). 
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Figure 1.11 Assembly of proteins/glycoproteins destined for the secretory pathway. 
(A) Nascent polypeptides are guided to the Sec61 translocon by SRP molecule that 
recognises the signal peptide sequence. (B) Binding of SRP to its receptor engages the 
ribosome to the translocon. (C) The nascent polypeptide chain is injected into the ER 
lumen co-translationally and signal peptide sequence is cleaved by signal peptidase. 
(D) Single transmembrane glycoproteins (i), multipass glycoproteins (iii) and 
secreted glycoproteins (ii) generated based on the number of hydrophobic stretches 
present. Red line represents hydrophobic site, red fork represents oligosaccharides.   
 
 Glycosylation of the emerging nascent polypeptide is catalyzed by the 
oligosaccharyltransferase (OST) complex. The OST complex is an integral membrane 
protein complex consisting of seven (mammal) or eight (yeast) subunits which 
facilitates co-translational and post-translational en bloc transfer of the preassembled 
high mannose oligosaccharide onto a polypeptide chain. The mammalian OST 
complex consists of ribophorin I, ribophorinII, DAD1, OST4, N33 or IAP, STT3A or 
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STT3B, and Ost48 and is located adjacent to each active translocon. siRNA mediated 
depletion of ribophorin I and in vitro cross-linking analyses indicated selective 
presentation of substrates by the subunits to the catalytic domain of the OST complex 
and led to the hypothesis that the elaborate OST subunits exist because each subunit 
present a different group of substrates to a catalytic core (Wilson et al.,  2008). The 
active site of eukaryotic OST is attributed to the STT3 subunit (Yan and Lennarz, 
2002; Nilsson et al.,  2003). Two types of STT3 catalytic subunit have been identified; 
STT3A and STT3B, both of which are involved in the transfer of OS-PP-DOL to the 
acceptor site. These isomers have been shown to have an overlapping, as well as 
complimentary role in oligosaccharyl transfer. STT3A which is located adjacent to 
SEC61 requires a distance of 65-75 amino acid residues from the large ribosomal 
subunit to access the acceptor site (Nilsson and von, 1993; Whitley et al.,  1996). 
Should an N-X-S/T sequon exist within this region, STT3B which is located further 
from the SEC61 is able to access this site at later stages. While STT3A functions co-
translationally, STT3B has a co- and post-translation role in oligosaccharyl transfer 
(Ruiz-Canada et al.,  2009).  
 Trimming of the appended oligosaccharide (Glu3Man9GluNAc2) starts as soon 
as they are attached to the asparagine residue within the triamino sequon. This 
indicates that in most cases, processing of the newly added glycan to a polypeptide 
may be initiated before the polypeptide is completely glycosylated and folded. In 
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fact, glycosylation has been shown to play an important role in glycoprotein folding. 
Upon covalent attachment of oligosaccharide to the polypeptide, the outermost α1,2 
linked glucose residue is trimmed by a membrane bound ER enzyme glucosidase I 
(Shailubhai et al.,  1991). This is followed by the trimming of the second α1,3 linked 
glucose residue by the soluble ER enzyme, glucosidase II. Glucosidase II is composed 
of α subunit which harbours the catalytic domain while the β subunit bears a KDEL-
like ER retention motif (Trombetta et al.,  1996) and a sequence homologous to the 
mannose binding domain of Mannose-6-phosphate (Man-6-P) receptor (Munro, 
2001). The resultant monoglucosylated structure is then recognised by two resident 
ER lectins, calnexin (CNX) or calreticulin (CRT). This is an important juncture in the 
glycoprotein’s life cycle. If a glycoprotein is misfolded, the ER glucosyltransferase 
acts as a conformation sensor that recognises non-native structure and utilises UDP-
glucose to reglucosylate the glycoprotein, prompting reassociation with CNX or 
CRT. Association with the ER lectins retains misfolded proteins as well as folding 
intermediates within the ER, allowing time for proper folding. Achieving a native 
structure may take several rounds of reglucosylation and deglucosylation. Parodi’s 
group was the first to characterise the abundantly expressed ER glucosyltransferases 
(Parodi et al.,  1984) but its significance was only understood much later (Hammond 
et al.,  1994; Trombetta and Helenius, 1998; Trombetta and Helenius, 1999; Trombetta 
and Helenius, 2000; Keith et al.,  2005). If the deglucosylated glycoprotein has a 
native tertiary structure, it will continue to the next stage of maturation. This is 
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followed by the removal of the final glucose residue, simultaneously releasing the 
non-glucosylated structure from the lectin’s clutch. 
Another crucial process at this stage that ensures correct protein folding is 
disulfide bond formation. This step is critical for the maturation of many proteins 
that transit the secretory pathway. Disulfide bond formation is catalyzed by 
oxidoreductases from the protein disulphide-isomerase (PDI) family which carry 
CXXC motif in thioredoxin domain. Besides formation of disulphide bonds, these 
enzymes also function as isomerases that change non-native disulfide linkages to 
native linkages (Ellgaard et al.,  1999; Ellgaard and Frickel, 2003; Ellgaard and 
Ruddock, 2005) and as chaperones to inhibit aggregation of misfolded proteins (Cai 
et al.,  1994). The role of calnexin and calreticulin in disulphide bridging is more 
selective. Disulphide bond formation in CD1d heavy chain is dependent on the 
presence of the ER lectin (Kang and Cresswell, 2002) but not in MHC I folding 
(Zhang et al.,  1995; Tector et al.,  1997). 
Following deglucosylation, glycoproteins exit the ER for either further glycan 
processing in the Golgi or to the cytosol for degradation. In both cases, prior to ER 
exit, they are earmarked for demannosylation which is performed by two of the three 
subfamilies of glycosylhydrolase family 47. This includes the ER 1-2mannosidase I 
(ERManI) and three EDEMs (ER degradation enhancing mannosidase like protein) 
comprising of EDEM1, EDEM2 and EDEM3 (Hosokawa et al.,  2001; Mast et al.,  
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2005; Olivari et al.,  2005). A possible evolutionary divergence occurs at this point. In 
S. cerevisiae, the ERManI homologue MnsI, removes the mannose residue from the 
middle branch to form isomer B, and this has been shown to initiate 
retrotranslocation and degradation of the misfolded protein in (Jakob et al.,  1998b). 
The corresponding mammalian ERManI which trims mannose to isomer B 
conformation does not have the same effect. The CNX/CRT binding offer protection 
from degradation and is important for cellular energy conservation. In fact, it is the 
isomer A formation which abolishes reglucosylation and recruitment into the 
CNX/CRT cycle and subsequently, removal of the misfolded glycoproteins 
(Ermonval et al.,  2001). Various theories have been proposed as to how isomer A is 
generated in the ER. One that’s gaining momentum describes the role played by 
EDEMs in demannosylation prior to degradation.Upon exiting the ER, the misfolded 
protein is ubiquitinated by SCF E3 ligase complex (Yoshida et al.,  2005; Yoshida, 
2005) and in some cases, deglycosylated by cytosolic peptide:N-glycanase PNGase1 
(Hirsch et al.,  2003; Misaghi et al.,  2004; Yoshida and Tanaka, 2010; Hosomi et al.,  
2010). Demannosylation of misfolded proteins ensures these proteins are not 
recruited into Golgi by ERGIC53/VIP36 cargo receptors which requires branch A 
mannose residue for recognition.  
However, if a glycoprotein is properly folded, it is sent on a different 
pathway. Firstly, the high mannose oligosaccharides are trimmed by various ER 
mannosidases. There are at least three known ER mannosidases based on their 
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sensitivity to inhibitor in vivo. Within the RER, ER mannosidase I (kifunensine 
sensitive) and ER mannosidase II (kifunensine insensitive) have been identified. ER 
mannosidase I hydrolyzes α-1,2-linked to form isomer B while ER mannosidase II 
activity results in isomer A or isomer C though it is a less common occurance (Weng 
and Spiro, 1993a; Trombetta, 2003). However, it is important to note that only a third 
of the glycoproteins that exit the ER are processed by ER mannosidases (Bischoff et 
al.,  1986). A summary of this early glycosylation stage is illustrated in Figure 1.12 
below. 
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Figure 1.12 Processing of newly synthesised glycoprotein in the ER. OST complex 
transfers the triglucosylated high mannose precursor onto the nascent polypeptide 
upon reconizing the Asn-X-Ser/Thr seqoun. [1] Immediately after oligosaccharyl 
transfer, the first and second glucose residue is removed by glucosidase I (GI) and 
glucosidase II (GII) respectively. [2] The monoglucosylated glycoprotein associates 
with ER lectin, calnexin/calreticullin and oxidoreductase ERp57 to ensure it is 
properly folded. Natively folded glycoproteins are deglucosylated by glucosidase II. 
[4] Deglucosylated glycoproteins are either immediately transported out of ER by 
ERGIC53, ERGL or VIP36 chaperones, or [3] & [4] demannosylated by ERManI 
before being escorted out by the chaperones. [A] A proportion of nearly native 
glycoproteins initially released by the lectin are also deglucosylated by GII [B], but 
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further progress is stopped by glucosyltransferase I (GTI) which reglucosylated the 
glycoprotein [C]. This step is repeated until a native conformation is achieved. [D] 
Non native glycoproteins and glycoproteins that fail to achieve the native 
conformation after several rounds of calnexin/calreticullin cycle are attracted to BiP. 
These glycoproteins are extensively demannosylated by ERManI and EDEMs before 
removal from ER for proteosomal degradation [E].  
[Figure modified from: (Hebert and Molinari, 2007)] 
 
Beyond this stage, processing of the high mannose ensemble differs between 
yeast and mammalian system. In yeast, trimming of mannose in the ER is followed 
by addition of mannose residues in the Golgi by Golgi mannosyltransferases, 
forming extended mannan structures. In the mammalian system, both Man9GlcNAc2 
and Man8GlcNAc2 oligosaccharides are recruited by ER cargo receptors 
ERGIC53/VIP36 to the Golgi, where they are trimmed down to Man5GlcNAc2 sugars 
by Golgi mannosidase I which specifically targets α-1,2-linked mannose. Three 
different isoforms of Golgi mannosidase I have been identified (GolgiManIA, IB and 
IC) distributed in the cis and medial Golgi (Herscovics et al.,  1994; Lal et al.,  1998; 
Tremblay and Herscovics, 2000). The resulting Man5GlcNAc2 glycan is a specific 
substrate for N-Acetylglucosaminyltransferase I (GNTI/MGAT1) in medial Golgi 
cisternae which adds a GlcNAc residue to the α-1,3-linked mannose on the A branch. 
Next, Golgi -mannosidase II cleaves the remaining two  and  linked mannose 
and commit to the biosynthesis of complex N-linked oligosaccharides by addition of 
GlcNAc by GNTII, GNTIII, GNTIV and GNTV. All the GlcNAc addition occurs in a 
sequential manner except for addition by GNTIII which, upon addition, inhibits 
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GNTII, GNTIV and GNTV activity. The synthesis of complex N-linked glycans starts 
with the attachment of GlcNAc residue by GlcNAc transferase II (GnTII). Beyond 
this stage, the glycans are modified by various glycosyltransferases in median and 
trans Golgi where terminal galactosyl, fucosyl or sialyl residues are added. The 
resulting diverse oligosaccharides will eventually be presented at the cell surface. 
Glycosyltransferases are classified based on the monosaccharide they add (for 
example, fucosyltransferases add fucose to the N-linked glycan) and the linkages 
they initiate (for example 1-2, 2-3 or 2-6). The choice of sugar and the linkages is 
determined by multiple factors which include the repertoire of glycosyltransferases 
expressed by the cell as well as the level of donor and acceptor molecules present at 
any given time (Kornfeld and Kornfeld, 1985; Dennis et al.,  2009).  
Besides the conventional pathway which involves removal of all three glucose 
residues before progressing on the glycosylation pathway, selected 
monoglucosylated high mannose structures are also subverted within the ER to 
different pathways. One such pathway involves addition of phospho N-
Acetylglucosamine residues to the mannose residues on the peripheral chains. This 
particular modification allows for recognition by the mannose-6-phosphate receptors 
and eventual trafficking of the tagged glycoprotein and its associated partners to the 
late endosomal and lysosomal compartments. In the second alternative pathway (or 
the endomannosidase I pathway), instead of removal of mannose residues by ER 
mannosidase I, the glycoprotein containing the monoglucosylated structure is 
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recruited to the Golgi apparatus where it serves as a substrate for endomannosidase. 
The various branches of the asparagine-linked glycosylation pathway is summarised 
in Figure 1.13.  
 
Figure 1.13  The various branching of asparagine-linked glycosylation pathway. 
During glycan processing in the ER, deglucosylation precedes trimming of mannose 
residues. At this stage, the mannose residues are trimmed in the ER prior to 
diversification [A], or phosphorylated for lysosomal targeting [B]. Alternatively, 
monoglucosylated structures can be recruited into the endo-mannosidase pathway 
where the final deglucosylation and subsequent demannosylation occurs within the 
Golgi apparatus [C]. During their transit in the Golgi, addition of a third N-
Acetylglucosamine residue by GnT I produces the hybrid glycan species [D]. Further 
mannose trimming and addition of the forth N-Acetylglucosamine residue marks the 
beginning of complex glycan formation [E] and diversification of the glycan 
structure.  (continued…) 
A 
B 
C 
D E 
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α Mnase I – α mannosidase I; α Mnase II - α mannosidase II; α Mnase III - α 
mannosidase III;  GnT I - N-Acetylglucosamine transferase I; P-GnT – Phospho N-
Acetylglucosamine transferase; GlcNAc ase – N-Acetylglucosaminidase 
Figure modified from: (Stanley et al.,  2009)  
 
 
1.5 Glycosylation and Cancer 
Interest in glycobiology accelerated when antibodies raised against tumour 
cell surface antigens were found to specifically recognise sugar epitopes on both 
tumour cells and developing embryos (Feizi, 1985). Abnormal expression of fetal 
glycans in adults is detected during metastatic cancer progression. Altered 
glycosylation of functionally important membrane proteins such as integrins, 
cadherins and growth factor receptors change the signaling capacity of these 
receptors and profoundly affect the proliferation, differentiation and migration 
potential of the cell (Mendelsohn et al.,  2007; Lau et al.,  2007; Pinho et al.,  2009a; 
Pinho et al.,  2009b). Glycosylation has also been shown to play an important role in 
homing of lymphocytes and metastatic cells (Mitoma et al.,  2007; Bos et al.,  2009). 
Several oligosaccharide structures found on both proteins and lipids have been 
identified and associated with human cancer. Cancer associated glycans commonly 
involve terminal residues such as sialic acid, fucose and galactose probably due to 
the fact that they are readily accessible to their environment. 
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1.5.1 Sialylation  
The role of sialylation in cancer has been reported in two different types of 
linkages of this sugar. Firstly, the expression of the linear poly sialic acid polymer 
have been shown to play an important role in controlling the strength of cell-cell and 
cell-matrix interaction by modulating the number of 2,8-linked sialic acid added 
(Figure 1.14[A]). These structures which are usually expressed in fetal tissues are re-
expressed during tumour progression (Livingston et al.,  1988; Moolenaar et al.,  
1990). Another type of sialic acid addition, α 2,6-linkage to galactose was commonly 
observed in histological sections of colon cancer specimens (Figure 1.14[B]) (Dall'Olio 
et al.,  1989). Increased expression of 2,6-linked sialic acid has also been shown to 
home metastatic human breast cancer cells, MDA-MB-231 to the brain in mouse 
models (Bos et al., 2009). Furthermore, rampant liver colonizing variants of murine 
colon cancer cell lines have been shown to express fourfold higher levels of 2,6 
sialyl transferase mRNA compared to the low liver colonizing population (Piscatelli 
et al.,  1995).  
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Figure 1.14 Tumour associated sialyl modification. [A] Polysialylation of cell 
adhesion molecules (N-CAM) during cancer progression consist of terminal α2-8 
linked sialic acid repeats (squares shaded red) linked to galactose residue (pink 
circle) via α2-3 linked sialic acid (purple square). [B] Another cancer associated sialyl 
modification involves addition of terminal α2-6 linked sialic acid (green squares). An 
increase in this type of glycosylation during cancer progression changes how tumour 
cells interact with their environment. 
 
1.5.2 Fucosylation  
Blood group antigens (H, h, ABO and Lewis) are glycan structures found on 
glycoproteins and glycolipids that carry ,  and -linked fucose (Figure 
1.15). 
42 
 
 
Figure 1.15 Diagram showing the glycan structure of various blood group antigens. 
Stepwise modification of these terminal structures on N-glycan, O-glycan or 
glycolipid (R) enriches the pool of oligosaccharide repertoire. Alteration in their 
expression profile due to pathological stress changes their binding property to 
various selectins. 
 
Under normal physiological conditions, these sugars have a spatially and 
temporally restricted expression. Abnormal or increased expression of these 
structures has been reported in pancreatic cancer (Yuan et al.,  1985) and 
hepatocellular carcinoma (Okada et al.,  1987; Zhang et al.,  2002). These structures 
can be further modified with the addition of terminal sialic acid, forming the 
corresponding sialyl Lewis antigens. The functional implication of Lewis antigen 
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over-expression in tumour cells was realised when it was found that sialyl Lewis X 
acts as a ligand for E-Selectin, a lectin like cell adhesion molecule expressed on 
activated endothelial cells. These molecules mediate leukocyte extravasation from 
the circulatory system by arresting them on endothelial cell surface prior to 
anchoring by a stronger receptor ligand interaction (Phillips et al.,  1990). 
Accordingly, the expression of Lewis antigens on tumour cell surface may play a key 
role during extravasation. 
In order to answer the question whether glycosylation is one of the factor that 
determine the secondary metastasis location, B16 mice were subcutaneously injected 
with liver and lung metastasizing variants of lewis lung carcinoma. Subsequent 
histochemical analysis of: 9 primary murine tumors recovered from the injection site, 
9 liver metastases and 13 lung metastases showed high levels of UEA I lectin binding 
property for the lung colonizing variant compared to the primary site and liver 
colonies (Kahn et al.,  1988). UEA I lectin which selectively binds to 1,2-linked 
fucose, point  to a possible role played by 1,2-fucose in homing the tumor cells to 
lung as a secondary site. A definitive role played by fucosylation in homing was later 
shown in murine cord blood hematopoietic stem and progenitor cells (CB-HSPCs). 
Poor homing of murine CB-HSPC to the bone marrow of immune deficient mice 
correlated with the expression levels of sialyl Lewis X. Pretreating the HSPC enriched 
cord blood cells with 1-3 fucosyltransferase in the presence of high energy fucose 
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donor (UDP-fucose) increased the cell surface level of sLex and consequently, 
increased cell rolling on P an E-Selectin and the engraftment of these cells to the bone 
marrow (Xia et al.,  2004). 
Fucosylation and sialylation have also been shown to change how cancer cells 
interact with their environment. Exogenous expression of (1-2)-Fucosyltransferase-1 
in hepatocarcinoma cells HepG2, inhibited sialyl-Lewis X expression and switched 
their preferred affinity from E-Selectin to P-Selectin (Mathieu et al.,  2004). In another 
study, enzymatic removal of either cell surface sialyl or fucosyl residues in H7721 
cells altered their preference to extracellular matrix components, fibronectin and 
laminin (Zhang et al., 2002). 
 
1.5.3 β1-6 Poly-N-Acetyllactosamine and β1-4 bisecting N-Acetylglucosamine 
An increase in 1-6 branching of poly-N-Acetyllactosamine from increased 
GNT-V activity is considered one of the most significant cancer associated glycan 
structures which displays typical ‘oncogenic’ characteristic (Dennis et al.,  1987; 
Laferte and Dennis, 1989). The increase in the resulting chain is controlled at the 
transcriptional level of GNT-V by viral activation or carcinogenic transformation.  
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Figure 1.16 Diagram illustrating complex glycan biosynthesis by GNT III and 
GNT V.  The precursor for complex glycan [A] is modified by various 
glycosyltransferase in the Golgi. GNT III mediated addition of β1-4 linked N-
acetylglucosamine generates a bisecting structure and terminates glycan chain 
elongation upon addition of terminal galactose (circle shaded pink) and sialic acid 
(green square)[B]. GNT V on the other hand introduces β1-6 linked N-
Acetylglucosamine which elongates through the formation of poly N-
Acetyllactosamine chain [C]. This broken wing formation further serves as a 
backbone for fucosylation and sialylation, giving it a definitive metastasis promoting 
characteristic. 
 
 Even though it is not clearly understood how this glycan structure can 
increase the metastatic potential of tumour cells, a few theories have been proposed. 
The 1-6 branching involves elongation of this specific GlcNAc branch, resulting in a 
different type of structure termed as a ‘broken wing’ conformation (Figure 1.16). 
Such structures are speculated to increase direct association with neighbouring 
A B C 
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proteins and thereby enhance the cell’s metastatic potential. Presence of this glycan 
on cell surface receptors may affect the physical characteristics and functional 
behaviour of these molecules. Another possibility is that the long antenna-like chain 
provides a backbone for the addition of multiple sialyl and fucosyl residues 
providing a platform for polyfucosylation, or sialyl Lewis production and selectin 
interaction (Varki et al., 2009). Poly-N-acetyllactosamines are also recognised by 
galectins on the cell surface. Galectin mediated lattice formation can alter the 
turnover rate of cell surface receptors and growth factors, duly affecting cell 
proliferation and differentiation (Partridge et al.,  2004; Lajoie et al.,  2009). 
Enhanced expression of another GlcNAc transferase known as GNT-III has 
also been implicated in increased metastatic potential. GNT-III catalyzes the addition 
of 1-4 linked bisecting GlcNAc branch (Figure 1.16). However, this type of 
branching did not always represent an unequivocal oncogenic characteristic as 
observed in 1-6 branching. While overexpression of GNT-III is observed in rat 
hepatomas (Miyoshi et al.,  1993), mouse hepatomas did not show a similar 
phenotype. However, GNT-III deficient mice showed retarded liver tumor 
progression (Stanley, 2002). Exogenous expression of GNT-III in highly metastatic 
mouse melanoma B16-hm cells on the other hand, suppressed metastasis (Yoshimura 
et al.,  1995). Further investigation of this initial observation showed that increased 
addition of bisecting sugar on E-cadherin molecules in these cells delayed turnover 
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of this protein compared to wild type E-cadherin. Accumulation of E-cadherin at cell-
cell border resulted in cell-cell aggregation and metastasis suppression (Yoshimura et 
al.,  1996). In conclusion, GNT-III mediated glycosylation can either enhance or 
suppress tumorigenesis depending on secondary factors. 
Aberrant glycosylation remains one of the key events in initiation of invasion 
and metastasis. Much progress has been made since the 1970s when the role played 
by glycosylation in cancer was first realised. However, the complexity of the subject 
makes it less attractive compared to popular subjects such as cell surface receptor 
and oncogenes even though glycosylation has been shown to have direct and indirect 
effect on the functional aspect these molecules (Hakomori, 2002). A better 
understanding of cancer glycobiology will not only provide a clearer understanding 
of the pathology of this disease, but could also be utilised as a tool for diagnosis, 
prognosis and treatment. 
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1.6  Objectives of thesis 
In earlier investigations, a novel role played by CD151 in influencing the 
glycosylation of  integrin was observed. Based on these data, using MDA-231 
cells as a model system, the current study was designed to investigate (a) when, 
where and how CD151 regulates α3β1 integrin’s glycosylation, (b) the type of 
glycomodification induced by CD151 and (c) the consequences of the 
glycomodification, using various molecular, biochemical and cell culture techniques. 
For this purpose: 
1) Cell lines expressing various mutations of CD151 will be generated. The 
influence of CD151 on another of its partners, α6β1/β4 integrin will also be 
studied. In addition, the contribution of other tetraspanins on glycosylation of 
α3β1 and their influence on α6β1/β4 integrins will be analysed. The functional 
implications of CD151 mediated changes to α3- and α6- integrins will be 
compared by performing Boyden chamber migration, adhesion, 
transendothelial migration and endothelial rolling assays.  
2) The extent to which tetraspanins CD9, CD151, CD63 and CD81 influence 
glycosylation of α3β1 integrin and cell surface glycotope presentation will be 
investigated using biochemical and lectin binding/flow cytometry assays on 
tetraspanin depleted cell lines.   
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3) The mode of glycomodification and the influence it may have on the 
tetraspanin’s function will be determined by Western blotting after enzymatic 
digestion of glycans on these molecules and glycosylation inhibitor 
treatments.    
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2. MATERIALS AND METHODS 
 
2.1 Cell culture  
The cell lines used in this study were maintained in DMEM media (Invitrogen) 
containing 10% final concentration of heat inactivated FBS (Invitrogen) and 50U/ml 
final concentration of Penicillin and Streptomycin (Invitrogen). The various cell lines 
used throughout this study are listed in Table 2.1 below: 
Table 2.1 Summary of cell lines used in this study 
Cell line Origin Description Source Reference 
MDA-MB-231 
(MDA-231) 
Human breast 
adenocarcinoma 
Invasive, 
pleural effusion 
CRUK (Cailleau et 
al.,  1978) 
MCF7 Human breast 
adenocarcinoma 
Non-invasive, 
pleural effusion 
CRUK (Soule et al.,  
1973) 
BT474 Human breast 
ductal 
carcinoma 
Invasive, solid 
ductal carcinoma 
CRUK (Lasfargues et 
al.,  1978) 
HeLa Human cervical 
adenocarcinoma 
Malignant solid 
tumour 
CRUK (Scherer et al.,  
1953)  
U87MG Human 
glioblastoma 
Astrocytoma CRUK (Ponten and 
Macintyre, 
1968) 
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2.1.1  Maintenance of cell lines 
 Cells were grown in 10cm gamma radiated tissue culture petri dish (Corning) 
in 10ml complete DMEM medium (except for BT474 cell line which was maintained 
in RPMI 1640 (Invitrogen) medium containing 10% FBS) at 370C in a humidified 
chamber permeated with 5% CO2. Cells were maintained by removing the media and 
washing them twice in 5ml sterile phosphate buffer before detaching them in 0.25% 
Trypsin(1X) (Invitrogen). Detached cells were further resuspended in an appropriate 
volume of DMEM medium containing 10% Foetal Calf Serum (10% DMEM) and 
transferred to 15ml tubes (Corning). Cells were centrifuged for 3 min at 800rpm in 
Beckmann tabletop centrifuge. Upon removal of media, 20% of the resuspended cell 
pellet was plated onto a fresh petri dish and passaged every 2-3 days or when they 
reached 70-80% confluency. 
 
2.1.2 Cryo storage and recovery of cell lines 
 Cells (~3X106) were detached and washed in 10ml of 10% DMEM once by 
centrifugation. The cell pellet was resuspended in 1ml cryo-medium (10% DMSO in 
10% DMEM) and frozen in a CryoTubeTM(Nunc) at -800C for 24 hours before 
transferring to liquid nitrogen for long term storage. 
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 Cells were recovered by thawing in a waterbath at 370C. Cells were transferred 
to 15ml tube containing 10ml prewarmed media and washed by pelleting the cells at 
800rpm for 3 min. Cell pellet was resuspended in 10ml fresh media and transferred 
to a petri dish. Freshly recovered cells were incubated for at least 48 hours before 
further manipulation.  
 
2.1.3 Mycoplasma testing 
Cell lines were regularly tested to ensure they were mycoplasma free using 
Mycoalert® Mycoplasma Detection Kit (Lonza) as per manufacturer’s 
recommendation. Reaction catalysed by the mycoplasma enzyme in the presence of 
the substrate provided with the kit leads to ADP ―> ATP conversion. The level of 
converted ATP is then detected by bioluminescent reaction which converts Luciferin 
in the presence of Luciferase.  
 
2.2 Generation of various plasmid constructs 
2.2.1 Generation of short hairpin constructs for tetraspanin knock-down 
pSUPERIORpuro (OligoEngine) based plasmids expressing short hairpin RNA 
(shRNA) targeting tetraspanins CD151 and CD81 were generated by Dr Fedor 
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Berditchevski based on published sequences (Winterwood et al., 2006; Mazzocca et 
al., 2005). The final sequence for CD63 shRNA construct was selected from a panel of 
CD63 siRNA by Dr Berditchevski. The pSUPERIORpuro constructs were generated 
by inserting double stranded short hairpin oligonucleotide containing BglII and 
HindIII restricted overhangs (SigmaGenosys) into the pSUPERIORpuro vector 
linearised with the same restriction enzymes. The shRNA cassette generated for 
tetraspanin CD151 is as follows: 
 
 
The target oligonucleotide sequences for all the tetraspanin short hairpin constructs 
are listed in Table 2.2 
Table 2.2  Target shRNA sequence for various tetraspanins 
Target protein Target sequence 
CD151 5’-AGTACCTGCTGTTTACCTACA 
CD81 5’-ATCTGGAGCTGGGAGACAA  
CD63 5’-GGTTTTTCAATTAAACGGA  
CD9 5’-ACCTTCACCGTGAAGTCCT 
pSuper-shCD9 construct was a kind gift from Prof E. Rubinstein (Inserm 1004, 
Villejuif, France). 
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2.2.2 – Generation of various sh resistant CD151 mutant constructs 
 MDA-231 cells lines expressing various permutation of CD151 were generated 
by reintroducing the pZeoSV based CD151 mutant constructs into MDA-231 CD151 
(-) cells. A point mutation was introduced to these constructs to confer resistance to 
CD151 shRNA by standard PCR protocol using QuikChange® Multi Site-Directed 
Mutagenesis as described in section 2.2.5. The silent sh resistant point mutation 
introduced is highlighted in red below: 
 shCD151 resistant primer sequence 
Forward 5’  CAACAGCCGGCACCGTTGCCCTCAAGTACCTGCTC 
Reverse 5’  GAGCAGGTACTTGAGGGCAACGGTGCCGGCTGTTG 
 
 Previously published CD151 mutant construct used in this experiment are 
CD151 palmitoylation mutant (Berditchevski et al., 2002), CD151 cytoplasmic C 
terminal substitution (Sawada et al., 2003), CD151SW6 mutant (Berditchevski et al.,  
2001). Two new constructs, CD151 glycosylation mutant (by Dr Berditchevski) and 
CD151 QRD (194 →196) INF substitution (jointly constructed with Dr Berditchevski) 
were also generated for this study. The glycosylation mutant of CD151 was 
generated by substituting the asparagine residue at position 159 with glutamine 
while the QRD mutant of CD151 was generated by swapping glutamine-arginine-
aspartic acid (QRD) triamino sequence with isoleucine-asparagine-phenylalanine 
(INF) residues as described by Kazarov et al. (2002) using standard PCR protocol. 
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The CD151 construct carrying a CD63 N-terminal region substitution (dN) was a 
kind gift from Dr L.Ashman. A schematic representation of all the CD151 variants 
used in this study is presented in Figure 2.1  
 
Figure 2.1  Cartoon representing the shCD151 resistant wild type and CD151 
mutants generated for reintroduction into MDA-231 CD151(-) cells. 
A point mutation was introduced to the N-terminal region where required (CTG → 
CTC). Glycosylation mutant CD151 was generated by substituting (AAC → CAG) 
while in QRD mutant, the following mutation was introduced (CAG-CGA-GAC → 
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ATC-AAC-TTC). In N- and C-tail mutants, N-tail of CD151 was swapped with the 
same region from CD63 while C-tail was substituted with a HA-tag. SW6 mutant 
comprised of CD151 LEL on a CD9 backbone. In the CD151 palmitoylation mutant 
construct, all six membrane proximal cysteine residues were swapped with alanine.  
 
 
2.2.3 Generation pLVTHMshα3 integrin construct 
The shα3 integrin construct was generated to target the following sequence:  5′ 
GCTACATGATTCAGCGCAA. The α3 integrin targeting sh oligonucleotide was 
first ligated into the BglII/HindIII cleaved pSuperiorPuro plasmid as previously 
described. The cloned product was confirmed by resolving EcoRI and ClaI digested 
plasmid on 2% agarose gel as well as sequencing. The successfully cloned product 
was then cleaved with EcoRI and ClaI and religated into the pLVTHM vector 
linearised with the same restriction enzymes. The final cloned product was 
transformed into competent bacterial cells and following plasmid purification, the 
presence of the cloned insert was confirmed by agarose gel electrophoresis and 
sequencing. 
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Figure 2.2 DNA digest profile of pLVTHM based α3 shRNA 
Successful cloning of α3 shRNA cassette in pLVTHM plasmid was confirmed on a 
2% agarose gel after restriction digest of the plasmid with EcoRI and ClaI. All four 
bacterial clones tested showed successful cloning. 
 
 
2.2.4 Ligation of various shRNA constructs 
All shRNA oligonucleotides inserts were purchased (SIGMAGenosys). To prepare 
the inserts for cloning (annealing of the two strands), an Eppendorf tube containing 
25 µl of 4ng/µl DNA resuspended in TE buffer was incubated on a heat block (1000C) 
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for 10 minutes and left to cool down to room temperature. A ligation mix was then 
prepared as follows and incubated overnight at 160C: 
pSuperiorPuro 50ng 
insert 10ng 
T4 DNA ligase (40,000 Units/ml) 0.5 µl 
10X Ligase buffer 1.0 µl 
H2O to 10 µl 
 
 
 
 
2.2.5 Site directed mutagenesis 
 The introduction of point mutation to plasmid DNA was performed using 
QuikChange® Multi Site-Directed Mutagenesis kit (Stratagene) as per 
manufacturer’s recommendation. 
 
2.2.6 Bacterial transformation 
 An aliquot (12.5µl) of E. coli DH5α competent cells (New England Biolabs) was 
mixed with 2µl of chilled ligation product and incubated for a 30 min on ice. 
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Transformation of bacterial cells was performed at 420C for 30 seconds in a heated 
waterbath and chilled immediately on ice for 2 min. The bacterial cells were rescued 
with 200µl LB medium and shaken in an incubator set at 370C for 30 min at 120rpm. 
Transformed cells were selected on LB agar plate supplemented with 100µg/ml 
ampicillin.  
 
 
2.2.7 Small and large scale plasmid preparation 
 Individual clones were transferred to Eppendorf tubes containing 1ml LB 
medium and 100 µg/ml ampicillin. The culture was incubated in a shaking incubator 
for 18-24 hours at 370C, 120rpm. Cells were harvested by centrifuging at 13,000 rpm 
for 10 seconds and the supernatant was discarded. Plasmid purification was 
performed with the Qiagen Plasmid Miniprep Kit® as per manufacturer’s 
instructions. Bacterial clones containing the desired plasmid constructs (verified by 
gel electrophoresis and sequencing) were grown in 250ml LB broth containing 
ampicillin and plasmid purification was performed with Qiagen Plasmid Maxiprep 
Kit® according to manufacturer’s protocol. 
 
 
60 
 
2.2.8 DNA sequencing 
 Various plasmid constructs generated were confirmed by sequencing. Briefly, 
100-200ng plasmid DNA, 3.2 pmol of an appropriate primer and dH2O was premixed 
to a final volume 10µl in an Eppendorf tube and sent for sequencing analysis at the 
Functional Genomics Unit, University of Birmingham. The plasmids generated and 
their corresponding sequencing primers are is listed below: 
 
Vector Sequencing primer 
pSuperiorPuro based 
shCD151, shCD9, 
shCD63  and sh CD81 
Forward: 
 T7  5’  TAATACGACTCACTATAGGG 
 
pLVTHM based sh 3 
Forward: 
5’ GTGAAAGTCGGGGCTGCAGGAATTC 
Reverse: 
5’ CGATTTAGGTGACACTATAGAATACACGG 
 
pZeoSV based CD151 
mutants 
Forward:         
T7          5’  TAATACGACTCACTATAGGG     or 
PZeoF   5’ TTCCAGAAGTAGTGAGGAGG 
Reverse:  
SP6       5’  ATTTAGGTGACACTATAG 
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2.2.9 Agarose gel electrophoresis 
The DNA restriction digest was mixed with 6 X gel loading buffer (0.25% w/v 
xylenecyanol, 0.25% w/v bromophenol blue, 30% v/v glycerol) and subjected to 
electrophoresis through 2% w/v agarose gel containing 0.5 µg/ml ethidium bromide 
in 0.5 X TBE buffer [made up of 45mM Tris Base, 45mM Boric acid and 2mM EDTA 
(pH 8.0)]. After electrophoresis, the resolved products were visualised and recorded 
in a UV gel documentation system (InGenius® Syngene).  
 
2.3 Establishing various cell lines 
2.3.1 Establishing tetraspanin knock-down cell line 
 The MDA-231 CD151(-) and MCF7 CD151(-) cells were generated by Dr Vera 
Novitskaya while MDA-231 CD63(-) cells was generated by Dr Berditchevski. Other 
tetraspanin knock down cell lines generated for this study includes HeLa CD151(-), 
MDA-231 CD9(-) and MDA-231 CD81(-). Transfection of MDA-231 cells was 
performed with GeneJammer (Stratagene) while MCF7 and HeLa cells were 
transfected using Fugene (Roche). The transfection mix was prepared as follows: 18µl 
of transfection reagent, Fugene or GeneJammer was added to 582µl of serum- and 
antibiotic-free DMEM medium in an Eppendorf tube, mixed and incubated for 10 
min at room temperature (RT). 6µg DNA of plasmid encoding the shRNA was then 
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added, mixed thoroughly and incubated at RT for a further 30-45 min. The 
transfection mix was added dropwise onto the adherent cells, swirled gently to mix 
and incubated overnight as previously described in section 2.1.1. After 24 hours, the 
transfection medium was removed and 10ml fresh DMEM medium containing 10% 
FBS, Pen/Strep and 1µg/ml puromycin (Sigma) was added. After another 24 hour 
incubation, the selection medium was replaced with fresh 10% DMEM medium 
containing 0.5µg/ml puromycin. The selection medium was changed every 2-3 days 
until resistant colonies started to grow. The colonies were detached and transferred 
to a fresh plate until it reached 80-90% confluency. The mixed population comprising 
of depleted, moderately depleted and undepleted tetraspanin was surface labelled 
with appropriate antibodies and sorted to select for tetraspanin-depleted cells (-ve 
population) and undepleted cells (+ve population). The level of knock-down 
achieved for various tetraspanins after cell sorting was determined by flow 
cytometry and Western blotting. 
 
2.3.2 Establishing of lentivirus based shα3 integrin knock-down cell line 
Lentivirus encoding shRNA which target α3 integrin subunit was produced as 
follows: 293T cells were grown for 18-24hrs to ~60% confluency on a 10 cm petridish. 
Transfection reagent was prepared by mixing 18µl of Fugene to 582µl of serum- and 
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antibiotic-free DMEM in an Eppendorf tube and incubated at RT for 10min. In a 
separate tube, a plasmid mix was prepared as listed in Table 2.2 below: 
 
 
Table 2.3- Ratio of plasmid mix for lentivirus production  
 Plasmid µg/10cm petridish 
shRNA vector pLVTHM shα3 integrin 2.4 
Packaging construct pSPAX (TronoLab) 2.3 
Envelope construct pMD2G-VSVG (TronoLab) 1.3 
 
The plasmid combination was then added to the transfection reagent, mixed well and 
incubated for a further 30-45 min at RT before adding dropwise to the 293T cells. The 
transfection mix was evenly distributed by gently swirling the petri dish and 
incubated for 5-18 hours. The transfection medium was then exchanged with fresh 
medium and incubated for 72 hours. The lentivirus containing supernatant was 
harvested and centrifuged at 1000 rpm for 5 min and filtered through a sterile 
0.45µm filter (Millipore) to remove cell debris. The viral supernatant was either used 
immediately for infection or 1ml aliquots were stored at -800C.  
 MDA-231 cells were prepared for infection by growing them for 24 hours in a 
10 cm petridish till they reached ~30-40% confluency. The medium was removed and 
10ml filtered viral supernatant was added and incubated for 24 hours. The 
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supernatant was then removed and 10ml fresh medium was added and incubated 
with cells for further 48 hours. Cells were detached and a small aliquot (~5%) of the 
cells was analysed by flow cytometry to detect for the presence of the GFP positive 
population. The presence of GFP positive cells signified successful viral infection. 
The mixed population containing GFP(+) and GFP(-) cells was surfaced labelled for 
α3 integrin (anti-α3 A3-IVA5 and PE conjugated secondary antibody) and sorted for 
GFP-positive / PE-negative population. GFP-positive control cells (i.e. cells 
expressing α3β1 integrin) were obtained by infecting MDA-231 cells with lentivirus 
generated from pLVTHM vector devoid of shRNA insert. 
 
2.3.3 Establishing various CD151 wild type and mutant cell lines 
 MDA-231 CD151 (-)ve cell lines reconstituted with various CD151 mutants 
were generated by transfecting appropriate plasmids using GeneJammer transfection 
reagent as described in section 2.3.1. Selection of transfected cells was performed in 
the presence of 300µg/ml Zeocin and resistant colonies were maintained in 10% 
DMEM Pen/Strep supplemented with 100µg/ml Zeocin until they reach confluency 
in a 10 cm petri dish. The cells were then sorted to obtain a population expressing the 
mutant CD151 at a level comparable to that of the wild type CD151 by presetting the 
sorting gate. Selected population was grown in 10% DMEM medium containing 
100µg/ml Zeocin and 0.5µg/ml puromycin.  The level of reconstituted CD151 
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expressed was confirmed by Western blotting and flow cytometry analysis. Cryo 
stocks of the cell lines were made before proceeding with various experiments. 
 
2.3.4 Flow cytometry 
Flow cytometry analysis was performed to quantitatively analyse cell surface 
epitope presentation. Prior to flow cytometry analysis, cells were passaged and 
grown in a 10 cm tissue culture dish for 18-24 hours in a tissue culture incubator. 2-
3x106cells were washed twice in sterile Dulbecco buffer and detaching with 2mls of 
Cell dissociation buffer® (Invitrogen) at 370C for 10 - 15min. The detaching cell 
clumps were loosened to form single cell suspension by pipetteing and transferred to 
a sterile 15ml centrifuge tube containing 10mls of cold 10% DMEM medium. The 
following steps were performed on ice and in prechilled centrifuge. Cells were 
washed by centrifuging them at 800rpm for 5 min at 40C in ice-cold 10% DMEM 
medium before resuspending in 1ml of 10% DMEM medium. Cells were counted and 
2x104 aliquots were taken for each antibody tested. The primary antibodies used for 
flow cytometry analysis are listed in Table 2.4.  
Antibody binding was performed in 96 well round bottom plates (Iwaki) 
placed on ice. 100µl of neat hybridoma supernatant or 100µl of 1µg/ml of purified 
antibody was aliquoted into labelled wells. Cells were then added to appropriate 
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wells, mixed and incubated for 1hr on ice. Cells were then washed twice in 10% 
DMEM by centrifuging at 800 rpm for 5 minutes and incubated in secondary 
antibody conjugated with fluoresceinisothiocyanate (FITC) or phycoerytherin (PE) 
(Dako) on ice for 30 min in the dark (100µl of 1:300 antibody/DMEM dilution). Cells 
were washed twice in 10% DMEM, resuspended 100µl Dulbecco buffer and 
transferred to FACS tubes containing 400µl of 2% paraformaldehyde (PFA). Mean 
fluorescence intensity was measured on EPICS XL Flow cytometry (Coulter) using 
System II software (Coulter).  
 
2.3.5 Cell sorting 
 Cells for sorting were prepared in a similar way as cell prepared for flow 
cytometry with a few modifications. Every step of the experiment was carried out in 
the tissue culture hood under sterile conditions. Primary and secondary antibodies 
used were azide free and filtered with 0.22µm filter prior to use. In the final step, 
instead of fixing in PFA, cells were resuspended in prechilled 10% DMEM medium. 
Cells were then gated and sorted by Mr David Lloyd from the Cancer Studies, 
University of Birmingham. The primary antibodies used in this study is listed in 
Table 2.4 
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Table 2.4  List of primary antibodies used for flow cytometry and cell sorting 
Epitope Antibody Source 
CD151 5C11 
11B1G4 
Hybridoma (Berditchevski et al.,  1997) 
Ascites (Fitter et al., 1995)  
CD9 C9BB 
BU16 
Hybridoma (Tachibana et al.,  1997) 
Purified mAb (The Binding Site, Birmingham) 
CD81 M38 Hybridoma (Fukudome et al.,  1992) 
CD82 M104 Hybridoma (Fukudome et al., 1992) 
CD63 6H1 Hybridoma (Berditchevski et al.,  1995) 
α3 integrin A3-IVA5 Hybridoma (Weitzman et al.,  1993) 
α6 integrin A6ELE Hybridoma (Lee et al.,  1995) 
β1 integrin TS2/16 Hybridoma (Hemler et al.,  1984) 
 
 
2.4 Biochemical analysis 
2.4.1 Cell lysis 
 Cell lysis was performed in either 1% Triton X-100, 1% Brij 96 or 1% Brij 98 
according to the lysis stringency required. Brij 96 and Brij98 were melted in a water 
bath at 500C prior to use. The 1% (v/v) detergent solution was prepared in PBS buffer 
by dissolving 1 PBS tablet (Oxoid) in 100ml dH2O supplemented with 1mM MgCl2 
and 0.5mM CaCl2 and adjusted to pH 7.4. Protease inhibitors (2mM 
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phenylmethylsulfonyl fluoride, 20µg/ml aprotinin and 20µg/ml leupeptine) and 
phosphatase inhibitors (2mM NaF, 0.5mM Na3VO4, 5mM Na4P2O7) were added to the 
lysis buffer immediately before use. Cells were lysed overnight on a rotating wheel 
in the cold room and the lysates were harvested by centrifugation in a chilled 
tabletop centrifuge at 13,000 rpm for 10 min. The clarified cell lysates were 
transferred to a fresh Eppendorf tube and their concentration was normalised.  
 
2.4.2 Normalisation of protein concentration 
 DC protein assay kit (Biorad) was used to normalise protein concentration. 
Briefly, reagent S was diluted in reagent A at 1:50 dilution. 25µl of the mix was 
aliquoted into a required number of well in a microplate. 5µl of cell lysate was added 
to each well containing the reagent mix followed by 200µl of reagent C. After 15 min 
incubation at room temperature, colorimetric reading was performed at 630nm 
absorbance. Appropriate dilutions were performed for each lysate based on the read 
out to normalise their concentration. 
 
2.4.3 SDS-Polyacrylamide gel electrophoresis 
 Cell lysates were diluted 1:3 with 4 X Laemmli buffer (0.5M Tris pH6.8, 4.4ml 
glycerol, 2.2ml 20% SDS, 1ml dH2O and 0.05g bromophenol blue). If required, 
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protein samples were reduced by adding β-mercaptoethanol at 1:20 dilution. Protein 
samples were denatured by boiling at 1000C for 5 min, except for the detection of 
CD151 with CD151 polyclonal antibody which requires ‘native proteins’ for 
detection. Proteins were resolved by SDS-PAGE using the MiniPROTEANIII system 
(Biorad). Table 2.5 represents the recipe for preparation of SDS-PAGE at various 
concentrations: 
Table 2.5 Recipe for two SDS polyacrylamide gels 
 5% Stacking 
gel 
8% 
resolving 
gel 
10% 
resolving 
gel 
12% 
resolving 
gel 
30% Acrylamide:Bis 1.6 ml 2.6 ml 3.3 ml 4 ml 
1.5 M Tris-HCl pH 8.8 - 1.25 ml 1.25 ml 1.25 ml 
1 M Tris-HCl pH 6.8 1.3 ml - - - 
20% SDS 50 µl 50 µl 50 µl 50 µl 
dH2O 7.6 ml 4.7 ml 4.0 ml 3.3 ml 
10% Ammonium 
Persulphate 
50 µl 50 µl 50 µl 50 µl 
TEMED 20 µl 40 µl 40 µl 40 µl 
 
The electrophoresis was performed at 18mA per gel in 1X running buffer (14.4g 
glycine, 3g Tris-HCl, 1g SDS dissolved in dH2O to a final volumn of 1 L) 
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2.4.4 Western Blotting 
 Proteins resolved by SDS-PAGE were transferred to a nitrocellulose 
membrane (Gelman Science) in Mini Transblot® system (Biorad) overnight at 40V in 
Tris-Glycine buffer (3.03g Tris base, 14.4g glycine and dH2O to a final volumn of 1 L). 
The membrane was rinsed and blocked with 5% non-fat dry milk in PBS-T (0.5% 
Tween-80 in PBS) for 1hr at room temperature. Incubation with primary antibody 
was performed overnight on an orbital shaker at 40C. The membranes were washed 
four times for 15 mins in PBS-T and incubated with horseradish peroxidase-
conjugated secondary antibody diluted 1:20,000 in 5% milk PBS-T for 1 hr at room 
temperature. The membranes were washed again 4 X 15 min and proteins were 
detected with chemiluminescence kit (Western LightingTM, PerkinElmer Life 
Sciences). Signal was visualised on HyperFilm® (Amersham) in the dark room. 
 
 
2.4.5 Immunoprecipitation 
 Immunoprecipitation (IP) or co-IP was performed to analyse protein complex 
formation within the cell. All steps were performed on ice. Cells were scraped from 
10cm plate and lysed in 500µl of lysis buffer as described above (2.4.1). 20-50µl of 
total lysates was put aside to be used as positive controls. The lysates were 
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precleared with 20µl goat anti-mouse IgG conjugated agarose beads (Sigma) at 40C 
on a rotating wheel for 2 hrs. Beads for protein capture were prepared by incubating 
20µl beads with 1ml hybridoma supernatant under the same conditions. As a 
negative control, beads were incubated in 500µl of wash buffer (lysis buffer without 
aprotinin and leupeptin). The beads were washed once in washing buffer and the 
buffer was removed by aspiration after centrifuging at 3,000 rpm for 1 minute. The 
precleared lysate was centrifuged for 30 seconds at full speed and then transferred 
into a fresh tube. The precleared lysate was then distributed equally to tubes 
containing antibody bound and unbound beads and incubated overnight on a rotator 
in the cold room. The beads were washed 5 times in washing buffer by centrifugation 
and co-IP complexes were eluted twice by incubating in 20µl 1 X Laemmli buffer for 
5 minutes at room temperature. The elution was boiled, resolved by SDS-PAGE and 
analysed by Western blotting.  
 
2.4.6 Preparation of 5:35:45 discontinuous sucrose density gradient 
 Cells from two confluent 10cm plates were scraped and washed once with ice- 
cold PBS. Cell lysate preparation and centrifugation was performed at 0-40C. Scraped 
cells were lysed in 950µl lysis buffer containing either 1% Triton X-100, 1% Brij96 or 
1% Brij98 made up in 25mM MES [2-(N-Morpholino) ethanesulfonic acid 
hemisodium salt] buffer, pH 6.5 (Sigma-Aldrich) for 3 hrs in the cold room. Lysates 
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were homogenised by passing through a 25G needle 10 times and centrifuged for 1 
min at 13,000 rpm to remove bubbles and cell debris. The supernatant was carefully 
transferred to a fresh Eppendorf tube and their concentration was normalised with 
appropriate lysis buffer solution. For sucrose density gradient assay, 90%, 35% and 
5% sucrose solutions were prepared in 25mM MES buffer supplemented with 1:500 
dilution of 10mg/ml aprotinin and leupeptin. The sucrose solutions were chilled 
before use. 850µl of cell lysate was mixed with 850µl of 90% sucrose and transferred 
to a prechilled 12ml Beckman ultracentrifuge tube. A second layer consisting of 1.7ml 
35% sucrose was carefully laid followed by 850µl of 5% sucrose layer on the top. 
Care was taken to maintain separate density layers. The tube was then secured in a 
bucket, clasped to a prechilled SW-40 rotor and centrifuged at 38,000 rpm for 16 hrs 
at 40C in a prechilled Beckman Ultracentrifuge. 400µl aliquots of the centrifuged 
assay was carefully transferred to Eppendorf tubes containing 130µl of 4 X Laemmli 
buffer while the pellet was resuspened in 400µl of 1 X Laemmli buffer. The fractions 
were analysed by SDS-PAGE and Western blotting. 
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2.5 Glycan analysis 
2.5.1 Deglycosylation (PNGaseF/EndoH) 
 Cell lysates prepared in 1% Triton X-100 lysis buffer was denatured by boiling 
for 10 min in the presence of 0.5% SDS. The boiling step was omitted for CD151 
Western blot detection. Deglycosylation assays to remove all N-linked glycan 
(PNGaseF) and non-complex N-linked glycans (EndoH) (from New England Biolabs) 
was set up as follows:  
 
 EndoH PNGaseF 
10X G5 Buffer 5 µl - 
10X G7 buffer - 5 µl 
10% NP-40 - 5 µl 
Cell lysate 43 µl 38 µl 
Deglycosylation enzyme 2 µl 2 µl 
 
 
The reaction mix was incubated at 370C for 18 hrs after which, 16µl 4X Laemmli was 
added and boiled at 1000C for 3 min to terminate the reaction. The deglcosylated 
product was analysed by SDS-PAGE and Western blotting. 
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2.5.2 Inhibition of N-linked glycosylation pathway 
 Cells were grown in the presence of various inhibitors for 48 -72 hours. Upon 
harvesting, cells were washed in cold PBS and lysed in 1% Triton X-100 lysis buffer 
for 18 hrs in a rotator in the cold room. Cell debris was removed by centrifuging at 
13,000 rpm for 10 min and cleared lysate was collected into a fresh Eppendorf tube. 
Protein concentration was normalised using DC protein assay kit (Biorad) and 
analysed for the changes in the glycosylation profile of various glycoproteins by SDS-
PAGE and Western blot analysis. The concentration of the various glycosylation 
pathway inhibitors used is listed below:  
Inhibitor Concentration Reference 
Castanospermine 1 mg/ml (Saul et al.,  1984) 
Kifunensine 2 µg/ml (Elbein et al., 1990) 
Deoxymannojirimycin 2 mM (Bischoff and Kornfeld, 1984) 
Swainsonine 2 µg/ml (Elbein, 1987) 
(chemical structures of the inhibitors are presented as supplementary data) 
 
2.5.3 Flow cytometry (glycan epitope) 
 Cells were grown in a 10 cm plate overnight, washed in PBS and detached 
with 1X trypsin (Invitrogen). Detached cells were washed once in PBS and 
resuspended in 1ml of chilled 1% BSA in PBS. Cells were counted and ~1X105 cells 
75 
 
was incubated in 200µl of 2µg/ml of biotinylated lectin (Vector Laboratories) for 30 
min on ice. The list of lectins used and the glycan epitopes they recognise is 
presented in Table 2.6. Lectin bound cells were washed once in 1% BSA/PBS by 
centrifugation and resuspended in 200µl 1:500 dilution of FITC conjugated Avidin 
(Sigma) in 1% BSA/PBS for 30 min on ice. Cells were washed again twice in BSA/PBS 
buffer and finally resuspended in 100µl of cold PBS. Labelled cells were fixed in 2% 
PFA and analysed on EPICS XL Flow cytometry (Coulter) using System II software 
(Coulter). 
Table 2.6 List of biotinylated lectins used for flow cytometry analysis 
[from www.VectorLabs.com; (Goldstein, 2002)] 
Biotinylated Lectin Glycan epitope 
ConcanavalinA α-linked mannose 
Aleuria aurantia Lectin fucose linked (α -1,6) to N-acetylglucosamine 
or fucose linked (α -1,3) to N-
acetyllactosamine 
Dolichos biflorus agglutinin  α-linked N-acetylgalactosamine 
Peanut Agglutinin galactosyl(β-1,3) N-acetylgalactosamine 
Phaseolus vulgaris 
Erythroagglutinin 
bisecting complex N-glycan  
Phaseolus vulgaris 
Leucoagglutinin 
Tri- and tetra- antennary N-linked glycans 
containing ( β-1,6) linked N-
acetylglucosamine 
Ricinus communis agglutinin 
I 
Terminal galactose and to a lesser degree, N-
acetylgalactosamine. 
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Sambucus nigra agglutinin (α-2,6) sialic acid attached to terminal 
galactose in and to a lesser degree, (α-2,3) 
linkage 
Soybean Agglutinin Terminal α- or β-linked N-
acetylgalactosamine and to a lesser extent, 
galactose residues. 
Ulex europaeus Agglutinin I glycoproteins and glycolipids containing (α-
1,2) linked fucose residues 
Wheat Germ Agglutinin N-acetylglucosamine and sialic acid 
 
 
2.5.4 Lectin blotting 
Glycoproteins were resolved by SDS-PAGE and transferred onto nitrocellulose 
membrane. For lectin blotting, membranes were blocked with 1% BSA in PBS-T for 1 
hr at room temperature and incubated in 1µg/ml lectin prepared in 1% BSA/PBS-T 
supplemented with 2mM CaCl2. Blots were washed 4 times, 15 min each wash and 
incubated in 1:2000 dilution of neutravidin conjugated with HRP (Sigma) in 1% 
BSA/PBS-T for 1 hr at room temperature. The blots were washed again 4x15 min and 
glycans were detected with chemiluminescence kit (Western LightingTM, PerkinElmer 
Life Sciences). Western blots were exposed to HyperFilm® (Amersham) in the dark 
for various times before development.  
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2.6 α3β1 integrin purification 
 In order to perform a large scale α3β1 integrin purification, monoclonal 
antibody to α3 integrin subunit (A3-IVA5) was purified from hybridoma culture 
supernatant and coupled to cyanogen bromide activated CNBr) Sepharose beads. 
The antibody coupled beads was used to purify α3β1 integrin from total cell lysate. 
α3β1 integrin was also prepared in a smaller scale using GD6 peptide. Both protocols 
are presented below.   
 
2.6.1 Antibody purification  
 Hybridoma cells were grown in T225 tissue culture flasks (IWAKI) in RPMI-
1640 medium (Invitrogen) containing 20% FBS (Invitrogen). The supernatant was 
collected by centrifugation and pH was adjusted to ~8.0 with 10 X PBS solution. The 
hybridoma supernatant was filtered through a 0.45µm filter and NaCl was added to 
a final concentration of 2.5M. Antibody was captured with Protein-A conjugated 
agarose beads (Sigma) on a rotating wheel overnight in the cold room (1ml packed 
beads was used per 100ml of hybridoma supernatant). Beads were centrifuged at 
3,000 rpm for 30 min at 40C and washed twice with 50 ml PBS containing 2.5M NaCl 
at pH 8.0. Beads were then packed into a 2 ml syringe plugged with glass wool. 
Stepwise elution of monoclonal antibody was performed by sequentially adding 1ml 
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aliquots with 100mM sodium citrate, pH 4.5 and each fraction was collected into 
separate tubes containing 100µl Tris-HCl, pH 8.8. Concentration of the eluted 
antibody was determined by measuring the optical density (OD) at 280nm using the 
NanoDrop 1000. The fraction(s) containing the highest antibody concentration was 
pooled together and dialysed overnight against 5L 0.1 M NaHCO3 buffer containing 
0.5M NaCl, pH 8.3-8.5 at 40C by constant stirring. The dialysed antibody was used for 
coupling. 
 
2.6.2 Antibody based α3β1 integrin purification 
Coupling of monoclonal antibody to CNBr beads 
 1 gram of activated CNBr beads (Sigma) were swelled in 10 ml cold 1mM HCl 
for at least 1 hr (1ml of swelled resin is required to couple 5-10 mg protein). Swelled 
resin was washed by gentle suction in a Buchner funnel with 10 ml of cold dH2O 
followed by 10 ml coupling buffer (0.1M NaHCO3 buffer containing 0.5M NaCl) and 
immediately mixed with the monoclonal antibody dialysed in coupling buffer. The 
coupling of antibody or BSA (control) with resin was performed by rotating the mix 
in a 15ml tube overnight in a cold room. The beads were sedimented by centrifuging 
at 3000 rpm for 15 minute. Absorbance of the supernatant was measured at 280nm 
before and after the coupling step to determine coupling efficiency. Post coupling 
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absorbance reading at around zero indicates efficient coupling. The beads were 
washed twice in coupling buffer and unreacted groups on the beads were blocked by 
incubating overnight in 0.1M Tris/0.5M NaCl, pH 8.3-8.5 by rotating in a cold room. 
Coupled beads were washed extensively first with coupling buffer followed by 
acetate buffer (0.1M NaAc/0.5M NaCl, pH 4) and the cycle of washes was repeated 
five times. Finally, the beads were washed in PBS and used immediately or stored at 
4-80C in the presence of 0.1% sodium azide.   
 
Purification of α3β1 integrin 
 MDA-231 CD151(+) and CD151(-) cells were grown in three 15 cm tissue 
culture plates for large scale α3β1 integrin purification. Cells were scraped into ice-
cold PBS and washed by centrifuging at 800rpm for 3 min at 40C. Washed cells were 
lysed in 3 ml 1% Triton X-100 lysis buffer overnight and non-solubilised cell debris 
was removed by centrifuging at 13,000 rpm for 10 min at 40C. Cell lysates were 
collected into fresh tubes and assayed with DC protein assay kit (Biorad) to 
standardise their concentration. A small aliquot of the lysate (~40 µl) was collected as 
total lysate and the rest was precleared on a rotator in the cold room with BSA 
coupled CNBr beads for 2 hr.  Precleared lysate was collected by centrifuging at 3000 
rpm for 10 min and incubated with anti-α3 antibody (A3-IVA5) coupled Sepharose 
beads on a rotator in the cold room overnight. Beads were washed five times with 
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lysis buffer and captured α3β1 integrin was eluted twice by incubating the beads 
with 100 µl of 0.1 M glycine (pH 2.6) for 5 min on ice. The eluate was collected after 
centrifuging the beads at 13,000 rpm for 1 min and immediately mixed with 20 µl 1 
M Tris-HCl (pH 8.8). The eluate was boiled in the presence of 1 X Laemmli for 3 min, 
resolved by either 8% or 12% SDS PAGE and analysed by Western and lectin 
blotting.  
 
2.6.3 GD6 peptide based α3β1 integrin purification 
Coupling GD6 peptide to CH-Sepharosebeads 
 Activated CH-Sepharose® 4B (Sigma) beads were swelled overnight in 1mM 
cold HCl at 1:200 (w/v). Swelled resin was washed twice in cold HCl (1mM). 2mg 
GD6 peptide was dissolved in 1ml coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 
8.0) and mixed with 100 µl of swelled resin in a cold room on a rotator for at least 4 
hours. Absorbance of the supernatant was measured at 280nm before and after the 
coupling step to determine coupling efficiency. Excess active groups were blocked by 
incubating in 0.1 M Tris-HCl, pH 8.0 for 1 hour. Beads were then washed 
sequentially in 1.5 ml coupling buffer, followed by 1.5 ml Tris buffer (0.1 M Tris-HCl, 
0.5 M NaCl, pH 8.0), 1.5 ml Acetate buffer (0.05 M NaAc, 0.5 M NaCl, pH 4.0) and 
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finally in PBS (pH 7.2). Coupled beads were either used immediately or stored in the 
cold room in the presence of 0.01% sodium azide. 
 
α3β1 integrin purification. 
 MDA-231 CD151(+) and CD151(-) cells were grown in a 10 cm tissue culture 
plates for α3β1 integrin purification. Cells were scraped into cold PBS and washed by 
centrifuging at 800rpm for 3 min at 40C. Washed cells were lysed in 500 µl 1% Triton 
X-100 lysis buffer overnight and non-solubilised cell debris was removed by 
centrifuging at 13,000 rpm for 10 min at 40C.  Cell lysates were collected into fresh 
tubes and assayed with DC protein assay kit (Biorad) to standardise their 
concentration. A small aliquot of the lysate (~40 µl) was collected as total lysate and 
the rest was precleared on a rotator in the cold room with BSA coupled CNBr beads 
for 2 hr.  Precleared lysate was collected by centrifuging at 3000 rpm for 10 min and 
incubated with 50 µl packed volume of GD6 peptide coupled CH-Sepharose beads 
on a rotator in the cold room overnight. Beads were washed five times in lysis buffer 
and captured α3β1 integrin was eluted by boiling in 50 µl of 1 X Laemmli for 5 min. 
The eluate was resolve in 12% SDS-PAGE and analysed by Western blotting. 
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2.7 Migration assay 
 Comparison of the migration potential of various MDA-231 cell lines was 
performed using a standard Boyden chamber assay method. The day before the 
assay was performed, the underside of tissue culture inserts with 8 µm pore 
polycarbonate membrane (Nunc) were coated with 100 µl of extracellular matrix 
components [10 µg/ml fibronectin (Sigma) or 2 µg/ml Laminin332 (a kind gift from 
Prof Johannes Eble)] and incubated overnight in the cold room. Cell lines were 
grown overnight to ~60% confluency in 10 cm tissue culture plates and detached 
with Cell Dissociation Solution (Invitrogen). Cells were washed once and 
resuspended in serum free DMEM medium. ~5 X 104 cells were resuspended in 500 
µl serum free DMEM medium and added into the tissue culture inserts. The inserts 
were then placed in a 24 well plate (Iwaki) containing serum free DMEM 
supplemented with 10ng/ml epidermal growth factor (EGF). Cells were allowed to 
migrate for 8 hours, after which, non-migrated cells were wiped off and the migrated 
cells were fixed in 2% PFA/PBS. Fixed cells were permeabilised and stained with 
0.1% Triton X-100/0.1µg/ml Hoechst 33342 Fluorescent dye/PBS solution for 30 
seconds and the inserts were rinsed twice with PBS. Polycarbonate membranes were 
peeled from the inserts and mounted on slides with DAKO mounting solution. 
Migrated cells were visualised with Nikon Eclipse E600 microscope. Up to seven 
random fields were photographed and scored using ImageJ nuclear/cell counter 
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software programme. Each combination of migration conditions was repeated up to 
four times (i.e. up to four tissue culture inserts was used for each condition) and 
independent assays were performed 2 – 3 times for each cell line.  
 When required, detached cells were pre-incubated with 10µg/ml monoclonal 
antibody diluted in 500 µl serum free DMEM on ice for 30 min. A fresh aliquot of 
10µg/ml of antibody was added immediately before transferring the cells into tissue 
culture inserts to proceed with the migration assay.  
 
 
2.8 BCECF cell labeling 
 Cells were labeled with 2,7-bis-(2-carboxyethyl)-5-(and-6)carboxyfluorescein-
acetoxylmethyl (BCECF-AM) for quantitative detection. Briefly, 1:100 dilution of 
BCECF-AM (from 1 mg/ml stock) was mixed with prewarmed DMEM medium 
containing 1 x 106 / ml viable cells. Cells were incubated at 370C for 15 minutes and 
washed twice with fresh medium. The stained cells are ready to be used in functional 
assays. 
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2.9 Cell Adhesion assay 
 Wells in a 96 flat bottom plate were marked and coated with 200 µl of various 
extracellular matrix dilutions for 2 hr at 370C. Each condition (1 µg/ml Laminin332, 2 
µg/ml Laminin332, 10µg/ml fibronectin and 10µg/ml BSA) was loaded in six wells. 
Coated wells were washed twice in PBS and blocked with 200 µl of 0.1% BSA/PBS for 
one hour at 370C. Blocked wells were rinsed once in PBS and loaded with 200 µl of 
BCECF-AM stained 2 X 104 cells in DMEM medium containing 0.1% BSA. Static 
adhesion was performed at 370C for 20-25 min and input reading was measured in a 
plate reader (Odyssey 2.1) at 485-538nm absorbance. The wells were washed 3 times 
in 200 µl of prewarmed DMEM/BSA medium and finally 200 µl of DMEM/BSA was 
added before reading the output on a plate reader. Percentage of cells which attached 
to the extracellular matrix was calculated from the ratio of (output reading)/(input 
reading). 
 
 
2.10 Transendothelial migration assay 
 Internal chamber of polycarbonate tissue culture inserts with 8 µm pore size 
was coated with 10 µg/ml fibronectin at 370C for 2 hr. Inserts were rinsed in PBS and 
2 X 105 human brain microendothelial cells (HBMEC) were loaded to each insert with 
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500 µl of 10% DMEM medium and the insert was immersed into a 24 well plate 
containing 500 µl of 10% DMEM medium. Cells were grown overnight in a tissue 
culture incubation chamber to obtain a confluent monolayer. The number of cell 
required to form a confluent monolayer overnight was determined by performing 
permeability assay as previously described (Fiuza et al.,  2002). Briefly, 0.036% 
Trypan blue and 0.8% BSA were dissolved in Hank’s Balanced Salt Solution (HBSS) 
[Invitrogen] and incubated at 370C for 10 min to form a stable Trypan blue-protein 
complex. Tissue culture inserts containing HBMEC monolayer plated at different cell 
concentration overnight (5 X 104, 1 X 105, 2 X 105 and 4 X 105) were washed in warm 
HBSS and transferred to 24 well plate containing 1 ml of HBSS. 500 µl Trypan blue 
complex was added to the inserts and incubated for 5 min in a tissue culture 
incubator. Cells are considered confluent if the 590 nm absorbance of the Trypan blue 
complex that diffused into the 24 well plate is < 1% of the absorbance for Trypan blue 
complex loaded into the tissue culture inserts.  
 Prior to performing the transendothelial migration assay, the HBMEC 
monolayer was stimulated by incubating the cells for 3 hr in 500 µl of 20ng/ml 
tumour necrosis factor α (TNF-α) in a tissue culture incubator. The stimulated 
endothelial cells were washed in 10% DMEM and 2 X 105 BCECF labelled MDA-231 
CD151(+) or CD151(-) cells resuspended in 500 µl of the 10% DMEM medium was 
added to the inserts. Assays for each cell lines were performed in triplicates for 
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statistical representation. Transendothelial migration assay was performed for 4 hr, 6 
hr and 8 hr. Non-migrated cells within the insert were wiped off with cotton bud and 
migrated cells were fixed in 2% PFA.  Number of migrated BCECF stained MDA-231 
cells were visualised and scored with Nikon Eclipse E600 microscope. 
 
 
2.11 Laminar flow assay 
 The assay was performed in flat glass capillaries (µ slides) with internal 
dimension of 0.3mm/3mm/50mm. Clean µ slides were immersed in 4% APES (3-
aminopropyl)triethoxysilane (Sigma) solution prepared in anhydrous acetone 
overnight in the dark and this step was repeated with fresh APES solution. µ slides 
were washed twice in acetone and finally in distilled water by sucking a few ml 
through using a vacuum pump. The µ slides were dried on tissue and the internal 
chambers were coated with P-selectin (10 mg/ml), E-selectin (10 mg/ml) (R&D 
Systems) or Laminin332 (4 mg/ml) (a kind gift from Prof Johannes Eble). The 
assembly of various components for the flow assay is described in Figure 2.3.  
87 
 
 
Figure 2.3 Assembly of various components for flow assay. 
The laminar flow assay was performed in a heated enclosure at 370C. The µ slide was 
secured on the microscope platform (A) A tubing network which allows the flow of 
cells and wash medium through the µ slide to the withdrawal syringe is controlled 
by an electronic valve (B). The flow speed is set electronically with a suction pump 
attached to the withdrawal syringe (C). Cell flow was recorded with a video recorder 
and analysis system attached to the microscope (D). (The image was kindly provided 
by Mr Phillip Stone) 
 
 The laminar flow assay was performed and documented at three different 
tumour cell flow rates (0.085 ml/min, 0.175 ml/min and 0.35 ml/min) as well as up to 
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5 min in static conditions where cell flow was halted and then resumed at the same 
rate after an interval of 30 sec, 1 min, 2 min and 5 min. 
2.12 Endothelial rolling assay 
Microslide preparation 
 The inner chamber of sterile glass µ slides were coated with 1% gelatine 
(Sigma) for ~30 min and washed with sterile PBS. Freshly prepared HUVEC was 
obtained from Prof Gerard Nash (IBR, University of Birmingham). HUVECs grown 
in a T25 flask were detached, washed and resuspended in 400 µl of 20% endothelial 
medium containing antibiotics and supplements (Medium 199 (Invitrogen), 20% 
foetal bovine serum (Sigma), 2.5 µg/ml Amphotericin (Invitrogen), 1000 U/ml 
penicillin (Sigma), 0.1 µg/ml streptomycin (Sigma), 1 mg/ml hydrocortisone (Sigma) 
and 1ng/ml epidermal growth factor (Sigma). The cells were loaded into 6 gelatine 
coated µ slides and left to attach to the slides for two hours in a tissue culture 
incubator. The µ slides were immersed in a petri dish containing 20 ml of endothelial 
medium and attached to a peristaltic pump set on timer so that fresh medium uptake 
occurs within the capillary tube every hour, overnight. The following day, the 
required number of endothelial slides was activated with 100U/ml TNFα (R&D 
Systems) for 3 hours. 
Rolling assay 
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 The ability of MDA-231 cells to roll on activated and non-activated HUVEC 
was compared by attaching the µ slide to the laminar flow assembly as described in 
Figure 2.3. The flow assay was performed at 0.085 ml/min, 0.175 ml/min and 0.35 
ml/min while shear rate was set at 0.025 Pa, 0.05 Pa and 0.1 Pa. The static adhesion 
assay on endothelial cells was performed by streaming in the MDA-231 cells at 0.35 
ml/min into the µ slides and the flow was stopped for 1 min, 2 min, and 5 min. 
Unbound cells were washed away by applying 0.1 Pa shear force. Number of cells 
before and after the wash was recorded and counted. 
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3. RESULTS AND DISCUSSION 
 
3.1   Generation and analysis of various tetraspanin knock-down cell 
lines 
3.1.1 Generation and analysis of CD151 knock-down cell lines 
To study the effect of CD151 depletion in tumour cell lines, endogenous CD151 was 
ablated by introducing CD151 targeting short hairpin RNA (shRNA) to three 
different cell lines: MDA-MB-231 (MDA-231), MCF7 and HeLa. The resulting drug 
resistant colonies were sorted for CD151 positive and CD151 negative populations. 
The level of endogenous CD151 in the final sorted population was determined by 
Western blot analysis [Figure 3.1(A)] while and cell surface expression level was 
determined by flow cytometry analysis [Figure 3.1(B)].  
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Figure 3.1 Comparison of CD151 levels in in wild type and CD151 ablated MDA-
MB-231, MCF7 and HeLa cell lines. 
(A) Total lysate was resolved in a 12% SDS polyacrylamide gel and the level of 
CD151 (anti-CD151 pAb) in each cell line was compared by Western blot analysis 
(upper panel). Loading calibration was confirmed by detecting for -actin (lower 
panel). The level of CD151 expression in parental MCF7 cell line (lane 3) was 
markedly low compared to MDA-231 (lane 1) or HeLa (lane 5) cell lines. (B) Flow 
cytometry analysis was performed to determine the cell surface expression levels of 
CD151. The value accompanying each peak represents the mean fluorescence 
intensity (MFI). 
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3.1.1.1  The effect of CD151 depletion in various cell lines 
 CD151 forms tight stoichiometric complexes with laminin binding integrins 
and contributes to their function (Serru et al.,  1999; Yauch et al.,  2000; Sterk et al.,  
2002b). Increased CD151 level has been associated with poor prognosis in prostate 
cancer (Ang et al.,  2004) and non-small cell lung cancer (Tokuhara et al.,  2001).  
CD151 is also reportedly upregulated during breast cancer progression (Yang et al.,  
2008). In this study I focused on the contribution made by CD151 in highly metastatic 
breast cancer cell line, MDA-231. While laminin binding integrins,  and 
6 4, are expressed in this cell line, the expression level of 3 1 integrin is markedly 
higher than 6 1 and 6 4 integrins. Consequently, as a first line of study, I 
investigated CD151’s contribution to the stability and cell surface presentation of 
3 1 integrin by flow cytometry and Western blot analysis.  
 
 
3.1.1.2  Flow cytometry analysis  
Flow cytometry analysis was performed to quantify cell surface expression level of 
integrin in MDA-231 CD151(+) and CD151(-) cells. As controls, the cell surface 
levels of  and  integrin subunits, as well as tetraspanins CD9, CD63, CD81, 
CD82 and CD151 was determined and summarised in Figure 3.2. The raw data for 
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this experiment is presented in Appendix 1.  Depletion of CD151 did not have any 
effect on the cell surface expression of tetraspanins CD9, CD63, CD81, CD82 or , 
,  and  integrin subunits. Investigation into the contribution made by cell 
density on the cell surface expression was made by plating cells to reach 50% and 
90% density prior to detachment for flow cytometry analysis. Again, no significant 
difference was observed in the cell surface expression levels of these proteins upon 
CD151 depletion at different cell densities. The results are summarised in Figure 3.2. 
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Figure 3.2 Flow cytometry analysis of MDA-231 CD151 (+) / (-) cells  
Cells were grown to 50% (blue bars) and 90% (green bars) confluence and analysed 
for the level of various cell surface proteins by flow cytometry. Monoclonal 
antibodies used are anti-  (A3-IVA5), anti-  (HAS3), anti- (A6-ELE), anti-  
(TS2/16), anti-CD9 (C9BB), anti-CD63 (6H1), anti-CD81 (M38), anti-CD82 (M104) and 
anti-CD151 (5C11). No significant difference was detected in the surface level of these 
proteins at either confluence upon CD151 depletion.  
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3.1.1.3  Western blot analysis of α3β1 integrin in MDA-231 CD151 (+) / (-) cell lines  
 Total levels of  integrin in MDA-231 CD151 (+) and CD151 (-) cells were 
analysed by Western blot under reducing conditions. Interestingly, I noted that while 
the total levels of the integrin remained comparable between the two cell lines, the 
mobility and intensity of the three light chain fragments of  integrin subunit 
generated under reducing condition were altered upon CD151 depletion [Figure 
3.3(A)].  These differences can be attributed to (1) changes in the proportion of each 
furin cleavage occurrence, (2) an alteration in the glycosylation of the integrin or (3) a 
variation in the splicing of the integrin’s light chain. To determine if glycosylation 
plays a role in this difference, glycoproteins in cell lysates were deglycosylated using 
Peptide: N-Glycosidase F (PNGaseF) and the 3 light chain fragments from MDA-
231 CD151 (+) and 151 (-) cell lines were compared by Western blot. Removal of 
glycan residues effectively negated the difference in the mobility of the integrin 
fragments between the two cell lines [Figure 3.3(B)].  
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Figure 3.3 Western blot analysis of  integrin light chain in MDA-231 CD151(+) 
and CD151(-) cell lines. 
Total cell lysate was resolved by 12% SDS-PAGE before and after PNGaseF treatment 
and probed for 3 light chain fragments on Western blot using anti- 3 pAb. (A) A 
difference was observed in the mobility of the  light chain fragments between 
CD151(+) (lane 1) and CD151(-) (lane 2) MDA-231 cells. (B) Pretreating the cell lysates 
with deglycosylation enzyme, PNGaseF, removed the sugar moieties attached to the 
integrin and consequently, the difference in the mobility of the  integrin light 
chains between the two cell lines was also eliminated (lanes 1 & 2). 
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 The glycosylation profile of 3 integrin subunit was also analysed by 
comparing their mobility under non reducing condition. Two different 
deglycosylation enzymes were used for this purpose; Endoglycosidase H (EndoH) 
which removes the high mannose and hybrid N-linked oligosaccharides but not the 
complex N-linked oligosaccharides, and Peptide: N-Glycosidase F (PNGaseF), which 
eliminates all three types of N-linked oligosaccharides, leaving just the protein 
backbone. Under non-reducing conditions, EndoH treatment revealed a difference in 
the mobility of the integrin molecules between the two cell lines [Figure 3.4 (B)] 
which was not immediately apparent prior to deglycosylation treatment [Figure 
3.4(A]. Conversely, complete removal of the sugars from the protein backbone by 
PNGaseF quenched this difference [Figure 3.4(C)]. These results indicate that the 
CD151 mediated changes in the mobility of  integrin subunit on Western blots are 
entirely due to its altered glycosylation state.  
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Figure 3.4 Western blot analysis of  integrin under non-reducing condition. 
Total cell lysates were resolved by 8% SDS-PAGE before and after EndoH or 
PNGaseF treatment and probed for 3 integrin subunit on Western blot using anti- 3 
pAb. (A) A slight difference was observed in the mobility of the  integrin subunit 
in CD151(+) (lane 1) and CD151(-) (lane 2) MDA-231 cells. (B) Removal of high 
mannose and hybrid glycan by pretreating the cell lysates with deglycosylation 
enzyme EndoH, enhanced the difference in the mobility of the integrin (red arrow). 
(C) Complete removal of all the glycan chains with PNGaseF negated the difference 
in the mobility of the  integrin molecule between the two cell lines (blue arrow). 
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3.1.1.4 Western blot analysis of  integrin in CD151 depleted MCF7 and HeLa cell 
lines 
 In order to determine the universality of CD151 mediated glycosylation 
changes to  integrin, a comparison of their mobility was made in CD151 depleted 
MDA-231, HeLa and MCF7 cell lines. The Western blot analysis of EndoH treated 
lysates showed change in the intensity of the various light chains of  integrin 
subunit in MDA-231 and HeLa cells, but not in MCF7 cells, upon CD151 depletion 
(Figure 3.5).  
 
 
Figure 3.5 Western blot 
analysis of light chains of  
integrin subunit in HeLa and 
MCF7 cell lines 
Cell lysates were resolved by 
12% SDS-PAGE, after EndoH 
treatment and probed for the 
light chain of 3 integrin 
subunit on Western blot using 
anti- 3 pAb. CD151 depletion 
markedly altered the intensity 
of  integrin light chain 
fragments in MDA-231 (lanes 
1 & 2) and HeLa (lane 3 & 4) 
cell lines but not in MCF 7 cell 
line (lanes 5 & 6). 
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3.1.2 Generation of CD9 (-), CD63 (-) and CD81 (-) MDA-231 cell lines  
 CD151, like all tetraspanins, form microdomains on the plasma membrane 
through homotypic and heterotypic lateral interactions with other members of the 
family. A hierarchy of primary, secondary and tertiary partners are then realised. 
Depending on their proximity, various components that make up a TERM can 
collectively influence each other’s function. To access the extent to which other 
tetraspanins within the CD151/ 3 1 associated TERM may influence  integrin 
glycosylation, a panel of CD9, CD63 and CD81 depleted MDA-231 cell lines were 
generated as detailed in the Materials and Methods (section 2.2 & 2.3). Depletion of 
each tetraspanin was confirmed by Western blot analysis (Figure 3.6).  
 The  integrin was immunoprecipitated with anti- 3 mAb from total cell 
lysates of the tetraspanin depleted cell lines and treated with EndoH to remove high 
mannose and hybrid oligosaccharides. The EndoH untreated and treated 
immunoprecipitation complex was resolved on 12% SDS PAGE and detected by 
Western blotting as presented in Figure 3.7. 
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Figure 3.6 Western blot analyses of CD9, CD63 and CD81 depletion in MDA-231 
cell lines. 
Upon shRNA introduction, antibiotic selected cells were surfaced labelled for CD9 
(BU16), CD63 (6H1) or CD81 (M38), gated and sorted for (+)ve  and (-)ve populations. 
Cell lysis of the selected populations were performed in 1% Triton X-100 and 
resolved by 12% SDS-PAGE. The shRNA knock-down levels for (A) CD9, (B) CD63 
and (C) CD81 was confirmed by Western blot analysis using C9BB, 6H1 and M38 
monoclonal antibodies respectively. 
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Figure 3.7 Western blot analysis of  integrin light chain from various tetraspanin 
depleted MDA-231 cell lines. 
The 3 1 immunoprecipitaion complex (mAb A3-IVA5) from 1% Triton X-100 lysed 
cells was resolved by 12% SDS-PAGE, before and after EndoH treatment and probed 
for light chain of 3 integrin subunit on Western blot using anti- 3 pAb. Depletion of 
CD151 showed a marked difference in the intensity of the three  integrin light 
chain fragments (lane 2) compared to the parental line (lane 1). While depletion of 
CD9 did not produce a similar shift, a slight change in the intensity of the middle 
band is detected upon CD9 depletion (lane 3). Depletion of CD63 (lane 4) or CD81 
(lane 5) did not produce a noticeable change in the intensity of  integrin light 
chains compared to the parental line.  
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3.1.3 Comparison of CD9 and CD81 associated  integrin pool 
 The CD151- tight association is attested by the fact that they remain 
associated under a relatively stringent detergent treatment such as 1% Triton X-100. 
The association of 3 1 with CD9 and CD81 is less robust. Nevertheless, both 
tetraspanins can be co-precipitated with when cells are lysed in 1% Brij96, 
signifying a secondary interaction between the tetraspanins and 3 1 integrin.  
Curiously though, CD9 depletion produced a slight difference in the mobility of light 
chain fragments of  integrin subunit on Western blot while CD81 depletion did not 
have the same effect (Figure 3.7). In order to determine if a difference exist in the 
3 1 integrin populations that associates with CD9 or CD81, the 3 integrin subunit 
that co-immunoprecipitation with CD9 or CD81 under 1% Brij 98 detergent condition 
was analysed. I also compared the CD151 co-immunoprecipitation complexes under 
1% Triton X-100 condition. Comparisons between CD9 and CD81 associated  
integrin indicated a difference in the ratio of the glycoforms that associate with these 
tetraspanins as indicated in Figure 3.8. The precipitate was treated with EndoH and 
their profile was compared by Western blot. As expected,  integrin co-precipitated 
in abundance with CD151 compared to CD9 or CD81.  
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Figure 3.8 Western blot analysis of CD151, CD9 and CD81 associated  integrin 
light chain. 
Co-immunoprecipitation (co-IP) of  integrin from precleared MDA-231 cell 
lysate was performed with anti-CD151 (5C11), anti-CD9 (C9BB) or anti-CD81 (M38) 
monoclonal antibodies. Co-IP complexes were deglycosylated with EndoH (NEB) as 
follows: sample was boiled in 1 X denaturation buffer for 10 minutes and incubated 
overnight at 370C in 1 X G5 buffer and 1µl of EndoH. The deglycosylated sample 
was then boiled in 1 X Laemmli buffer, resolved by 12% SDS-PAGE and analysed for 
the light chain fragments of 3 integrin subunit by Western blotting. A relative 
difference in the intensity of the doublet in the middle (as indicated by the arrows) 
from the CD81 co-precipitate (lane 4) was not observed during CD9 co-precipitation 
(lane 3).  Lanes (1), (3) and (4) represents identical exposure time to show the relative 
abundance of  integrin that co-precipitate with each of the tetraspanin. Lane (2) is a 
shorter exposure of lane (1).  
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3.1.4 Western blot comparison of various cell surface glycoproteins in MDA-231 
CD151(+) and CD151(-) cell  lines 
The main functional characteristic of tetraspanin is realised through their ability to 
form lateral interactions with other cell surface proteins. Consequently, the extent of 
CD151’s influence on glycosylation of other cell surface proteins was investigated by 
comparing the mobility of the light chain fragments of  integrin subunit (forms 
tight association with CD151), CD63 (a highly glycosylated member of the 
tetraspanin family) and emmprin, an extracellular matrix metalloproteinase inducer 
membrane protein shown to associate with α3β1 integrin (Berditchevski et al., 1997) 
Western blot comparison of these proteins in the two cell lines, with and without 
EndoH treatment, is presented in Figure 3.9.  
 No difference in migration or intensity was observed for all three proteins 
upon CD151 depletion. A more stringent assessment was made by pretreating the 
lysate with EndoH to remove the presence of high mannose and hybrid 
oligosaccharide that may obscure any slight difference before analysing by Western 
blot. Again no difference in the mobility of the bands was observed, regardless of 
their CD151 status.   
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Figure 3.9 Western blot analysis of  integrin subunit, CD63 and emmprin in 
MDA-231 CD151(+) and CD151(-) cells. 
The cells were lysed in 1% Triton X-100 and resolved by 12% SDS-PAGE before and 
after EndoH treatment and analysed by Western blot. The upper panels represent 6 
integrin light chain immunoprecipitated with mAb A6-ELE and detected by rabbit 
polyclonal antibody against  integrin light chain; the middle panels represent 
CD63 detected with mAb (IB5) while the lower panels represent emmprin detected 
with mAb (8G6). Both EndoH untreated (lanes 1 and 2) and treated (lanes 3 and 4) 
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samples showed no difference in the migration profile of the glycoproteins upon 
CD151 depletion.    
 
3.1.5 Analysis of  integrin’s association with CD151 in MDA-231 cell line 
 CD151 forms tight interactions with both  and  integrins via 
the QRD tri-amino sequence within the large extracellular loop of CD151 (Kazarov et 
al., 2002). Loss of the tight interaction between 3 1 integrin and the QRD mutant of 
CD151 under 1% Triton X-100 condition have also been reported elsewhere (Baldwin 
et al., 2008; Zevian et al., 2011). Interestingly however, depletion of CD151 only 
affected the glycosylation of  integrin but not  integrin. I hypothesised that one 
of the reason for this observation may be because CD151 preferentially associates 
with  integrin over  integrin in MDA-231.  To test this hypothesis,  and  
integrins were immunoprecipitated from equal amounts of total cell lysate prepared 
in 1% Triton X-100 lysis condition, and compared for the level of CD151 that co-
precipitated with each of the integrin. Even though CD151 has been widely reported 
to form primary interaction with laminin binding integrins, the co-
immunoprecipitation analysis showed CD151 forming a preferentially or stronger 
associated with  integrin over  integrins in MDA-231 cells when analysed 
under 1% Triton X-100 condition [Figure 3.10 (A) & (B)]. In fact, the level of  
integrins that complexed with CD151 in MDA-231 cells under this condition, 
compared to  integrin, was so low that it was almost negligible.  
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 Furthermore, Western blot analysis for 3 and 6 integrin subunits that co-
precipitated with CD151 under 1% Triton X-100 condition confirmed the earlier 
observation on preferential tight interaction between CD151 and 3 1 integrin 
compared to 6 integrins [Figure 3.10 (C) & (D)]. These results may offer an 
explanation as to why CD151 depletion altered glycosylation of  integrin but not 
 integrin in MDA-231 cells even though they have both been reported to interact at 
the QRD motif on LEL of CD151 with similar stoichiometry.  
 In order to determine whether 6( 1/ 4) integrins are recruited into the 
CD151 TERM in MDA-231 cells, I performed the immunoprecipitation assay under 
1% Brij96 condition and compared the level of 3 1 and 6 1/ 4 that co-precipitated 
with CD151. Western blot analysis showed that under these experimental conditions, 
CD151 associated with both 3 1 and 6( 1/ 4) integrins at comparable levels. In 
fact, the level of 6 1/ 4 integrins that co-precipitated with CD151 was slightly 
higher than 3 1 integrin. This result shows that even though CD151 preferentially 
forms tight association with 3 1 integrin in MDA-231 cells, 6 1/ 4 integrins are 
still recruited into the CD151 associated TERM at high levels.   
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Figure 3.10  Comparison of CD151’s association with  and  integrins.  In the 
first experiment (A & B),  integrin and  integrin was immunoprecipitated(IP) 
with mAb A3-IVA5 and A6-ELE respectively, from MDA-231 cell lysate (A) Western 
blot analysis of the integrins from total cell lysate (TL) (lane 1), 5µl of  IP (lane 3) 
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and 5µl of  IP (lane 4) was performed using a polyclonal antibody which 
recognises both 3 and 6 integrin subunits (AA6A). (B) Equal loads (15µl) of  IP 
and  IP was used to detect for the presence of CD151. An abundance of CD151 was 
detected in the  co-IP (lane 2) while only a weak signal was detected for CD151 
that co-precipitated with  (lane 4). A long exposure was required for this blot in 
order to detect the low level of CD151 in 6 co-IP. In the second experiment (C & D), 
CD151 was IP-ed with mAb 5C11. (C) The presence of CD151 in the TL (lane 1) and 
IP (lane 3) was confirmed using anti-CD151 rabbit polyclonal antibody. (D) The 
relative abundance of  and  integrins in TL (lane 1) and in the CD151 IP (lane 3) 
was detected with anti  antibody, AA6A. A large amount of  was detected in 
CD151 co-IP (lane 3, upper band) compared to the weak signal detected for  in 
CD151 co-IP (lane 3, lower band). (E) Secondary association between CD151 and 
3 1 / 6( 1/ 4) integrins subunits were analysed under 1% Brij 96 lysis condition. IP 
of CD151 was confirmed by Western blot [E(i), lane 3]. CD151 co-precipitated 
comparable levels of 3 1 and 6( 1/ 4) integrins under this condition [(ii), lane 3]. 
Control IP (Ctr) in all the experiments consists of IP of lysate with beads without 
mAb bound to it. IP was performed in 1% TritonX-100 [(A) - (D)] and 1% Brij 96 (E) 
the immunoprecipitates were resolved by 12% SDS-PAGE for Western blot analysis. 
 
 
3.1.6 Analysis of 6 integrin subunit in various tetraspanin depleted cell lines 
 Even though CD151 seems to preferentially associate with 3 1 integrin, 6 
integrins are still recruited into the CD151 TERMs. My results so far showed that 
depletion of CD151 did not have any influence on the mobility of the light chain 
fragment of 6 integrin subunit when analysed by Western blotting. Besides 
glycosylation, another post translational modification of 6 integrin subunit which 
associates with both 1 and 4 integrin subunits has previously been reported in 
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human prostate and colon cancer cell lines (Davis et al.,  2001). Here, a cleaved form 
of α6 subunit was detected. This cleaved variant of 6 integrin subunit which is 
missing the extracellular -propeller region was named the 6p variant. Biochemical 
and kinectis analysis of this variant showed it was glycosylated as per normal but 
had a three-fold increase in half life compared to the full length 6 subunit. While 
endogenous 6p was found associated with 1 or 4 subunit, exogenous expression 
of this truncated form of 6 integrin subunit was not capable of dimer formation. In 
DU145 cells, it was found that all 6p variants can be surface biotinylated compared 
to 50% of the full length subunit. These observations taken together prompted the 
conclusion that 6p is not a degradation product, but resulted from cleavage that 
occurred at the cell surface (Davis et al.,  2002; Demetriou and Cress, 2004). The 6p 
variant was later described as a product of ectodomain shedding due to proteolytic 
cleavage by urokinase-type plasminogen activator (uPA) (Demetriou et al.,  2004).  In 
their paper, Demetriou and Cress (2004) hypothesised that the ectodomain shedding 
only occurred when the 6 subunit is not tightly associated with CD151 (however, 
whether the proteolitic cleavage led to ectodomain shedding or the head region 
remained associated with β subunit was not explored in the study). 
 Consequently, I investigated the role played by CD151 in 6 integrin clipping 
in MDA-231 cells. Since my results so far seem to indicate that CD151 mainly forms 
secondary interactions with 6 1/ 4 integrins, I also wanted to compare the 
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influence of other tetraspanins within a TERM on 6 integrin subunit’s clevage.  For 
this purpose, Western blot analysis for the integrin was performed on total lysates 
and immunoprecipitation of 6 1/ 4 integrin from MDA-231, CD9-, CD63-, CD81- 
and CD151-knock-down cell lines. The predicted molecular weight of the 6p variant 
consisting of 497 amino acid residues is ~56.5 kD 
(www.bioinformatics.org/sms/index.html). However, owing to glycosylation, it 
resolves at a slighty higher position at ~65 kD.      
 In agreement with findings from the Cress laboratory, I found that depletion 
of CD151 increased the level of 6p variant in MDA-231 under non-reducing 
conditions [Figure 3.11(A)]. Additionally, I found that depletion of CD9 and CD81 (to 
a lesser extent) reduced the level of 6p variant in this cell line under non-reducing 
conditions. Interestingly, I also found a difference in the level of 6p variant detected 
under non-reducing [Figure 3.11(A)] and reducing conditions [Figure 3.11(B)]. For 
example, while some reduction was observed in 6p level in MDA CD9(-) cells 
under non-reducing condition, it was almost undetectable under reduced conditions. 
This difference probably reflects the presence of furin cleaved 6p fragments which 
under reducing conditions, will not be detected as an intact ~65kD fragment as 
illustrated in [Figure 3.11(C) iv & v].  
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Figure 3.11 Analysis of 6 integrin subunit in various tetraspanin depleted cell 
lines.  
The level of 6p integrin fragment (red arrow) in various tetraspanin depleted cell 
lines was analysed either from total cell lysate (TL) under non-reducing conditions 
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(A); or after immunoprecipitation of the 6 1/ 4 integrin with mAb A6-ELE under 
reducing conditions (B). (A) Depletion of CD151 showed an increase in the level of 
6p fragment in TL of MDA-231 cells (lane 2) compared to the parental line (lane 1). 
Depletion of CD9 (lane 3) and CD81 (lane 5) resulted in a decrease in the level of 6p 
fragment compared to the parental line. Depletion of CD63 did not seem to have any 
effect on the total level of 6p fragment. (B)  A similar pattern was observed in the 
level of 6p fragment under reducing conditions. However, a general decrease was 
detected in the level of 6p under this condition. It is especially obvious in CD9 
depleted cell line where 6p band was almost absent (lane 3). The proteins were 
resolved by 12% SDS PAGE and detected by Western blotting using anti-α6 pAb 
which binds both α3 and α6 light chain subunits. Samples were reduced by adding 
1:20 v/v β-mercaptoethanol before denaturation. 
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3.1.7 DISCUSSION 
 In this study, I found that depletion of CD151 in metastatic breast cancer cell 
line, MDA-231, did not have any effect on the total and cell surface levels of its 
primary partners, 3 1 integrin and 6 1/ 6 4 integrins. Flow-cytometry analysis of 
several other membrane proteins such as CD9, CD63, CD81, CD82 as well as  and 
 integrin subunits, revealed no difference in the level of these proteins upon CD151 
depletion.  Functionally, members of the tetraspanin family are associated with 
microdomain formation as well as intracellular and extracellular trafficking. The 
lacklustre effect CD151 depletion had on the cell surface presentation of various 
membrane proteins, including its primary partners 3 1 and 6 1 integrins, may 
indicate that CD151 does not regulate these proteins or it may also reflect a 
compensatory role played by other members of this family following CD151 
depletion.   
 However, a detailed study of the 3 integrin subunit revealed a novel role 
played by CD151 during post-translation modification of the integrin. Depletion of 
CD151 altered the glycosylation of this integrin as observed from its mobility and 
band intensity on Western blots. The loss of this difference upon PNGaseF 
deglycosylation treatment confirmed CD151’s role in glycosylation of 3 1 integrin. 
Depletion of CD151 in HeLa cell line produced similar, but not identical, changes to 
the glycosylation of 3 1 integrin demonstrating it to be a general phenomenon 
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exerted by CD151 on its partner. The differences observed between MDA-231 and 
HeLa cells may reflect the different repertoire of endogeneous glycosyltransferases 
expressed in each cell line. However, CD151 depletion in MCF7 cell line did not alter 
the integrin’s mobility on Western blot even though EndoH treatment was 
performed to remove non-complex sugars that may mask the mature complex glycan 
(Figure 3.5). A possible explanation for this can be attributed to the fact that the level 
of endogenous CD151 in the MCF7 cell line is very low compared to MDA-231 and 
HeLa cell lines (Figure3.1) As such, depletion of CD151 in MCF7 cells, which was 
already expressing very low level of the tetraspanin, did not elicit the same level of 
response on the  integrin glycosylation.  
 Analysis of 6 integrin, another stoichiometric CD151 partner, in MDA-231 
cell line showed no difference to its mobility or intensity on Western blot upon 
CD151 depletion. Furthermore, EndoH treatment of the lysate, which should 
accentuate any difference in glycosylation, remained unchanged (Figure 3.9). A 
possible explanation for this observation is the sensitivity, or lack of it, of Western 
blot assay in detecting subtle changes. Another possible explanation is that the N-
linked glycosylation sites on the folded 6 integrin are located at an angle/site where 
they are independent from any CD151 influence. Furthermore, this result may also 
represent a difference in how the CD151/ 3 1 complex and CD151/ 6( 1/ 4) 
complexes are trafficked during their transit in the ER and Golgi, whereby 
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glycosylation of 3 1 integrin is determined by CD151 while 6 1/ 6 4 integrins are 
not (Baldwin et al., 2008).  
 Alternatively, this observation may be due to a difference in the stoichiometry 
of the association between CD151 and 3 1 over 6 1 or 6 4 in MDA-231 cell line. 
In order to investigate this possible angle, I compared the level of tight CD151/ 3 1 
pairing to CD151/ 6( 1/ 4) by co-immunoprecipitaion assay under 1% Triton X-100 
condition. Western blot analysis clearly indicates that CD151 preferentially forms 
tight association with 3 1 compared to 6 1/ 6 4 in MDA-231 cell line (Figure 
3.10). Consequently, 3 1 integrin’s glycosylation is modulated by CD151 while 
glycosylation of 6 integrins which do not form tight interaction with CD151 are not.  
This observation implies that tight association between CD151 and its partner may be 
a prerequisite for CD151 to exert its influence on their glycosylation profile. The 
possibility of preferential partnering is of particular interest since both 3 1 integrin 
and 6 integrins are capable of forming tight interaction with CD151. This 
observation raises several important questions. Firstly, what are the factors that 
determine the hierarchy of preferential association? Secondly, when a laminin 
binding integrin (in this case 6 1 / 6 4) is not tightly associated with CD151, do 
they have a new partner. And if they do, how does this alternate association affect 
their function.   
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 CD151’s influence in the glycosylation of  integrin seems to hinge on their 
direct association. However, although CD9 is considered to be a secondary partner of 
the integrin, it is still able to exert its influence on the integrin’s glycosylation (Figure 
3.7). Another secondary partner, CD81, did not have the same influence. One 
possible explanation for the difference in CD9 and CD81’s influence is that CD9 may 
have a global role within the glycosylation pathway. For example, it may play an 
important role in trafficking molecules towards or away from compartments that are 
involved in specific glycomodification such as terminal glycan addition. 
Consequently, its depletion will affect a whole spectrum of proteins it is associated 
with including 3 1 integrin (This point will be discussed further in the later 
sections). Alternatively, the selective influence of secondary partners may also 
indicate the existence of independent subpopulation of 3 1 integrin within the 
TERM or different types of TERM complex (ie. [CD151/ 3 1/CD9], 
[CD151/ 3 1/CD81] and [CD151/ 3 1/CD9/CD81] complexes). Comparison of 3 1 
integrin population that co-precipitated with CD9 or CD81 showed a difference in 
the glyco-population of the integrin. This observation not only accounts for the 
difference in behaviour of the two tetraspanin towards the integrin, but it also 
suggests a functional hierarchy within various 3 1/CD151 complexes.  
 While depletion of CD151 did not have any effect on the glycosylation of 
α6 1/ 4 integrins, it did seem to affect another post translational modification 
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attributed to α6 integrin subunit, the uPA mediated integrin clipping which resulted 
in the generation of α6p form. Depletion of CD151 increased the level of α6p while 
depletion of CD9 and CD81 decreased its level. The clevage of α6 integrin subunit 
which occurs at or near the cell surface alters the affinity and avidity of receptor – 
ligand interaction and allows rapid cellular response to changes in its environment.  
This modification is thought to be developmentally regulated since a dynamic 
membrane remodelling system is crucial during rapid growth (Peschon et al.,  1998; 
Zhao et al.,  2001). The existence of 6p fragment was first identified in DU145 
moderately metastatic prostate cancer cell lines. Metastatic progression in prostate 
cancer has been linked to, among other factors, 6 integrin subunit’s class switch 
from 6 4 to 6 1 (Demetriou and Cress 2004), down-regulation of CD9 (Wang et 
al.,  2007) and up-regulation of CD151 (Ang et al., 2004), while RNAi knock-down of 
uPA and uPAR inhibited prostate cancer cell invasion (Pulukuri et al.,  2005). The 
α6p variant was first characterised in prostate cancer cell line, and was proposed to 
increase tumour cell migration by limiting its adhesion to Lm511. Depletion of 
CD151 in MDA-231 cells, which incidentally resulted in increased α6p variant 
presentation (Figure 3.11) has been shown to reduce its migratory potential towards 
Lm332 (Baldwin et al., 2008). Furthermore, I found that depletion of CD9 in MDA-
231 resulted in decreased α6p expression. Reduced CD9 expression prosate cancer on 
the other hand, is associated with increased metastatic potential. These contradicting 
responses may indicate that other factors are also involved in determining the 
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outcome of α6 integrin cleavage. For instance, difference in the affinity of α6β1/β4 
integrins towards different laminins may influence the tumour cell’s response. 
Moreover, how cells respond when they are directly sitting on the laminin may defer 
from how they respond when they are migrating towards the laminin which is 
presented as a haptotactic attractant. These observations taken together, paints a 
complex and dynamic relationship that exists between integrin receptors and their 
ligands in modulating the invasive process. Accordingly, it underscores the 
importance of considering not only the level, but also the post-translational 
modification of cell surface receptors in understanding the metastatic process. 
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3.2 Generation of various CD151 mutant and wild type reconstituted 
MDA-231 cell lines  
 In this study, I uncovered a previously unknown role of CD151 in modulating 
glycosylation of  integrin. In order to identify CD151’s characteristic that 
contributes to this function of the protein, a series of MDA-231 cell lines expressing 
various CD151 mutants were generated as follows: (1) CD151 glycosylation-deficient 
mutant (CD151/GLY), (2) CD151 palmitoylation-deficient mutant (CD151/PLM), (3) 
CD151 C-terminal deletion (CD151/dC), (4) CD151 N-terminal substitution with N-
terminal domain of CD63 (CD151/dN), (5) CD151 QRD →INF substitution at position 
194-196 in the large extracellular loop   (CD151/QRD),  and a (6) Chimera consisting 
of CD151 large extracellular loop on a CD9 backbone (CD151/SW6). These constructs 
were reintroduced into the MDA-231 CD151 (-) cell line.  Besides the panel of CD151 
mutants, I also generated a wild type CD151 reconstituted cell line (CD151/REC). 
Detailed description of the mutant constructs and cell lines generated is presented in 
the Materials and Methods (Section 2.2.2 and 2.3.3).  
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3.2.1 Flow cytometry analysis of MDA-231 CD151 mutant cell lines 
 The mutant CD151 cell lines generated was first analysed by flow cytometry 
to ensure that the CD151 mutants were expressed at a level comparable to the wild 
type CD151. Flow cytometry analysis showed the reconstituted cell lines to express 
similar levels of the tetraspanin as depicted in Figure 3.12.  The mean of 
fluorescence intensity value is accompanied in Table 3.1. However, I also observed 
that the CD151(PLM) mutant was less stable compared to other mutants in MDA-231 
cell line. The expression level of this mutant decreased by 50% within a period of 1 
week after fresh cell sorting. 
 
Figure 3.12 Flow cytometry analyses of cell surface CD151 levels on the panel of 
CD151 mutant cell lines. Cells were incubated in primary anti CD151 mAb (5C11), 
followed by FITC conjugated goat anti mouse secondary antibody. Cells were 
washed after each incubation and the level of the CD151 epitope was measured on 
EPICS XL Flow cytometry (Coulter) using System II software (Coulter).  
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Table 3.1  Flow cytometry analysis of cell surface level of CD151 detected with anti 
CD151 (mAb 5C11)  
 CD151 
(+) 
CD151 
(-) 
CD151 
(REC) 
CD151 
(PLM) 
CD151 
(GLY) 
CD151 
(dC) 
CD151 
(QRD) 
CD151 
(SW6) 
CD151 
(dN) 
MFI 17.3 0.9 17.5 15.2 18.7 18.3 19.6 16.8 17.1 
MFI: Mean fluorescence intensity 
 
3.2.2 Biochemical analyses of the CD151 mutants in MDA-231 
 The panel of CD151 mutant cell lines generated were analysed biochemically 
to assess the stoichiometry of their association with their primary partner,  
integrin. This association was examined by lysing the cells in 1% Triton X-100, a 
condition which only maintains tight primary interactions. Upon lysis, CD151 was 
immunoprecipitated with anti-CD151 mAb (5C11) bound IgG beads and analysed for 
CD151 and 3 integrin by Western blotting.  
  Co-immunoprecipitation analysis shows that the tight association of CD151 
with  integrin was markedly reduced with the introduction of QRD->INF 
mutation in the LEL (Figure 3.13) as previously described (Kazarov et al., 2002). 
Furthermore, mutation of the QRD site in LEL of CD151 affected its detection by 
CD151 mAb, 11B1.G4. This finding is also consistent with a previous study where 
substitution of glutamine to lysine (Q194K) of the QRD triamino sequence in CD151 
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reduced their ability to be precipitated by mAb 11B1.G4 by ~60% (Yamada et al.,  
2008).  
 
Figure 3.13 Analysis of CD151 and  integrin interaction in various CD151 
mutant cell lines. 
(A) Cells were lysed and immunoprecipitation (IP) of CD151 was performed under 
1% Triton X-100 condition. The eluate was resolved by 12% SDS PAGE and analysed 
by Western blotting for CD151 mAb (11B1.G4) and  integrin (rabbit polyclonal).  
CD151’s strong association with 3 1 under this condition (lane 1) is lost upon 
depletion of the tetraspanin (lane 2). Association of CD151 with 3 integrin in cells 
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reconstituted with CD151 glycosylation mutant (lane 4), C-tail deletion (lane 5), 
CD9/CD151 chimera, SW6 (lane 7) and N-tail substitution (lane 8) was comparable to 
the wild type CD151.  However, as expected,  integrin’s association with CD151 is 
reduced in cell lines expressing QRD mutant forms of CD151 (lower panel, lane 6) 
compared to the parental line (lower panel, lane 1). (B) Immunoprecipitation of 
CD151 was performed in CD151 (-) cell line reconstituted with CD151 (REC) and 
CD151 (QRD) and the level of CD151 was analysed by Western blot with CD151 
monoclonal antibody (11B1G4) [i] and CD151 rabbit polyclonal antibody [ii]. A 
comparable level of CD151 was detected in co-IP of both cell lines when detected 
with CD151 pAb [ii] even though the CD151 mAb did not give and signal for QRD 
(i). This result confirms that the reduced level of 3 that co-precipitated with CD151 
in QRD mutant (iii) is due diminished capacity of the integrin to form tight 
association with CD151 (QRD) mutant.  
 
 
 The panel of CD151 mutant cell lines were also assayed for their ability to 
recruit 3 1 integrin into the TERM. For this purpose, the cells were lysed in 1% 
Brij96 lysis buffer and CD9- and CD81- containing complexes were 
immunoprecipitated. The efficiency of the immunoprecipitation was confirmed by 
Western blot analysis for CD9 or CD81. The immunoprecipitation complex was then 
analysed for the presence of 3 1 integrin by Western blotting (Figure 3.14). 
 The level of 3 integrin that co-precipitated with CD9 or CD81 in CD151 
(PLM) mutant cell line was markedly reduced compared to the level of wild type 
CD151. This result is in accordance with previous observations on the role played by 
palmitoylation of tetraspanin in lateral interactions (Berditchevski et al., 2002). In 
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addition, CD151 (dN) and CD151 (SW6) mutants showed reduced level of 3 1 
integrin co-precipitation with both CD9 and CD81 IP. However, this reduction was 
not as drastic as the reduction observed for CD151 (PLM). CD151 (GLY), CD151 (dC) 
and CD151 (QRD) showed similar levels of co-precipitation with CD9 compared to 
the wild type CD151. Interestingly, CD151 (QRD) mutant which loses its capacity to 
associate tightly with 3 integrin subunit is still capable of recruiting 3 1 integrin 
into the TERM under 1% Brij96 condition. Similar observation have recently been 
reported on the ability of CD151 (QRD) mutant to form secondary lateral interaction 
under Brij99:Brij96V (1:1) lysis condition (Zevian et al.,  2011).  
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Figure 3.14 Analysis of CD151 mutant panels for potential secondary interaction 
formation. 
CD9 (mAb C9BB) and CD81 (mAb M38) co-immunoprecipitation complex captured 
in 1% Brij96 lyses buffer condition was resolved in 12% SDS PAGE and analysed by 
Western blot. The presence of CD9 (1a) in CD9 IP and CD81 (2a) in CD81 IP was 
confirmed by western blot to ensure the IP was successful. The level of  integrin 
that co-precipitated with CD9(1b) and CD81(2b) in each of the MDA-231 CD151 
variant cell line was compared. Presence of CD151 enables 3 1 integrin’s 
recruitment into the TERM in both CD9 and CD81 IP (lane 2).The level of  
integrin that co-IPed with CD9 and CD81 was markedly reduced in the absence of 
CD151 (lane 3) as well as in the CD151 (PLM) mutant (lane 6), however CD81 always 
coprecipitated slightly higher levels of the α3β1 integrin in these cell lines compared 
to CD9. CD151 (dN) (lane 8) and CD151 (SW6) (lane 10) demonstrated a less 
dramatic reduction in the level of 3 1 integrin that co-IPed with CD9 and CD81. 
Reconstitution of the wild type (lane 4), glycosylation deficient mutant (lane 5), C-tail 
deletion (lane 7) and QRD mutant (lane 9) co-precipitated similar levels of the 
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integrin compared to the parental line (lane 2). In the control experiment (lane 1), IP 
was performed in the absence of mAb. 
 
 
3.2.3 Analyses of  integrin light chain in CD151 mutant cell lines 
 The glycosylation profile of  integrin light chain fragment in the panel of 
CD151 mutant cell lines was analysed to determine the CD151 characteristics that 
influences the integrin’s glycosylation. Western blot analyses of  integrin light 
chain were performed on total cell lysate extracted with 1% Triton X-100. The various 
mutant cell lines presented an interesting mix of the 3 integrin light chain fragments 
glycosylation profile as depicted in Figure 3.15. Only the reconstitution of MDA-231 
CD151 (-) cell line with the wild type CD151, C-terminal deleted CD151 (dC) or N 
terminal substituted CD151 (dN) reverted the glycosylation profile of  integrin 
light chain fragment to a wild type phenotype. Reconstitution of palmitoylation 
mutant CD151 (PLM), glycosylation mutant CD151 (GLY), QRD →INF substitution 
CD151 (QRD) and CD9/CD151 chimera CD151 (SW6) were unable to restore the 3 
integrin light chain fragment glycoforms. 
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Figure 3.15  Western blot analyses of  integrin light chain and CD151 in various 
CD151 mutant cell lines. 
Total lysate of MDA-231 cell lines harbouring various permutations of CD151 were 
resolved by 12% SDS-PAGE and analysed by Western blot (WB) for  interin light 
chain (upper panel) and CD151 (middle panel).  Reconstitution of MDA-231 CD151(-) 
cell line with the wild type CD151 (lane 3) or CD151 mutants carrying C-terminal 
deletion (lane 5) or N-terminal substitution (lane 8) were able to revert the 
glycosylation profile of  light chain fragment to the pattern observed in the CD151 
(+) cells (lane 1). However, reconstitution with CD151 palmitoylation-deficient 
mutant (lane 4), QRD mutant (lane 6), SW6 mutant (lane 7) and glycosylation-
deficient mutant (lane 10) were unable to do so and a CD151 (-) phenotype for  
integrin light chain fragment (lane 2) persisted in these cell lines. WB of actin 
confirms equal loading of the lysates (lower panel).  
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3.2.4 Sucrose gradient floatation analyses of MDA-231 CD151(+) and CD151(-) 
cell lines  
 It has previously been reported that 3 1 integrin transfected in B lymphoid 
Daudi cell line partitioned into the light fractions of 1% Brij97 sucrose density 
gradient floatation assay only in the presence of CD151 (Charrin et al., 2003). Brij 96 
and Brij 97 lysis conditions have previously been shown to maintain secondary level 
of interaction and produce discrete and intact TERM complexes which are distrupted 
under the Triton X-100 condition which only maintains primary interactions. Even 
though more molecules are detected in tetraspanin complexes precipitated under Brij 
96/97 conditions, both primary and secondary interaction represent functional 
relevence. Tertiary interactions between tetraspanins and other molecules are 
detected under conditions milder than Brij 96 such as Brij 98, Brij99 and detergent 
free conditions. Under these conditions, indiscriminate membrane domains are 
generated comprising of tetraspanin complexes and raft associated components 
(Class et al., 2001).  
 In this study, I found that glycosylation and palmitoylation of CD151 as well 
as tight association of CD151 with 3 1 integrin, are all required for CD151 to 
modulate glycosylation of 3 1 integrin. Consequently, since the glycosylation 
profile of 3 integrin in CD151 depleted cell line is similar to that of CD151(GLY), 
CD151(PLM) and CD151(QRD) mutants, we wanted to determine if recruitment into 
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the light fractions of 1% Brij96 sucrose density gradient correlated with CD151’s 
characteristics which influences the glycosylation of the integrin. For this purpose, 
we first performed 5-35-45% discontinuous sucrose density gradient assay (SDG) in 
1% Brij98, 1% Brij96 and 1% Triton X-100 to determine the effect of detergent strength 
on 3 1 integrin partitioning in MDA-231 CD151(+) and CD151(-) cells. The results 
are presented in Figures 3.16 (Brij98), 3.17 (Brij96) and 3.18 (Triton X-100). 
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Figure 3.16 Western blot analyses of  and  integrin distribution in sucrose 
density gradient fractionation assay in 1% Brij 98. 
Sucrose density gradient fractionation assay of cell lysate from (A) MDA-231 CD151 
(+) and (B) MDA-231 CD151 (-) cells prepared in 1% Brij 98 was resolved by 12% SDS 
PAGE and analysed by Western blot for the distribution of and  integrin 
subunits. Under these experimental conditions, the integrins were detected in the 
heavy fractions (lanes 7-10) and in light fractions (lanes 1-4) of the gradient in both 
cell lines. (P: cell pellet) 
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Figure 3.17 Western blot analyses of  and  integrin distribution in sucrose 
density gradient fractionation assay in 1% Brij 96. 
Sucrose density gradient fractionation assay of cell lysate from (A) MDA-231 CD151 
(+) and (B) MDA-231 CD151 (-) cells prepared in 1% Brij 96 was resolved by 12% SDS 
PAGE and analysed by Western blot for the distribution of and  integrin 
subunits. Under these experimental conditions, the integrins were detected in the 
heavy (lanes 5-8) and light fractions (lanes 1 & 2) for lysate prepared from MDA-231 
CD151(+) (A). However, in the absence of CD151,  and  integrin subunits failed 
to localise to the light fractions (B), lane 1&2. (P: cell pellet).  
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Figure 3.18 Western blot analyses of  and  integrin distribution in sucrose 
density gradient fractionation assay in 1% TritonX-100. 
Sucrose density gradient fractionation assay of cell lysate from (A) MDA-231 CD151 
(+) and (B) MDA-231 CD151 (-) cells prepared in 1% Triton X-100 was resolved by 
12% SDS PAGE and analysed by Western blot for and  integrin subunit 
distribution. Under these experimental conditions, the integrins were only detected 
in the heavy fractions (lanes 7-10), but not in the light fractions (lanes 1-4) of the 
gradient in both cell lines. (P: cell pellet) 
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 Comparison of 3  integrin fractional distribution in MDA-231 CD151 (+) 
and CD151 (-) cell lines under three different detergent condition showed a 
difference only when the extraction was performed in 1% Brij 96 buffer. In agreement 
with previously published work (Charrin et al., 2003), the 3 1 integrin was only 
recruited into the light fraction of SDG in the presence of CD151. Analysis of 6 
integrin subunit showed a similar distribution pattern to 3. 
 Since a difference was observed in the distribution of 3 integrin subunit 
during 1% Brij96 SDG between CD151 (+) and CD151 (-) cell lines, we analysed 
various fractions collected for the presence of several tetraspanin proteins (CD151, 
CD9, CD63 and CD82) as well as a lipid raft associated protein, Src. Western blot 
analysis of the various fractions obtained from 1% Brij96 SDG showed no difference 
in the distribution of any of these proteins upon CD151 depletion (Figure 3.19).    
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Figure 3.19 Western blot analyses of the distribution of various membrane 
associated proteins sucrose density gradient fractionation assay in 1% Brij 96. 
SDG of cell lysate from MDA-231 CD151 (+) (left panel) and (B) MDA-231 CD151 (-) 
(right panel) prepared in 1% Brij 96 was resolved by 12% SDS PAGE and analysed by 
Western blot. Under these experimental conditions, no difference was observed in 
the distribution of CD9, CD63, CD82 and Src proteins upon CD151 depletion (P: cell 
pellet). 
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3.2.5 Sucrose gradient floatation analyses of MDA-231 CD151 (GLY) cell line  
Ablation of CD151 in MDA-231 cells inhibited the recruitment of the 3 1 integrin to 
the light fractions of 1% Brij96 SDG. In order to determine if changes in membrane 
distribution may somehow affect glycosylation of the integrin, SDG was performed 
on MDA CD151 (GLY) cells in 1% Brij96 lysis condition. Our result showed 
glycosylation status of CD151 was irrelevant to its role in modulation the membrane 
distribution of 3 1 and 6 1/ 4 integrins. Under these conditions, CD151 (GLY) 
was capable of recruiting these integrins to the light fractions of 1% Brij96 SDG 
(Figure 3.20).  
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Figure 3.20  Western blot analyses of MDA CD151(GLY) sucrose density gradient 
fractionation assay in 1% Brij 96   
SDG of cell lysate from MDA-231 CD151 glycosylation mutant prepared in 1% Brij 96 
was resolved by 12% SDS PAGE and analysed by Western blot. Under these 
experimental conditions, presence of glycosylation mutant CD151 (A) as well as both 
 and  integrins subunits (B) were detected in the light fractions of the sucrose 
gradient (fractions 1-3), similar to that observed in parental line.  (P: pellet; TL: total 
lysate) 
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3.2.6 Sucrose gradient floatation analyses of MDA-231 CD151 (PLM) and (QRD) 
mutant cell lines  
 It has previously been reported that palmitoylation of CD151 is crucial for its 
role in recruiting 3 1 integrin to the light fractions of Brij96 SDG (Yang et al., 2002). 
In order to confirm this observation, and to determine the contribution of CD151’s 
tight association with 3 1 integrin in its ability to recruit the integrin to the light 
fractions, we also included CD151 (QRD) mutant cell line in this study. For the sake 
of uniformity, 1% Brij96 SDG was performed with MDA-231 CD151(+), CD151(-), 
CD151 (PLM) and CD151 (QRD) and detected for 3 1 integrin. Since I consistently 
found that the expression level of CD151 (PLM) decreased after several passages, I 
freshly sorted the CD151 (PLM) cell line one day before performing the SDG assay.  
 Surprisingly, I found that only the CD151 depleted MDA-231 cells were 
unable to recruit 3 1 integrin into the light fractions (fraction 1-4) of 1% Brij96 SDG 
(Figure 3.21B). CD151 (PLM) (Figure 3.21C) and CD151 (QRD) (Figure 3.21D) 
behaved similarly to the parental line (Figure 3.21A) and was able to recruit the 
integrin to the light fractions of SDG. Apart from its inability to restore the 
glycosylation of 3 integrin, no other biochemical changes have so far been 
attributed to CD151 (GLY). Consequently, its ability to recruit 3 1 integrin into the 
light fractions of the gradient was not unexpected (Figure 3.20). However, 
palmitoylation-deficient CD151 loses its ability to form lateral interaction with other 
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membrane proteins and recruit 3 1 integrin into the TERM while QRD mutation 
affects the tight interaction between 3  integrin and CD151. Yet, despite these 
major changes to their biochemical properties, both mutants were able to recruit 
3 1 integrin into the light fractions of 1% Brij96 SDG. The CD151 (PLM) and CD151 
(QRD) mutants were also able to recruit 6 integrins to the light fractions of 1% 
Brij96 SDG in MDA-231 cells (presented as supplementary data). 
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Figure 3.21 Western blot analysis of various MDA-231 sucrose density gradient 
fractionation assay in 1% Brij 96   
SDG of cell lysate from MDA-231 (A) CD151 (+), (B) CD151(-), (C) CD151 (PLM), and 
(D) CD151 (QRD) prepared in 1% Brij 96 was resolved by 12% SDS PAGE and 
analysed by Western blot. Under these experimental conditions, presence of the 
various permutation of CD151 was detected in the light and heavy fractions of 
sucrose density gradient (right panels). Correspondingly,  integrin subunit was 
detected in the light fractions of the sucrose gradient (fractions 1-3) from MDA-231 
(A) CD151(+), (B) CD151(-), (C) CD151(PLM) and (D) CD151 (QRD) cell lines. Only 
depletion of CD151 failed to recruit the integrin to the light fraction of SDG (B).   
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3.2.7 DISCUSSION 
 
 A panel of MDA-231 cell lines were establishedto determine the characteristics 
of CD151 that controls the glycosylation of the 3 integrin subunit. Most of these 
characteristics have previously been described, but the biochemical assays were 
performed in the presence of endogenous CD151. Consequently, I used an 
endogeneous CD151 free environment to study the characteristics of various CD151 
permutations. Palmitoylation deficiency of CD151 has previously been shown to 
reduce the capacity of the tetraspanin to recruit 3 1 integrin into the TERM 
(Berditchevski et al., 2002). Furthermore, even though increased degradation of 
CD151 due to palmitoylation deficiency has been shown to be compensated by an 
increase in its synthesis (Berditchevski et al., 2002) altered subcellular localisation of 
nascently expressed palmitoylation tetra-mutant CD151 has also been suggested to 
reduce the half life of the protein (Yang et al., 2002). Additionally, knock-down of 
DHHC2, a CD9 and CD151 palmitoylating enzyme, have been shown to have a 
destabilizing effect on the tetraspanin but not on the level of the 3 integrin (Sharma 
et al.,  2008). These studies have also reported that CD151 palmitoylation had no 
effect in its ability to form tight association with 3 integrin.   
 In agreement to previous findings, CD151 (PLM) showed a marked decrease 
in its ability to co-precipitate 3 1 integrin with CD9 and CD81 in 1% Brij96 (Figure 
3.14). However, I also found that under 1% Triton X-100 condition, co-precipitation 
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of 3 1 with CD151 (PLM) was reduced compared to parental line (Figure 3.13A). 
This was unexpected as palmitoylation deficiency has been shown to have no 
bearing on the tight association of 3 1 integrin with CD151.  A possible explanation 
may lie in the fact that, during the course of the study, I found that the stability of 
CD151 (PLM) tetraspanin was compromised in MDA-231 cell line. I consistently had 
to sort this cell line to maintain a comparable level of the mutated tetraspanin to the 
parental line. I speculate that while total level of 3 1 integrin may not be affected in 
this cell line, increased degradation rate of CD151 may affect the cellular ratio of 3 
associated and 3 non-associated pools of CD151 (i.e. nascent CD151). Thus resulting 
in a reduced level of 3 1 co-precipitating with CD151 in the CD151 (PLM) cell line. 
Furthermore, previous studies on palmitoylation mutated CD151 were performed in 
cells expressing endogenous CD151 which may have masked the true characteristics 
of this mutant.  
 The tight association between CD151 and 3 1 integrin have been narrowed 
down to the QRD tri-amino sequence within the LEL of CD151 (Kazarov et al., 2002). 
And in agreement with this finding, I too found that the mutation introduced to the 
QRD site reduced the level of 3 1 integrin co-precipitating with CD151 in 1% Triton 
X-100 lysis condition (Figure 3.13). Secondary interaction between CD151 (QRD) and 
other components of TERM are however unaffected under 1% Brij 98 and 1:1 
Brij99:Brij96V conditions (Baldwin et al.,  2008; Zevian et al., 2011). In this study, we 
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found that recruitment of 3 1 integrin to the CD9 and CD81 associated TERM by 
CD151(QRD) was similar to the wild CD151 levels under 1% Brij96 lysis condition. 
Similar results have also been reported under 1:1 Brij99:Brij96V lysis condition 
(Zevian et al., 2011). 
 All other mutants [CD151: (GLY), (dC), (dN) and (SW6)] showed similar 
stoichiometry in their association with 3 integrin to wild type CD151 when IP of 
CD151 was performed under 1%Triton X-100 condition (Figure 3.13). Furthermore, 
CD151(GLY) and CD151(dC) were able to recruit 3 integrin to the CD9 and CD81 
associated TERM at similar capacity as the wild type CD151 (Figure 3.14). 
Interestingly, CD151(dN) and CD151(SW6) recruited 3 integrin into the CD9 and 
CD81 associated TERM at a reduced capacity even though they both were able to 
form tight stoichiometric association with the integrin (Figure 3.14). A possible 
explanation for this observation is that both these constructs carry elements of other 
tetraspanins within them. CD151(SW6) is basically a CD9 molecule carrying  CD151 
LEL fragment while CD151(dN) is substituted at the N-terminal region with CD63. In 
both cases, even though they are capable of tight association with 3 integrin subunit 
through LEL, their lateral interactions may also be dictated by elements that interact 
with CD9’s transmembrane and cytoplasmic regions or CD63’s N-terminal region, 
respectively. Consequently, which TERM they are recruited into becomes a ‘push 
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and pull’ situation within the chimera and may explain why a reduced level of 3 
integrin co-precipitated with CD9 and CD81. 
 My results showed that palmitoylation- and glycosylation- deficient mutants, 
QRD substitution mutant and SW6 CD9/CD151 chimera are unable to restore the 
glycosylation profile of the integrin to a wild type phenotype (Figure 3.15). The 
inability of these CD151 mutants to restore glycosylation profile of  integrin 
suggests a multi- layered influence of CD151 on glycosylation of 3 integrin. Tight 
association of CD151 with 3 1 integrin, recruitment into the TERM and 
glycosylation of the CD151 molecule itself all collectively contribute to the integrins 
glycosylation. Any distruption to this equilibrium alters the glycosylation of the 
integrin.  
 Interestingly, while, QRD->INF, SW6 and palmitoylation mutations affect 
either primary or secondary lateral interactions associated with CD151 and α3β1 
integrin, glycosylation mutation which did not affect their tight association or their 
recruitment into the TERM, was unable to revert the glycosylation of the integrin to a 
wild type phenotype. Previous studies have shown a distinguishing difference 
between CD151(+) and CD151(-) cells in the way 3 integrin is distributed when 
sucrose density gradient is performed under conditions that keep a discrete TERM 
intact (Charrin et al.,  2003b). We confirmed this in our model by performing SDG in 
1% Brij98, 1% Brij96 and and 1% Triton X-100 for MDA-231 CD151 (+) and CD151(-) 
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cell lines. SDG in 1% Brij98 showed 3 integrin’s distribution in heavy and light 
fractions for both cell lines. SDG performed in 1% Triton X-100 on the other hand 
distributed 3 integrin to only the heavy fractions in both cell lines, distinguishing it 
from lipid raft component. SDG in 1% Brij96 showed that in the absence of CD151, 3 
integrin was not distributed into the light fractions. To determine if a co-relation 
exists between their ability to float into the light fractions and glycosylation of 
CD151, I performed SDG in 1% Brij96 with CD151(GLY), CD151(PLM) and 
CD151(QRD). In all three cell lines, 3 1 integrin was distributed into the light 
fractions of the SDG. Thus membrane distribution is independent of glycosylation 
status of 3 integrin subunit. Furthermore, I also found that recruitment into the light 
fractions was not solely dependent on TERM formation or CD151- 3 1 tight 
interaction. This was an intriguing observation, especially since it contradicts two 
previous findings that concluded palmitoylation-defecient CD151 does not localise 
nor recruit 3 integrin into the light fractions of SDG.  
 In the first study, SDG was performed on MDA-231 cells with or without 2-
Bromopalmitate treatment (a potent inhibitor of protein palmitoylation). No 
difference was observed in the distribution of CD151 and 3 integrin between these 
two lysates (Berditchevski et al., 2002). However, the SDG was performed under non-
detergent condition which does not discriminate TERM assemblies from ‘larger 
indiscriminate pieces of membrane’ that are usually produced under this condition. 
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This may explain why, in their study, the CD151/α3β1 complexes were not recruited 
into the light fractions (fractions 1-3) of the SDG. Similarly, in this study, SDG 
performed under 1% Brij98 condition did not show any difference in the distribution 
α3β1 integrin even in the absence of CD151 (Figure 3.16). In the second study, 
introduction of palmitoylation tetramutant of CD151 failed to localise CD151 and 3 
integrin into the light fraction of 1% Brij 96 SDG (Yang et al., 2002), a condition that 
we used in our study. One possible explanation for this discrepancy is that their 
assay was performed using an N-terminal tagged CD151 palmitoylation tetramutant 
construct and this may have a bearing on how the protein interacts with its 
microenviroment. Furthermore, CD151(PLM) used in this study is mutated at all six 
palmitoylation sites as previously described (Berditchevski et al., 2002).  
 While the recruitment of 3 1 integrin by CD151(PLM) into the light fractions 
of SDG would rely on their tight association, the ability of CD151(QRD) mutant to 
recruit 3 integrin into the light fractions would solely depend on its capacity to form 
or be recruited into TERM. These two results, taken together, imply that CD151 is 
distributed into, and recruits 3 1 integrin into the light fraction of 1% Brij 96 SDG as 
part of [ 3 1/CD51/TERM] complex as well as separate entities. And this entity may 
consist of [ 3 1/CD51] complex or [ 3 1/CD151/non-TERM] components. 
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3.3  CD151’s role in glycosylation of  integrin 
 The N-linked glycosylation pathway is a multistep process with various 
factors influencing the glycosylation profile of the end product. Glycosidases and 
glycosyltransferases present within the endoplasmic reticulum (ER) and Golgi 
apparatus contributes through enzymatic modification while various chaperones 
determine when and where these modifications occur. The synergy between the 
enzymatic components and trafficking machinery determines the final glycosylation 
product. Tetraspanin function has largely been attributed to membrane associated 
complex formation and trafficking. Therefore, we hypothesised that CD151 may be 
influencing the glycosylation of 3 1 integrin by recruiting and channelling it to a 
specific pathway during the glycosylation process. To determine how or where 
CD151 exerts it influence along the glycosylation pathway, chemical inhibitors which 
terminate the glycosylation process at various stages were introduced into the 
growth medium. Inhibitor treated and untreated MDA-231 CD151 (+) and CD151 (-) 
cell lines were then harvested and comparison of their  integrin light chain 
fragment mobility on Western blot was made. 
The progression of the glycosylation process can be inhibited at various stages using 
different inhibitors as summarised in Figure 3.22 
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Figure 3.22 Inhibition of the glycosylation pathway with various chemical 
inhibitors. 
(i)Tunicamycin (TM) inhibits the transfer of N-acetylglucosamine-1-phosphate from 
UDP-N-acetylglucosamine to dolichol phosphate, blocking the synthesis of all N-
linked glycan. Deoxynojirimycin (DNJ) and Castanospermine (CST) inhibits 
glucosidase I and glucosidae II. Kifunensine (KIF) is a strong inhibitor of ER -1,2- 
mannosidase I and Golgi mannosidase I while Deoxymannojirimycin (DMJ) mildly 
and strongly inhibits ER mannosidase I and Golgi mannosidase I respectively.  
Swansonine (SW) is a strong inhibitor of Golgi -mannosidase II.  The progression of 
the glycosylation process can be inhibited with these compounds at various stages. 
Inhibition with CST or DNJ can also be used to distinguish between glycoproteins 
that commit to the conventional ER mannosidase pathway and the Endo 
(i) 
(i) 
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mannosidase pathway. (ii) Chemical structure of various glycosylation inhibitors 
used in this study 
 
 
3.3.1 Inhibition of the glycosylation pathway to determine the site of CD151’s 
influence on  integrin glycosylation 
 CD151 has previously been reported to associate with  integrin during the 
very early stage of secretory pathway transition either in the ER or pre-Golgi 
compartments. This stable association is suggested to precede even the  dimer 
formation (Berditchevski et al., 2001). Consequently, I mapped CD151’s influence on 
glycosylation of  integrin by inhibiting the glycosylation pathway progression at 
the early stages. MDA-231 CD151 (+) and (-) cells were grown in the presence of 
kifunensine, deoxymannojirimycin and swansonine, and cell lysates were analysed 
by Western bloting for  integrin. The detailed experimental procedure is presented 
in the Materials and Methods section.  
 The difference in the mobility of 3 integrin light chain between the two cell 
lines were maintained when the glycosylation progression is inhibited in cis (Golgi 
mannnosidase I) and medial Golgi (Golgi mannosidase II) [stage (E) and (G) 
respectively in Figure 3.22]. However, inhibition of ER mannosidase I with 
kifunensine revoked this difference [stage (D) in Figure 3.22] (Figure 3.23). Based on 
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this observation, CD151’s influence on glycosylation of 3 integrin can be traced to 
the trimming of the first mannose residue in the ER.  
 
 
Figure 3.23  Western blot analysis of 3 integrin light chain upon inhibition of the 
glycosylation pathway. 
MDA-231 CD151(+) and CD151 (-) were grown in the absence or presence of various 
glycosylation pathway inhibitors (Swainsonine, 2µg/ml; Deoxymannojirimycin, 
2mM; Kifunensine, 2µg/ml) for 2-3 days, harvested and analysed by Western blotting 
for 3 integrin light chain. In the absence of inhibitors, difference in mobility is 
observed between CD151(+) (lane 1) and CD151(-) (lane 2) cells. Inhibition of the 
Golgi mannosidase II in the medial Golgi with swansonine (SW) maintained this 
difference (lanes 3 and 4). The difference between the two cell lines was still 
exhibited when treated with deoxymannojirimycin (DMJ) which predominantly 
inhibits Golgi -mannosidase I in cis Golgi (lanes 5 and 6). However, inhibition of ER 
-mannosidase I with kifunensine (KIF) abrogated this difference (lanes 7 and 8).   
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3.3.2 Partial characterisation of glycosyl moieties on  integrin purified from 
MDA-231 CD151(+) and CD151(-) cell lines 
 I have identified that CD151 influences the glycosylation of 3 integrin from 
the very first mannose trimming stage. In order to determine how changes in the 
early stage can affect the final glycosylation status of the integrin, I performed a large 
scale purification of the integrin from MDA-231 CD151(+) and CD151(-) cells and 
compared their lectin binding property on Western blot. Large scale purification of 
3 1 integrin from MDA-231 CD151(+) and CD151(-) was performed using anti-  
mAb (A3-IVA5) coupled to CNBr-activated beads. Lectins are protein or 
glycoproteins capable of binding to specific carbohydrate moieties. Due to their 
substrate specificity, they are often used to identify the presence of specific 
glycotopes. Detection with lectins that showed clear results was repeated with a fresh 
batch of purified integrins to confirm their binding pattern and the result is 
presented in Figure 3.24. 
 From the four lectins used in this study, two of them UEA I and PHA-E, 
showed altered binding capacity towards 3 and 1 integrin subunits. PHA-L and 
WGA did not show any difference in their binding capacity towards either subunit.  
 
 
153 
 
 
Figure 3.24 Western blot analysis of lectin binding assay on  integrin purified 
from MDA-231 CD151(+) and CD151(-) cells. 
Purified integrins from MDA 231 CD151(+) [lanes 1, 3, 5, 7 and 9] and CD151(-) [lanes 
2, 4, 6, 8 and 10] cells were resolved on a 10% SDS PAGE gel. Equal loading was 
confirmed by Western blot for  integrin (lanes 1 and 2). The red arrows represent 
positions of the integrin subunits on Western blot. The purified integrins were 
compared for their lectin binding property with four lectins: PHA-E (  linked 
GlcNAc) [lanes 3 and 4], PHA-L (  linked GlcNAc) [lanes 5 and 6], UEA I (  
linked fucose) [lanes 7 and 8] and WGA (GlcNAc and sialic acid) [lanes 9 and 10]. 
Depletion of CD151 resulted in marked decreased of  linked GlcNAc (lanes 3 
and 4) and almost complete loss of 1-2 linked fucose (lanes 7 and 8) that adorn the 
3 subunit and its associated partner, 1 subunit. The binding of PHA-L and WGA 
was not affected. [UEA I: Ulex Europaeus Agglutinin I; WGA: Wheat Germ 
Agglutinin; PHA-E: Phaseolus vulgaris Erythroagglutinin; PHA-L: Phaseolus 
vulgaris Leucoagglutinin ] 
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3.3.3  The effect of tetraspanin CD151 depletion on cell surface glycotope 
presentation 
 So far, my results indicate that depletion of CD151 did not change the cell 
surface expression levels of any of the proteins analysed (Figure 3.2).  However, it 
did change the glycosylation of  integrin even though it did not have an 
apparent effect on the glycosylation of all other cell surface proteins analysed (Figure 
3.9). In order to determine if CD151 may change the glycosylation of cell surface 
proteins other than 3 1 integrin, I analysed the lectin binding property of MDA-231 
CD151(+) and CD151(-) cells by flow cytometry. A panel of lectins which recognise 
various glyco-motifs were used in this analysis and relative abundance of each 
glycan was compared between parental and CD151 depleted cell line. The panel of 
lectins used in this study as described previously in Table 2.5 is listed below:  
Biotinylated Lectin Glycan epitope 
ConcanavalinA α-linked mannose 
Aleuria aurantia Lectin fucose linked (α -1,6) to N-acetylglucosamine 
or fucose linked (α -1,3) to N-
acetyllactosamine 
Dolichos biflorus agglutinin α-linked N-acetylgalactosamine 
Peanut Agglutinin galactosyl (β-1,3) N-acetylgalactosamine 
Phaseolus vulgaris 
Erythroagglutinin 
bisecting complex N-glycan  
Phaseolus vulgaris 
Leucoagglutinin 
Tri- and tetra- antennary N-linked glycans 
containing ( β-1,6) linked N-
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acetylglucosamine 
Ricinus communis agglutinin 
I 
Terminal galactose and to a lesser degree, N-
acetylgalactosamine. 
Sambucus nigra agglutinin (α-2,6) sialic acid attached to terminal 
galactose in and to a lesser degree, (α-2,3) 
linkage 
Soybean Agglutinin Terminal α- or β-linked N-acetylgalactosamine 
and to a lesser extent, galactose residues. 
Ulex europaeus Agglutinin I glycoproteins and glycolipids containing (α-
1,2) linked fucose residues 
Wheat Germ Agglutinin N-acetylglucosamine and sialic acid 
 
 Depletion of CD151 reduced the cell surface binding capacity of UEA I by 52% 
and SBA by 43% (Figure 3.25).  These two lectins specifically recognise 1-2 linked 
Fucose (UEA I) and terminal  or  linked N-acetylgalactosamine or galactose 
residues (SBA). All other lectins tested did not show significant difference in their 
binding capacity towards MDA-231 CD151(+) and CD151(-) cells. Interestingly, while 
the lectin blot assay on 3 1 integrin reflects the cell surface UEA I binding property, 
the Western blot analysis was not in agreement with flow cytometry data on PHA-E 
binding property (Figures 3.24 and 3.25).  
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Figure 3.25 Flow cytometry analysis of lectin binding assay performed on MDA-
231 CD151(+) and CD151(-) cell lines. 
The lectins used for this experiment are Aleuria Aurantia Lectin (AAL), 
Concanavalin A (CON-A), Dolichol Bifloris Agglutinin (DBA), Peanut Agglutinin 
(PNA), Phaseolus vulgaris Erythroagglutinin E (PHA-E), Phasoelus vulgaris 
Leucoagglutinin L (PHA-L), Ricinus Communis Agglutinin I (RCA I), Sambucus 
Nigra Agglutinin (SNA), Soybean Agglutinin (SBA), Ulex Europeus Agglutinin I 
(UEA I) and Wheat germ Agglutinin (WGA). Depletion of CD151 in MDA-231 cell 
line resulted in a striking decrease in UEA and SBA binding capacity on the cell 
surface (black arrows). These lectins bind 1-2 linked Fucose and terminal  or  
linked N-acetylgalactosamine respectively. Data is collated from three separate 
experiments. Raw data for all three experiments are presented in Appendix (2). (*) 
indicates significant difference between parental and depleted cell line (P < 0.05). (*) 
MFI ratio is calculated as follows: (MFI detected in depleted cell line/MFI detected in 
parental line). 
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3.3.4 The effect of tetraspanin depletion on cell surface glycosylation profile 
 Western blot comparison of 3 integrin light chain fragments in CD9, CD63 
and CD81 depleted MDA-231 cell lines showed a difference in the mobility of the 
integrin only in the CD9 depleted cell line (Figure 3.7). However, all three 
tetraspanins are known to associate with other glycosylated protein. In fact, CD81 
has been shown to influence the glycosylation of its primary partners, EW1/2 (Stipp 
et al.,  2003) and CD19 (Shoham et al.,  2006). Furthermore, glycosylation of H,K, 
ATPase  subunit, a CD63 partner, is important for lysosomal targeting (Vagin et al.,  
2004). Therefore, we investigated if depletion of these tetraspanins had any 
consequences on various glycotope presentation on the surface of MDA-231 cells. 
Using the same panel of lectins we used previously, cell surface lectin binding assay 
was performed and analysed by flow cytometry.  
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Figure 3.26 
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Figure 3.26….continued 
 
Figure 3.26 Flow cytometry analysis of lectin binding assay performed on MDA-
231 parental and tetraspanin depleted cell lines.  
Comparison was made between parental and CD9 depleted (A), CD63 depleted (B) 
and CD81 depleted (C) MDA-231 cell lines for their lectin binding capacity. The 
graphs represent an averaged result from three independent experiments. The lectins 
used for this experiment are Aleuria Aurantia Lectin (AAL), Concanavalin A (CON 
A), Dolichol Bifloris Agglutinin (DBA), Peanut Agglutinin (PNA), Phaseolus vulgaris 
Erythroagglutinin E (PHA-E), Phasoelus vulgaris Leucoagglutinin L (PHA-L), 
Ricinus Communis Agglutinin I (RCA I), Sambucus Nigra Agglutinin (SNA), 
Soybean Agglutinin (SBA), Ulex Europeus Agglutinin I (UEA I) and Wheat germ 
Agglutinin (WGA). Raw data for all three experiments are presented in Appendix 
(2). (*) indicates significant difference between parental and depleted cell line (p < 
0.05). (*) MFI ratio is calculated as follows: (MFI detected in depleted cell line/MFI 
detected in parental line). 
  
 Depletion of CD9 resulted in 100% increase of cell surface level of 2-6 linked 
sialic acid based on their SNA binding capacity, as well as a 22% decrease in SBA and 
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29% decrease in UEA binding capacity. Binding of other lectins did not show obvious 
difference [Figure 3.26 (A)].  Depletion of CD63, on the other hand, resulted in a 
general increase in the binding capacity of all lectins. Specifically, UEA I and PNA 
(galactosyl ( -1,3) N-acetylgalactosamine) binding increase by 100% while SNA and 
SBA binding increase by 56% and 51% respectively [Figure3.26(B)]. And finally, 
depletion of CD81 resulted in a significant increase (92%) in the level of UEA I (  
linked fucose) binding and a 35% increase in SNA binding capacity [Figure 3.26(C). 
Interestingly, depletion of all four tetraspanins, CD151, CD9, CD63 and CD81, seems 
to affect  linked fucosylation in MDA-231 cells. Depletion of CD151 and CD9 
reduced while depletion of CD63 and CD81 significantly increased their cell surface 
expression.  
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3.3.5 DISCUSSION 
 Inhibition of the glycosylation pathway at various stages of glyco-maturation 
identified the first mannose trimming stage as the starting point of CD151’s influence 
on the glycosylation of 3 integrin. Upon inhibition of ER -mannosidase I by 
kifunensine, the mobility of 3 integrin light chain fragment from MDA-231 
CD151(+) and CD151(-) cell lines were similar (Figure 3.23, lanes 7 & 8). This 
observation also indicates that within the ER, the integrin is processed by a 
kifunensine sensitive ER -mannosidase I (Weng and Spiro 1993a). However a 
difference in their mobility was detected when inhibition was performed with 1-
Deoxymannojirimycin (DMJ), a specific inhibitor of Golgi -mannosidase I (Bischoff 
and Kornfeld, 1984). Migration of 3 light chain fragment from CD151(+) cell line 
was slower than in CD151 (-) cells when analysed by Western blot (Figure 3.23, lanes 
5 & 6). DMJ was initially reported as a potent Golgi -mannosidase I inhibitor, but 
was later shown to inhibit ER -mannosidases as well. However, due to their much 
lower potency compared to kifunensine, it has been suggested that they may not 
efficiently inhibit all ER mannosidase I activity (Elbein et al.,  1990; Weng and Spiro 
1993a).  
 The best approach to determine how CD151 alters the glycosylation of 3 
integrin subunit would be to perform a mass spectrometry analysis of the integrin’s 
glycan structures from the two cell lines, upon various glycosylation inhibition 
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treatments. However, since those experiments were not performed in this study, we 
suggest here a few possibilities on how CD151 may influence the glycosylation of 3 
integrin. The presence of CD151 may impose a conformational restraint that restricts 
the mannose-processing in 3 integrin subunit within the ER. Another plausible 
explanation is that, CD151 which has been trimmed by ER mannosidase I, exits the 
ER and inadvertently, bring along with it its tightly associated partner, α3β1 integrin, 
eventhough the integrin has not been trimmed by ER mannosidase I. The tight 
association between CD151 and 3 1 hastens the integrin’s exit from ER, resulting in 
an unprocessed higher molecular weight form (possibly Man9GlcNAc2) being 
presented for trimming by Golgi -mannosidase I. In the absence of CD151, the 3 
integrin subunit is processed by ER -mannosidase I resulting in the slightly reduced 
molecular weight form of the Man8GlcNAc2 isomer (B). This may also explain why 
the glycosylation deficient CD151 is unable to influence the glycosylation of the 
integrin. Alternatively, it could be due to a combination of both events, where 
CD151- 3 1 in its ligated form, due to constrained mannosidase I activity within the 
ER, takes an early exit. As a result, the 3 integrin’s rapid departure from ER in the 
presence of CD151 will make it a substrate for Golgi -mannosidase I which is 
capable of removing all 1,2-manose residues, resulting in a Man5GlcNAc2 structure.  
 The mammalian family of  1,2-mannosidases differ in their kinetics, 
subcellular localisation and substrate specificity (Moremen et al.,  1994). Even though 
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the slow advancing 3 1 integrin from CD151(-) cells will eventually be trimmed to 
Man5GlcNAc2 structure, variation in the high mannose form that reach the Golgi 
makes them preferred substrates for different isomers of Golgi -mannosidase I. The 
Golgi -mannosidase I isomer have previously been shown exhibit substrate 
specificity (Lal et al., 1998; Tempel et al.,  2004), distinct subcompartmentalisation 
within the Golgi and cell specificity (Igdoura et al.,  1999). Consequently, changes in 
the kinetics of mannose processing upon CD151 depletion may change the 
compartmentalisation of the integrin within the ER, resulting in the altered state of 
3  integrin glycosylation. Furthermore, we found that the glycosylation of CD151 
plays an important role in influencing the 3 1 integrin’s glycosylation (Section 3.1; 
also described in Baldwin et al., 2008). These observations, taken together, may 
indicate that not only the presence of CD151, but glycosylation of CD151 molecule 
itself may recruit or steer the 3 1 integrin towards a select group of mannosidases 
and glycosyltransferases which inadvertently influences the glycosylation of the 
integrin.  
 While CD151 changes the glycosylation of 3 integrin subunit, the type of 
glycan that are presented on 3 will depend on the repertoire of glycosyltransferases 
present in these cells. A good example of this, is how CD151 itself is differently 
glycosylated in MDA-231, MCF7 and HeLa cell lines as observed from the difference 
in their mobility by Western blotting (Figure 1). In order to determine the glyco-
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modification induced by CD151 in MDA-231, a comparison was made on the lectin 
binding capacity of 3 integrin purified from CD151(+) and CD151(-) cells. Depletion 
of CD151 showed a marked decrease in the level of 1,2-linked Fucose and bisecting 
GlcNAc- (1-4) linked glycans presented on the 3 1 integrin. Both glycan structures 
have been shown to play a role in metastasis as described in the Introduction 
chapter. Fucosylation is especially important to enhance selectin binding and homing 
of haematopoietic cells. Increased expression of 1,2-linked Fucose which forms 
Lewis b/y antigen structures is a poor prognosis for lymph node negative breast 
carcinomas (Madjd et al.,  2005). Consequently, it is interesting to note that CD151, 
identified as a metastasis promoter in breast cancer seem to promote the presentation 
of these antigens on 3 1 integrin. Furthermore, analysis of the cell surface glycan 
expression showed a marked decrease in the expression of 1,2-linked Fucose on the 
cell surface. The bisecting GlcNAc- (1-4) branching detected with PHA-E has a more 
ambiguous role in metastasis (as described in the Introduction chapter - 1.5.3). This 
characteristic reflects the pro-and anti-metastatic stance CD151 molecules assume 
based on their environment. Incidentally, we observed a decrease in the level of 
PHA-E binding by 3 1 integrin upon CD151 depletion even though the surface 
expression of this glycotope was not duly effected.  
 Analysis of cell surface glycan presentation in MDA-231/ CD9, CD63 and 
CD81 depleted cells gave an interesting result. Notably, depletion of CD9 doubled 
the level of 2-6 linked sialic acid, another tumour associated glycan, presented on the 
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cell surface. Depletion of CD81 on the other hand, doubled the level of cell surface 
1,2-linked Fucose. Though the consequences of these changes is still unknown, it is 
interesting to note that these tetraspanins seem to modulate the cell surface 
expression of various tumour associated glycans. Depletion of CD63 on the other 
hand resulted in a general increase of all the cell surface glycans probed for. This 
result may mean that CD63 plays an important role in glycosylation. On the other 
hand, CD63 is also known for its role as a major lysosomal targeting glycoprotein 
with a –GYEVM- lysosome targeting motif on its C-tail (Metzelaar et al.,  1991). 
Consequently the accumulation of cell surface glycotope upon CD63 depletion may 
be due to sluggish internalisation and degradation rather than changes to the 
glycosylation process itself. The role that some of these tetraspanins may play in ER-
Golgi-lysosome trafficking will be explored further in the later sections.   
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3.4 Physiological implications of changes in the glycosylation of 3 integrin  
 CD151 has been shown to either promote or suppress tumour progression in 
various studies. These opposing influences is usually attributed to the tetraspanin’s 
interaction with various membrane and cytoplasmic proteins [as reviewed in (Stipp, 
2010)]. However, no functional data are available on the consequences of CD151 
mediated glycosylation changes in 3 integrin. In order to determine the contribution 
made by 3 integrin glycosylation to its function, I performed a Bowden chamber 
haptotactic migration assay towards Laminin332 (Lm332), a ligand for 3 1 integrin 
(Nishiuchi et al., 2003). In this investigation, I first performed the migration assay to 
confirm the specifity of 3 1-Lm332 interaction in our model cell line, MDA-231. 
Upon confirmation, we designed a migration assay experiment to address the role of 
3 integrin glycosylation in migration towards Lm332.  
 
3.4.1 Establishing the contribution of integrin  and in migration 
of MDA-231 cells towards Lm332 
 In order to confirm the specificity of the interaction between 3 1 integrin and 
Lm332, we performed the migration assay of MDA-231 cells in the presence or 
absence of function blocking antibody to 3 integrin subunit (A3-IVA5). We also 
used A3-X8 antibody which has been shown to slightly inhibit cell migration 
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(Hintermann et al.,  2001). Integrins 6 1 and 6 4 on the other hand bind to several 
types of laminins including Lm332.  To assess the contribution of the 6 integrins in 
migration, we blocked the integrin’s function with anti- 6 (GOH3) monoclonal 
antibody. In the control experiment, we used the isotype control mAb to a 
cytoplasmic protein (PKC ). An 8 hour of migration was performed and the number 
of cells that migrated toward Lm332 was scored. 
 A bar chart comparing the migratory potential of MDA-231 cells upon various 
antibody treatments is presented in Figure 3.27. Pre-incubation of MDA-231 cells 
with a mildly blocking antibody, A3-X8, reduced the migration potential of these 
cells towards Lm332 by almost 50% compared to pretreatment with an isotype 
control, anti PKC. In cells preincubated with 3 1 blocking antibody, A3-IVA5, their 
migration potential was inhibited by 88% compared to the isotype control. 
Interestingly, pre-incubating the cells with GOH3 mAb which blocks the function of 
6 integrins reduced the migration potential of these cells compared to isotype 
control by 41%. However, the level of inhibition was not dissimilar to level of 
inhibition observed upon A3-X8 pretreatment which mildly blocks 3 1 integrin 
function during cell migration. In both cases, ~50% decrease was observed compared 
to the isotype control. The drastic decrease in migration potential upon blocking of 
3 1 integrin function with A3-IVA5 antibody shows that under these experimental 
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conditions, migration of MDA-231 cells towards Lm332 is predominantly mediated 
by 3 1 integrin.  
 
Figure 3.27 Migration potential of MDA-231 cells towards 2µg/ml Lm332 upon 
various antibody treatment. 
Cells were prepared for migration assay by preincubating with mAb (10µg/ml) for 30 
min at 40C. MAbs used are: A3-IVA5 (anti- 3 integrin subunit), GOH3 (anti- 6 
integrin subunit), A3-X8 (anti- 3 integrin subunit) and isotype control, anti-PKC. 
Cells were allowed to migrate towards Lm332 for 8hrs and migrated cells were fixed 
and counted. Data are presented as average number of migrated cells per 
microscopic field (10X objective). Results are shown as mean + SD calculated from 
two separate experiments, each performed in duplicates. p values are calculated 
using a two tailed t test. The values at the base of the bar represent the average 
number of cells per viewing field. Raw data for this experiment is presented in 
Appendix 3. 
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3.4.2 Establishing the role of 3 1 integrin glycosylation in migration towards 
Lm332  
 Having established that 3 1 integrin plays a major role in migration of MDA-
231 cells towards Lm332, I then went on to investigate the role played by CD151 and 
CD151 mediated glycosylation of 3 1 integrin in migration towards the ligand. For 
this specific purpose, I selected a panel of MDA-231 cell lines:  MDA-231 CD151 (+), 
MDA-231 CD151 (-), MDA-231 CD151 (-) reconstituted with wild type CD151 or 
glycosylation mutant CD151. I also included a MDA-231 3 integrin knock down cell 
line in this experiment. Knock-down of 3 integrin level in the MDA-231 sh( 3) cell 
line was confirmed by Western blot and flow cytometry analysis (Figure 3.28).  
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Figure 3.28  Flow cytometry and Western blot analyses of MDA-231 3 knock 
down cell line. 
(A) Cell surface expression of 3 1 integrin in the parental and 3 knock-down cell 
lines were analysed by flow cytometry with anti- 3 mAb, A3-IVA5. The mean of 
fluorescent intensity value for 3 integrin reduced from 42.3 to 1.03 upon depletion 
of the integrin. (B) MDA-231 ( 3+) and ( 3-) cell lysate was resolved by 12% SDS-
PAGE and analysed by Western blot for 3 integrin and actin levels. The integrin 
was almost completely depleted in MDA-231 3(-) (lane 2) cell line while actin levels 
confirms equal loading. 
  
 Migration assay to determine if changes in glycosylation of 3 integrin has 
any influence on ligand interaction, was performed under the same conditions with 
MDA-231 CD151(+), CD151(-), CD151 wild type reconstitution [CD151(REC)], CD151 
glycosylation mutant reconstitution [CD151(GLY)] and CD151(+)/ 3(-). We included 
MDA-231 CD151 glycosylation mutant (CD151 GLY) cell line in this study since 
171 
 
glycosylation mutation of CD151 retained all the biochemical properties of wild type 
CD151 but exihibited CD151(-) phenotype in relation to glycosylation of 3 integrin 
subunit.   
 The migration potential of MDA-231 cells towards Lm332 is reduced by 91% 
upon CD151 depletion (Figure 3.29). Re-expression of wild type CD151 restored the 
migration potential of MDA-231 CD151(-) cell line by (129%) compared to the control 
[CD151(+) cell line]. However, CD151 glycosylation mutant was unable to restore the 
migration potential of these cells to wild type levels and remained reduced at 17.5%. 
Migration of 3 1(-) cells were also greatly affected: 25.5% compared to the parental 
line. The inability of CD151(GLY) to restore the migration potential of these cells 
towards Lm332 and the result obtained with 3 1 depleted cells shows that under 
these conditions, migration of MDA-231 cells towards Lm332 is predominantly 
through its interaction with 3 integrin and is dependent on the glycosylation of the 
integrin.  
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Figure 3.29 Migration potential of various MDA-231 derived cells lines towards 
2µg/ml Lm332. 
Haptotactic migration assay of various MDA-231 cell lines (wild type, CD151(-), 
CD151 reconstituted, CD151 glycosylation mutant and α3 integrin subunit knock-
down) towards Lm332 was performed for 8hrs. Migrated cells were fixed, 
permiabilised, stained with Hoechst 33342 and counted. The data are presented as 
average number of cells per microscopic field (10X objective). Results are shown as 
mean + SD calculated from two separate experiments, each performed in triplicates. 
The values at the base of the bar represent the average number of cells per viewing 
field. Raw data for this experiment is presented in Appendix 4. 
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 To determine the extent to which CD151 influences the migration potential of 
MDA-231 cell, migration assay was performed under the same condition except the 
membrane was coated with 10µg/ml of fibronectin. Fibronectin is not a natural 
ligand for 3 1 integrin. No significant differences were observed in migration 
potential of MDA-231 CD151(+) and CD151(-) towards fibronectin under this 
condition (Figure 3.30). This result further emphasises the specificity of CD151/ 3 1 
interaction to Lm332 and the role played by 3β1 integrin glycosylation in migration 
towards Lm332.  
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Figure 3.30Migration potential of various MDA-231 CD151(+) and CD151(-) cell 
lines towards 10µg/ml fibronectin. 
Haptotactic migration assay towards fibronectin was performed and data are 
presented as average number of cells per microscopic field (10X objective). Results 
are shown as mean + SD calculated from two separate experiments, each performed 
in quadruplicates. Depletion of CD151 did not have a significant impact on the 
migration potential of MDA-231 cells towards fibronectin. The values at the base of 
the bar represent the average number of cells per viewing field.  Raw data for this 
experiment is presented in Appendix 5. 
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3.4.3 Adhesion assay 
 It has previously been reported that presence of CD151 stabilises the active 
conformation of 6 integrins and is important for adhesion strengthening in NIH 3T3 
cell line (Lammerding et al.,  2003). This characteristic was, however, attributed to 
CD151’s interaction with cytoskeletal component. In this study we wanted to 
determine if CD151 and CD151 mediated glycosylation of 3β1 integrin contributes 
to direct ligand binding by performing a 30 minute static adhesion assay. For this 
purpose, adhesion assay was performed on 1µg/ml Lm332, 2µg/ml Lm332, 10µg/ml 
fibronectin and 10µg/ml BSA.  
 The results show no difference in attachment of MDA-231 CD151(+) and 
MDA-231 CD151(-) to Lm332 or fibronectin in 30 min static adhesion assay (Figure 
3.31). Results from migration assay and adhesion assay taken together seem to 
indicate that CD151 mediated glycosylation changes to 3 integrin influences a 
specific type of interaction between the integrin and its ligand, Lm332. 
 
 
 
 
 
176 
 
 
         
Figure 3.31   Adhesion assay of MDA-231 CD151(+) and CD151(-) to Lm332 and 
fibronectin. 
30 minute adhesion assay was performed with BCECF-AM-labelled MDA 231 
CD151(+) (red bar) and CD151(-) (green bar) cells on Lm332 (1µg/ml and 2µg/ml 
concentrations), Fibronectin (10µg/ml) and BSA (10µg/ml). No difference was 
observed in the binding capacity of the two cell lines towards the matrices. The 
experiment was performed in triplicate and the calculated percentage of adherent 
cells for each experiment is presented in Appendix 6. 
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3.4.4 Comparison of 3 integrin light chain that bind to GD6 peptide and to A3-
IVA5 monoclonal antibody  
 It has previously been reported that a synthetic peptide corresponding to 
residues 3011-3032 of murine Laminin 1 chain is capable of binding to 3 1 integrin 
from detergent extracts of human melanoma cell line, C8161 (Gehlsen et al.,  1992). 
This peptide sequence, KQNCLSSRASFRGCVRNLRLSR, also known as GD6 
peptide, carries a 67% homology to human laminin 1 subunit, one of the 
components of Laminin111. Even though Lm111 is not a primary ligand for 3 1 
integrin, it is still capable of binding to this integrin, albeit, with a lower affinity 
compared to Lm332. Consequently, I decided to compare the glycosylation profile of 
3 integrin from MDA-231 CD151(+) and CD151(-) cell lines that interacts with this 
peptide, in order to determine if glycosylation of the integrin plays a role in binding 
to this ligand fragment.  
 GD6 peptides were coupled to activated CH-Sepharose and incubated with 
cell lysate prepared from MDA-231 CD151(+) and MDA-231 CD151(-) cell lines. 
Bound proteins were eluted, resolved on a 12 % SDS PAGE and analysed by Western 
blot for 3 integrin light chain fragment. As a control, cell lysate from both the cell 
lines were incubated with CH-Sepharose beads in the absence of GD6 peptide. 3 
light chain fragments were also immunoprecipitated with anti- 3 antibody, A3-
IVA5, and analysed by Western blot for comparison. 
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 Western blot analysis of 3 integrin immunoprecipitated with anti- 3 
antibody showed a difference in the mobility between 3 purified from CD151(+) 
and CD151(-) cells [(Figure 3.32A)]. The GD6 peptide pull down on the other hand 
strongly interacted with a distinct pool of glycoforms of the integrin, resulting in the 
loss of difference in the 3 integrin pulled down from the two cell lines [(Figure 
3.32(B)]. This result seems to suggest a role played by glycosylation of 3 integrin in 
their binding capacity. Based on their Western blot profile, the GD6 peptide seems to 
prefer the two lower molecular weight glycoforms of 3 integrin which are highly 
expressed in CD151(+) cells but are reduced in the CD151(-) cells. 
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Figure 3.32  Western blot comparison of 3 integrin light chain from A3-IVA5 
mAb IP and GD6 peptide pull down. 
(A) A3-IVA5 Immunoprecipitation of 3 1 integrin from MDA-231 CD151(+) (lane 1) 
and MDA-231 CD151(-) (lane 2) Note the difference in the mobility of 3 subunit 
light chain fragment. (B) GD6 peptide purified 3 1 integrin from MDA-231 
CD151(+) (lane 1) and MDA-231 CD151(-) (lane 2) shows no difference in their 
mobility on Western blot. As a control to eliminate non-specific binding of 3 1, 
lysate was incubated with beads without GD6 peptide (Ctr lane). The eluate was 
resolved by 12% SDS-PAGE and detected by Western blot with anti- 3 pAb. The 
Western blot data clearly shows that a peptide based on biological ligand seems to 
interact with a specific glycoforms of 3 1 integrin from both cell lines.  
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3.4.5   Laminar  flow assay  
 Saccharides that form a lattice on the cell surface have been shown to slow 
down fast flowing leukocytes till they settle to a rolling motion on endothelial cell 
surface. Interactions between the Lewis antigen structures, presented on their cell 
surface glycoproteins such as PSGL-1 and CD44, with selectin molecules presented 
on the endothelial cell surface initiate this process. These interactions allows the 
leukocytes within the vasculature to adopt a rolling motion and tether to the cell 
surface before firmly anchoring to the endothelial cells through receptor-ligand 
interactions (Ley et al.,  2007). Various studies have proposed that circulating tumour 
cells adopt the same mechanism when disseminating to secondary sites when it was 
found that P-Selectin deficiency and E-Selectin blocking attenuated metastasis (Kim 
et al.,  1998; Kobayashi et al.,  2000). In order to investigate the role of CD151 and 
CD151 mediated glycosylation in this rolling and tethering mechanism, I conducted a 
series of flow assays against various immobilised compounds/ligands.  
 MDA-231 cells were flown at three different rates (0.085ml/min 0.175ml/min 
and 0.35ml/min) into a flat micro slide tube precoated with E-Selectin, P-Selectin and 
Laminin 332 at saturating concentrations. The tumour cells did not appear to roll on 
these ligands; instead they steadily flew through the capillary tube. Following that, 
cell stream was halted mid flow for up to 5 minutes before resuming at the same flow 
rates. Upon restarting the flow, all the cells washed off from the coated surface. Since 
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firm interaction between the tumour cells and the matrix was not achieved within 5 
minutes to withstand the subsequent shear force, a different approach was employed 
to study the interaction between tumour and endothelial cells. The flow assay was 
conducted on a monolayer of human umbilical vein endothelial cells (HUVEC), 
grown within microslides. The tumour cells were allowed to flow on the bed of 
HUVEC at different flow rates (0.085ml/min, 0.175ml/min and 0.35ml/min) to 
determine the best rate for them to roll like leukocytes on the endothelial layer. 
Again, no rolling was observed at these flow rates. Attempts at a lower flow rate 
clogged the tumour cells within the tubing network.  
 
3.4.6 Endothelial rolling assay 
 It is generally thought that tumour cells escape through the vasculature to 
secondary sites by attaching itself to circulating leukocytes and thrombocytes or 
within a capillary bed. Both processes can clog and temporarily arrest tumour cell 
flow. In leukocytes, integrin function have been shown to become activated at slow 
rolling and tethering stage (McEver and Zhu, 2010). To explore this angle of tumour 
cell dissemination in vitro, endothelial monolayer was grown in a microslide and the 
flow of MDA-231 cells in these microslides was halted for 5 minutes, 2 minutes and 1 
minute before resuming the flow. The number of tumour cells visible per a 
microscopic field upon initial flow suspension and the number of cells that remain 
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attached after 5 minute wash was scored for both MDA-231 CD151(+) and CD151(-) 
cells. During preliminary analysis, suspending the flow for either 2 minutes or 5 
minutes did not produce significant difference in the ratio of cells that remained 
stuck after 1 minute of wash, between the two cell lines. Stopping the flow for 1 
minute, however, showed a marked difference between MDA CD151 (+) and CD151 
(-) cells. Up to 80% of the MDA 151(+)  cells remained stuck to HUVEC after 5 minute 
wash while only 20% of the MDA 151 (-) cells remained (Figure 3.33, CORD 1). More 
interestingly, I found that when HUVEC from different sources were used, MDA 
CD151(+) and CD151(-) cells showed a varied interaction as presented in Figure 3.33. 
Since the adhesion assay was performed at a short interval of 1 minute, the 
endothelial-tumour cell interaction that’s producing this variation is most likely a 
saccharide based interaction. 
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Figure 3.33  Endothelial attachment assay of MDA-231 CD151(+) and CD151(-) 
cells. HUVECs purified from 4 different umbilical cords were grown as a monolayer 
in a µ slide. The MDA-231 CD151(+) and CD151(-) cells were streamed into the µ 
slide at 0.35mlm/min and the ability of the cells to attach to HUVECS within 1 min 
was assayed by stopping and restarting the pump after 1 minute at the same shear 
rate (0.1Pa) as the flow rate. Cells that remained attached after 5 minutes wash was 
recorded and scored. A batch dependent difference was observed on how quickly the 
tumour cell lines interacted with HUVECs.  
 
 The results generated from 1 minute attachment assay of MDA-231 cells in 
HUVECs clearly shows that in three out of the four cases tested, the presence of 
CD151 effects how quickly the tumour cells bind to the endothelial layer. From the 
four HUVEC preparations collected from different individuals, two of them (Cord 1 
and 3) showed a higher number of CD151(+) cells attaching to the endothelial layer 
compared to CD151(-) cells, one did not distinguish between CD151(+) and (-) cells 
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(Cord 4), while a final one had the opposite effect where CD151(-) cells adhered more 
readily than CD151(+) cells (Cord 2).  
 
3.4.7 Tumour cell transendothelial migration assay 
 Albeit with some inconsistency, CD151 seems to play a role in the ‘pre-
extravasation’ stages of metastasis. To establish whether CD151 is involved in 
extravasation during metastasis, I conducted transendothelial migration assay where 
the transendothelial migration potential of MDA-231 CD151(+) and CD151(-) cells 
across human brain microvascular endothelial cell line (HBMEC 1) was compared. 
The migration assays were performed for 4 hours, 6 hours and 8 hours.  
 The results from this study showed no significant difference in the 
transendothelial migration potential of MDA-231 CD151(+) and MDA-231 CD151(-) 
cells across the endothelial layer at any of the time points recorded (Figure 3.34).     
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Figure 3.34 Transendothelial migration assay of MDA231-CD151(+) and CD151(-) 
cells across HBMEC 1 cells. 
HBMEC-1 endothelial cells were grown as a tight monolayer within the internal 
chamber of tissue culture inserts. 500µl of 10% DMEM containing 2X105 BCECF 
stained MDA-231 cells were introduced into the insert chamber and the 
transendothelial migration assay was performed for 4 hours, 6 hours and 8 hours. No 
difference was observed in the ability of the MDA-231 CD151 (+) / (-) cells to 
transmigrate across the endothelial layer at all three time points. Raw data for this 
experiment is presented in Appendix 7. 
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3.4.8  DISCUSSION 
 
 In this study, I showed that depletion of CD151 in MDA-231 cells had a 
dramatic impact on the ability of the cells to migrate towards Lm332 in a Boyden 
chamber migration assay. Furthermore, while reconstitution of wild type CD151 into 
the CD151(-) cells restored their migratory potential, reconstitution of the 
glycosylation-deficient mutant was unable to do so. CD151(GLY) cell line shared all 
the biochemical properties of wild type CD151, except for the ability to influence the 
glycosylation of 3 integrin. The inability of the CD151(GLY) cell line to restore the 
migration potential to the wild type CD151 level under the same conditions, strongly 
suggests the importance of 3 1 integrin glycosylation pattern in this particular type 
of cell migration. The migration potential of these MDA-231 cells was also reduced 
upon 3 1 integrin depletion. However, the migration potential of these cell were 
almost three times higher than in CD151(-) cells. This results probably reflects the 
trace level of 3 1 integrin expressed by the cells.  
 Blocking of 6 1/ 4 integrin function had a mild inhibitory effect on 
migration of MDA-231 cells towards Lm332, a level comparable to the function 
blocking elicited by another 3 1 blocking antibody, A3-X8. I have earlier shown that 
depletion of CD151 increased the level of 6 clipped variant, 6p, in MDA-231 cells 
(Figure 3.11). Consequently, depletion of CD151 may inhibit migration of MDA-231 
cells towards LM332 by collectively changing the glycosylation profile of 3 1 
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integrin and reducing the number of functional 6 1/ 4 integrin at the cell surface 
through proteolitic cleavage. However, it should be reiterated here that 3 1 is the 
main receptor for Lm332.  Consequently, while both integrins may play a role in 
migration towards Lm332, we predict that 3 1 integrin plays the dominant role in 
inhibiting the migration potential of MDA-231 cells. 
 It has previously been reported that overexpressing glycosyltransferase GnT-
V stimulated while GnT-III inhibited 3 1 mediated cell migration in MNK45 human 
gastric cancer cell line (Zhao et al.,  2006). In this study, the authors hypothesised that 
GnT-III overexpression introduced the bisecting 1-4 linkage which inhibits the 
addition of 1-6 branching by GnT-V and as a result, migration potential of these 
cells towards Lm332 was reduced. A concomitant decrease in GnT-V activity upon 
GnT-III expression and vice versa determines 3 1 migratory potential. However, in 
this study, the decrease in bisecting GlcNAc- (1-4) presentation on 3 1 integrin 
upon CD151 depletion was followed by a corresponding decrease in their migration 
potential. Furthermore, the decrease in PHA-E lectin binding property of 3 1 
integrin was not reciprocated by an increase in PHA-L binding indicating that CD151 
did not affect the level of 1-6 branching on 3 1 integrin. Thus, it is possible that 
decreased (1-4) GlcNAc branching must be accompanied by an increase in (1-6) 
GlcNAc branching for it to have a promigratory effect. Furthermore, in this model 
system, depletion of CD151 also virtually removed all the 1-2 linked fucose from 
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3 1 integrin. 1-2 linked fucosylation is a terminal modification usually attached to 
(1-6) GlcNAc branching. These long ‘broken wing’ conformation serves as a 
‘backbone’ which gives maximum exposure for the terminal 1-2 linked fucose to 
interact with its environment (as discussed in the Introduction chapter). I 
hypothesise that the promigratory effect of increased (1-6) GlcNAc expression may 
indirectly be due to increased fucose residues being expressed on these branches. 
While in this study, depletion of CD151 did not change the level of (1-6) GlcNAc 
branching, the presence of 1-2 linked fucose was almost completely lost. And this 
loss may have contributed to the decrease in migration towards Lm332.  
 Depletion of CD151 specifically effected 3 1(strongly) and 6 1/ 4(mildly), 
mediated cell migration as I found no significant difference in the ability of MDA-231 
CD151(+) and CD151(-) cells to migrate towards fibronectin, a ligand for 5 1 
integrin. Furthermore, depletion of CD151 did not produce much difference in its 
ability to adhere directly on fibronectin or Lm332 in a 30 minute static adhesion assay 
indicating that only a specific type of 3 1 and 6 1/ 4 integrin function is affected. 
Perhaps, the most convincing result we obtained on the contribution of 3 1 integrin 
glycosylation to ligand binding is from the pull-down assay performed with Lm111 
based GD6 peptide (Figure 3.30). Western blot analysis of the 3 1 integrin pool 
pulled down with GD6 peptide showed no difference in 3 integrin light chain 
fragment between the CD151(+) and CD151(-) cell lines even though a difference was 
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detected in the subunit when immunoprecipitation was performed with anti 3 
antibody (A3-IVA5).  
 The importance of integrin glycosylation in receptor-ligand interaction has 
previously been reported for 5 1 and 3 1 integrins. Strategically located N-linked 
glycosylation site have been shown to be crucial for the integrin’s folding and dimer 
formation (Zheng et al.,  1994; Isaji et al.,  2006). More pertinently, it has been 
reported that enzymatic removal 2,8-linked polysialic acids from 5 1 integrin 
inhibited its binding to fibronectin (Nadanaka et al.,  2001). Conversely, desialylation 
of purified 3 1 integrin increased their capacity to bind fibronectin (Pochec et al.,  
2003; Pochec et al.,  2006). These findings imply that glycosylation not only effects 
integrin-ligand interaction, but it may also change the receptor’s affinity towards 
non-conventional ligands.   
 In this study, I found that 1-2 linked fucosylation rather than sialylation was 
affected upon CD151 depletion in MDA-231 cell line. The 1-2 linked fucose 
structure is usually found on lewis b and lewis y antigens, a family of blood group 
antigens. Expression of other members of this blood group antigens such as the lewis 
a and lewis x have been shown to facilitates the rolling of leukocytes on endothelium 
by linking to selectins expressed on the endothelial cell surface (Fuhlbrigge et al.,  
1996). To investigate if 1-2 linked fucose is in anyway involved in selectin 
interaction, I performed laminar flow assay on selectin and Lm332 coated microslides 
with CD151(+) and CD151(-) MDA-231 cells. Additionally, I also simulated 
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‘leukocyte like rolling’ with these tumour cell lines on HUVEC. Neither of these 
approaches induced a leukocyte type rolling in MDA-231 cells. This may be due to 
the tumour cell size (10 m), deeming it unable to withstand the force generated by 
shear flow. A growing body of evidence suggests that tumour cells extravasate from 
vasculature via other mechanisms. One of the most common sites for tumour 
extravasation is while moving through the capillary bed where tumour cells are 
known to be temporarily trapped. In fact, experimental metastasis in mouse models 
show introduction of tumour cells via tail vein injection almost always resulted in 
lung metastasis since this is where the tumour cells encounter its first bed of 
capillaries (Elkin and Vlodavsky, 2001).  Furthermore, interaction of tumour cells 
with other cells such as the leukocytes and platelets have also been shown to 
facilitate its exit from the blood vessel.  
 Building an experimental model to study this type of metastatic modes, our 
initial study showed presence of CD151 hastened the tumour cell attachment to the 
endothelial layer. A fourfold increase was observed in the percentage of MDA-231 
CD151(+) cells able to attach to HUVEC compared to CD151(-) cells within one 
minute. However, the binding efficiency of the two cell lines differed when different 
batches of HUVEC were used. With some batches of HUVEC, CD151(+) cells bound 
more readily than CD151 (-) cells. In other batches, either the opposite or no 
difference was observed on how CD151(+) and CD151(-) cells interacted with 
HUVEC. It has previously been reported that cell surface glycans such as galectin 3 
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and galectin 9 plays an important role in immediate interaction (< 2minutes) with 
laminin 1 (Lm111) (Friedrichs et al.,  2007). Since my experiments showed a 
difference between the two cell lines only at a short interval (1 minute), I hypothesise 
that this interaction too is most probably a glycan based interaction. Furthermore, the 
fact that there is a variation between different batches of HUVEC implies that this 
specific interaction may not be due to 3 1 adhesion strengthening characteristic 
which is typically attributed to CD151. No difference was however observed between 
the two cell lines upon longer incubation (> 2 minutes). This suggests that the 
removal of CD151 did not significantly contribute to the ability of tumour cells to 
attach to endothelial layer. 
 In order to determine if CD151 exerts its influence in these experiments by 
changing the surface glycosylation and not by affecting the 3 1 integrin’s function 
as a cell surface receptor, transendothelial migration assay was performed. No 
difference was observed in the ability of MDA-231 CD151 (+) and CD151 (-) cells to 
migrate through / across the endothelial layer, confirmining that CD151 depletion 
does not affect the receptor-ligand interaction of α3β1 or α6β1/β4’s during 
transendothelial migration. It is also interesting to note that increased cleavage of α6 
integrins to form the α6p variant upon CD151 depletion did not seem to affect their 
ability to migrate across the endothelial layer. A possible explanation for this 
observation is that α6p variant formation occurs on both α6β1 and α6β4 integrins 
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which have opposing effects on cell migration. As a result, it may have negated each 
other’s influence. Furthermore, the abundance of other functional receptors at the cell 
surface such as α3β1 integrin may have a more dominant role as well as sufficiently 
compensate α6p’s influence during transendothelial migration.  
 Taken together, the observations made during both the endothelial rolling and 
transendothelial migration assay is reminiscent of Leukocyte Adhesion Defeciency, 
LAD I and LAD II syndromes. In both cases, a defect in leukocyte adhesion 
deficiency is observed.  LAD I is due to a mutation in the β2 integrin molecule while 
LAD II arise from a genetic defect in Golgi GDP-fucose transporter which results in 
the loss of expression of selectin ligands on leukocytes. In the case of the former, 
leukocytes are able to roll on endothelial cells but are unable to transmigrate through 
the endothelial layer. LAD II on the other hand showed markedly reduced capacity 
for leukocytes to roll but they were able to transmigrate through the endothelial layer 
without any difficulty (Hirschberg, 2001). Depletion of CD151 in MDA-231 cells, in 
most cases, shows a ‘LAD II like’ symptom when it comes to interaction with 
endothelial cells.  A milder and more arbitrary (observed when different batches of 
HUVEC were compared) influence of CD151 depletion compared to LAD II  is most 
probably because it only affects the surface expression of 1,2 linked fucose. Other 
types of fucosylation (i.e 1,3 linked fucose, 1,4 linked fucose or core 1,6 linked 
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fucose) were not greatly affected since their capacity to bind AAL upon CD151 
depletion was not duly altered (Figure 3.25).  
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3.5 Tetraspanin trafficking and function from glycosylation 
perspective 
 Almost all tetraspanins are N-link glycosylated, though the number of 
oligosaccharide branches they carry may differ from one tetraspanin to another. CD9 
and CD151 for example, contain a single N-linked glycan, while CD63 and CD82 
have three potential glycosylation sites. CD81 on the other hand is non-glycosylated. 
Despite glycosylation being a major post-translation modification, relatively little is 
known about the nature of their glycosylation and the physiological the role it may 
have in the tetraspanin molecule’s cellular function. In this part of study, my main 
objective was to investigate the role that glycosylation of tetraspanins may play in 
the molecule’s function. I also show how the glycosylation pathway can be exploited 
for cancer therapy from the integrin perspective. 
 
3.5.1 Characterisation of tetraspanin glycosylation 
 Tetraspanins are characterised as N-linked glycoproteins. In this part of the 
study we looked into the glycosylation nature of CD9, CD63, CD82 and CD151. For 
this purpose, 1% Triton X-100 extracted total cell lysate was treated with glycosidases 
EndoH and PNGaseF. As previously mentioned, EndoH removes high mannose and 
hybrid N-linked oligosaccharides while PNGaseF cleaves off high mannose, hybrid 
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and complex oligosaccharides from the protein backbone. The lysate was then 
resolved on 12% SDS-PAGE and analysed by Western blotting for CD9 and CD151 
(Figure 3.35) as well as CD63 and CD82 (Figure 3.36) under non reducing condition 
for their glycosylation status and profile.  
 
Figure 3.35 Western blot analysis of EndoH and PNGaseF treated MDA-231 cell 
lysate for CD9 and CD151. 
(A): Western blot analysis of endogenous CD151 in MDA-231 gives a diffused 
glycosylated band at ~25kD (lane 1, black arrow). EndoH treated sample shows 
reduction in the intensity of the glycosylated band the appearance of a non-
glycosylated low molecular weight band (lane 2, red arrow). The PNGaseF treated 
sample on the other hand produced only the deglycosylated form of CD151 (lane 3, 
red arrow). (B): Western blot analysis of endogenous CD9 (lane 1) shows the 
presence of a glycosylated (black arrow) and non-glycosylated (red arrow) form of 
CD9. EndoH treatment (lane 2) removes the glycan residues resulting in the 
detection of only the non-glycosylated form. Interestingly, CD9 is resistant to 
cleavage by PNGaseF (lane 3) (WB CD151: anti CD151 polyclonal; WB CD9: C9BB) 
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 Analysis of CD9 and CD151 upon glycosidase treatment confirms that they 
are both N-linked glycosylated proteins. However, we also found that CD9, while 
resistant to PNGaseF treatment, was susceptible to cleavage by EndoH. This is a 
possible indication of phospho-mannosylation, a glyco-modification that commits 
the protein for lysosomal targeting via interaction with mannose-6-phosphate 
receptors. Susceptibility to PNGaseF can be restored upon phosphatase treatment 
(Zhao et al., 1997). 
 
Figure 3.36 Western blot analysis of EndoH and PNGaseF treated MDA-231 cell for 
CD82 and CD63.  
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Western blot analysis of untreated (lane 1), EndoH treated (lane 2) and PNGaseF 
treated (lane 3) lysate for CD82 (A) and CD63 (B) shows the presence of glycosylated 
protein under all three conditions.  
 Analysis of CD63 and CD82 upon glycosidase treatment showed both 
tetraspanins responding only partially to EndoH and PNGaseF mediated 
deglycosylation. Partial resistance to EndoH indicates the presence of complex 
glycans. The presence of CD63 and CD82 glycoforms upon PNGaseF treatment 
suggests that, as with CD9 molecule, CD63 and CD82 too may be subjected to 
phospho-mannosylation.  
 
3.5.2 Mapping the tetraspanin route within ER 
 The observation made on the glycosylation status of CD9 and CD151 indicates 
that even though they are both N-link glycosylated, the nature of their glycosylation 
commits them into different pathways within the ER and Golgi apparatus. 
Trafficking within the ER and Golgi determines the glycan constituent of a 
glycoprotein which, in turn, may contribute to its functional role. Inhibition of the 
glycosylation pathway, as I and others have shown, can be used to track the route 
that a glycoprotein takes during their ER to Golgi transit. In this study, I have 
identified CD9 to be phospho-mannosylated, a modification which will definitely 
contribute to one of its function as a lysosome targeting membrane protein. A 
simplified illustration of the multiple routes that exists within the N-linked 
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glycosylation pathway is presented in Figure 1.13.  Molecules commited to the N-
linked glycosylation process take a conventional glycosylation pathway, 
endomannosidase I pathway or phosphomannosylation pathway. In this study, the 
early routes taken by tetraspanins CD9, CD63, CD82 and CD151 is compared by 
inhibiting the glycosylation pathway with castanospermine, an inhibitor of 
glucosidase I and II. Inhibition with castanospermine allows for the distinction of 
proteins that take the conventional pathway and the endomannosidase pathway as 
illustrated in Figure 3.22.  
 Accordingly, MDA-231 cells were grown in medium supplemented with 
1mg/ml castanospermine for 2 days. Harvested cells were lysed in 1% Triton X-100 
and analysed by Western blotting. The glycosylation profile of CD9, CD63, CD82 and 
CD151 as well as a cell surface glycoprotein, emmprin, was compared to their 
counterpart from untreated cells. Western blot analysis showed all 4 tetraspanins and 
emmprin responding differently to castanospermine treatment (Figure 3.37). 
Emmprin, like CD63 and CD82, has 3 glycosylation sites. Upon castanospermine 
treatment, glycosylation of emmprin is abruptly terminated as seen from the 
appearance of tighter lower molecular weight bands. CD82 on the other hand 
responded very mildly to castanospermine. This may indicate that they are mainly 
committed to the endomannosidase pathway. CD63 too gave two distinct glyco-
populations which were more or less, equally represented. In both CD63 and CD82, 
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the higher molecular weight group (black braket) shows similar profile as the 
untreated sample. A second lower molecular weight smear is also detected (red 
bracket) for these tetraspanins. The presence of two different populations may either 
mean that the upper population represents a ‘leak’ due to insufficient inhibition, 
similar to that seen in emmprin, or that they are committed to more than one 
pathway. Furthermore, the lower molecular weight population generated in 
response to castanospermine treatment did not share the abrupt termination in 
glycosylation seen in emmprin. This observation further suggests that CD63 and 
CD82 are not only committed to more than one pathway, but, inhibition of 
deglucosylation of these molecules did not terminate the glyco-modification of these 
tetraspanins. 
 CD9 on the other hand showed an increase in molecular mass of its 
glycosylated pool upon castanospermine treatment. This is probably due to the 
presence of uncleaved glucose residues. While the mobility of CD151 bands during 
Western blot analysis did not change upon castanospermine treatment, its total level 
was markedly reduced. 
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Figure 3.37 Castanospermine inhibition and Western blot analysis of various 
glycoproteins. 
(A) Presence of castanospermine (Cst) arrests glycan diversification in emmprin and 
a tighter low molecular weight band is observed (+ lane, black arrow, right panel). 
Longer exposure of the blot (left panel) reveals incomplete blocking which ‘leaks’ a 
higher molecular weight smear corresponding to the mature glycosylated form 
detected in untreated sample (- lane,). (B) Glycosylation of CD82 remains mainly 
unaffected by Cst treatment. (C) Cst treatment effects glycosylation of CD63, 
however, there was no abrupt termination as seen with emmprin. Instead, upon Cst 
treatment, CD63 has two groups of glycosylated forms. One of them resembles the 
untreated CD63 profile (black bracket) while a second lower molecular weight 
group is also generated (red bracket). (D) Molecular weight of glycosylated CD9 
population increased upon Cst treatment (black arrow) while the level of CD151 
decreases in the presence of Cst (E). Equal loading of samples was determined from 
Western blot of actin level (F) 
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3.5.3 The effect of castanospermine on  and  integrin subunits 
 Castanospermine’s effect on most of the glycoproteins tested seems to rest 
squarely on their glycosylation except for CD151 where the level of the protein was 
affected. Since CD151 associates tightly with laminin binding 3 and 6 integrins, I 
investigated the effect castanospermine may have on these integrins. Lysate was 
prepared from MDA-231 cells cultured for 2 days with or without 1mg/ml 
castanospermine. Proteins were resolved by 12% SDS PAGE and analysed by 
Western blot for 3 and 6 integrin light chain under reducing condition. 
Remarkably, I found that the level of 3 and 6 integrins was diminished upon 
castanospermine treatment (Figure 3.38).  In order to determine if this is a cell line 
specific response, I analysed for 3 integrin level in two other cell lines, U87MG 
(human neuronal glioblastoma/ astrocytoma cell line) and BT474 (breast cancer cell 
line established from human invasive ductal carcinoma) upon castanospermine 
treatment. Both the cell lines exhibited similar response whereby the level of 3 
integrin was reduced upon castanospermine treatment. However, the level of 
reduction differed between cell lines. This observation indicates that, while 
castanospermine may broadly affects α3β1 integrin level, the level of down-
regulation differed from one cell line to another (Figure 3.39). 
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Figure 3.38 Western blot analyses of 3 and 6 integrins upon castanospermine 
treatment of MDA-231 cell line.  
MDA-231 cells were grown in the absence or presence of 1mg/ml castanospermine 
for 2-3 days, harvest and lysed in 1% Triton X-100. The level of 3 and 6 integrins in 
treated and untreated samples were analysed by Western blot (lower panel). Actin 
level was detected for loading control (upper panel). 
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Figure 3.39 Western blot analyses of 3 integrin in U87MG and BT474 cell lines 
upon castanospermine treatment. 
U87MG (left panel) and BT474 (right panel) cell lines were grown in the presence of 
1mg/ml castanospermine for 3 days. The level of 3 integrin light chain reduced 
upon castanospermine treatment in U87MG cell line (left panels). The α3 integrin 
subunit level was mildly affected upon castanospermine treatment in BT474 cell lines 
(right panels). 
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3.5.4 The effect of castanospermine on other integrins and integrin associated 
proteins 
 
 Integrins, a major cell surface receptor family, play an important role in cell 
adhesion, migration and survival. During tumorigenesis, the expression levels of 
various members of this family have been shown to be upregulated. The pronounced 
effect of castanospermine on the level 3 and 6 integrins would clearly affect the 
potency of cancer cells. Consequently, I investigated the effect castanospermine 
might have on the level of other integrins such as 2, 5 and 1 in MDA-231 cells. 
Furthermore, I also compared the levels of integrin associated proteins such as 
epidermal growth factor receptor (EGFR), Talin and Src. 
 The level of 2 integrin was reduced after incubating the cells in the presence 
of castanospermine for 3 days.  5 integrin, 1 integrins and EGFR on the other hand 
showed a difference in glycosylation but not the levels of the protein based on the 
band shift. The level of talin and Src, two integrin associated cytoplasmic proteins, 
were not affected upon castanospermine treatment (Figure 3.40). 
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Figure 3.40 Western blot analysis of various proteins upon castanospermine 
treatment. 
MDA-231 cells were grown in the presence of 1mg/ml castanospermine for 3 days, 
harvested, resolved by 10% SDS PAGE and detected for various proteins. 
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3.5.5   Castanospermine dosage effect on the level of 3 and 6 integrin subunits 
 Castanopermine’s ability to affect the levels of 2, 3 and 6 integrins besides 
inhibiting the glycosylation of 5, 1 and EGFR indicates a potential use for this drug 
in cancer treatment. This previously undescribed effect of castanospermine on the 
integrins was further investigated by looking at the affect dosage had on the efficacy 
of this drug. For this purpose, MDA-231 cells were grown in DMEM medium or 
DMEM supplement with 0.1mg/ml and 0.5mg/ml castanospermine for 2 days. Cells 
were then lysed in 1% Triton X-100 and analysed by Western blot for 3 and 6 
integrin levels. 
 The reduction in the 3 and 6 integrin levels was higher at 0.5mg/ml 
compared to 0.1mg/ml indicating castanospermine inhibition affects the level of 3 
and 6 integrins in a dose dependent manner (Figure 3.41). However, no difference 
was observed in the level of the integrin when treated with 0.5mg/ml or 1.0mg/ml 
implying a saturation effect. 
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Figure 3.41 The effect of castanopermine dose on the level 3 and 6 integrins.  
Cells were grown in the presence of castanospermine at various concentrations for 2 
days. Western blot analysis of 3 and 6 integrins resolved on 12% SDS PAGE 
clearly shows that suppression of the integrin level is dependent on the concentration 
of castanospermine. The level of the integrins in untreated (UT) (lane 1) sample is 
higher compared to 0.1mg/ml castanospermine (CST) (lane 2) treated sample. The 
level is reduced further when incubated with 0.2mg/ml (lane 3) and 0.5mg/ml (lane 4) 
CST. Comparison of 0.5mg/ml and 1.0mg/ml (lane 5) CST treatment however does 
not show a much difference in the suppression levels indicating under these 
conditions, CST inhibition is saturated at around 0.5mg/ml.  
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3.5.6  DISCUSSION 
 Generally, there are three established pathways that a glycoprotein can follow 
within the ER. Firstly, the conventional pathway when their deglucosylation occurs 
prior to ER mannosidase trimming. Another type of glyco-modification involves 
phosphorylation of mannose residue which directs the glycoprotein to specific 
locations such as the late endosome and lysosomal compartments. A third pathway 
involves the exit of glycosylated protein into the Golgi apparatus where both glucose 
and mannose residues are removed by Golgi endo-mannosidase. These various 
pathways that a glycoprotein may take can be determined by treating with specific 
glycosidases and glycosylation pathway inhibitors. Phospho-mannosylated 
glycoproteins are deglucosylated by EndoH treatment but not PNGaseF treatment 
(Sahagian et al.,  1981; Sahagian et al.,  1982; Zhao et al.,  1997).  Western blot analysis 
to determine EndoH and PNGaseF susceptibility for CD9, CD151, CD63 and CD82 
revealed novel characterics for some of these tetraspanins.  CD151’s susceptibility to 
PNGaseF cleavage but not to EndoH illustrates that this tetraspanin carries a 
complex oligosaccharide residue (Figure 3.35). CD9’s response to deglycosylated 
treatment by EndoH but not by PNGaseF characterises it as a phosphomannosylated 
glycoprotein. CD63 and CD82 on the other hand, were only partially deglycosylated 
by PNGaseF, suggesting the possibility that these two tetraspanins may carry both 
complex and phosphomannosylated glycans (Figure 3.36). Phosphorylation of 
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mannose residue by GlcNAc phosphotransferase on N-linked glycans prepares the 
glycoprotein for mannose-6-phosphate receptor mediated lysosomal targeting. Both 
CD63 (Metzelaar et al., 1991) and CD82 (He et al.,  2005) have been previously been 
described to carry lysosomal targeting motif on their C-tail domain. The presence of 
mannose-6-phosphate receptor ligand on their glycan structure may further augment 
this function. The association of CD9 with MHCII on the other hand, have been 
specifically attributed to the its recruitment into exosomes and not lysosomal 
compartment during CD4+ T cell mediated dendritic cells activation (Buschow et al.,  
2009). This inconsistency may be due to the fact that only a small fraction of CD9 is 
glycosylated compared to the total CD9 expression levels (Figure3.35). Alternatively, 
it may also reflect multifunctional nature of CD9 where it associates and targets 
molecules to different compartments. 
 Glycoproteins recruited into the endomannosidase pathway can be 
distinguished by treating the cells with a plant alkaloid, castanospermine, which 
inhibits the glucosidase I and glucosidase II activity. Glycoproteins that follow the 
endo mannosidase route are unaffected by this inhibition since they can be 
effectively trimmed by endomannosidase I and they go ahead with glyco-
maturation. Western blot analysis of CD9 and emmprin showed a sudden change in 
their glycoprofile, identifying them to the conventional pathway. CD82 on the other 
hand was only mildly affected by castanospermine treatment. This indicates that 
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CD82 predominatly follows the endomannosidase I pathway. CD151 on the other 
hand showed a decrease in its level upon castanospermine treatment. It has 
previously been shown that castanospermine inhibited calnexin binding during 
protein folding which resulted in proteosomal degradation of nicotinic acetylcholine 
receptor (Keller et al.,  1998). Since the level of CD151 reduced upon castanospermine 
treatment, I hypothesised that CD151 may be subjected to a similar fate. In earlier 
chapters, I have shown that CD151 forms primary, and predominatly secondary 
association with α3β1 and α6β1/β4 integrins respectively (Figures 3.13 and 3.14). 
Consequently, I analysed the responses of these integrin to castanospermine 
inhibition. Interestingly, I found the levels of both integrins to be markedly reduced 
upon castanospermine treatment (Figure 3.38). While castanospermine may have a 
direct role in down regulating the CD151, this result may also suggest that CD151’s 
instability is due to its association α3/α6 integrins.  
 Further analysis of other integrins and integrin associated protein revealed 
only 2 1 level to be affected by castanospermine treatment. 5 1 and EGFR levels 
were not affected though their glycosylation was altered (Figure 3.40). Furthermore, 
we also found that castanospermine effect can be modulated by their dosage (Figure 
3.41). This ‘semi-specific’ effect of castanospermine on cell surface receptors as well 
as their dosage dependent activity makes them an ideal candidate for therapeutic 
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intervention, especially since these integrins have been identified as one of the major 
cell surface receptor involved in cancer and its progression. 
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4. CONSPECTUS AND FUTURE WORK 
  
 The primary focus of this study was to investigate the significance of 
CD151/α3β1 association using an in vitro model system. Several novel observations 
were made during the course of the investigation, on the role of CD151/α3β1 axis as 
well as other associated molecules such as CD9, CD63, CD81, CD82 and α6β1/β4 
integrins. These observations are summarised below:  
1) CD151 regulates glycosylation of α3β1 integrin and this alteration has 
physiological consequences (Sections 3.1 & 3.4). In the MDA-231 cell line, presence of 
CD151 increases the level of α1,2 linked fucose presented on α3β1 integrin. CD151’s 
influence on the glycosylation of α3β1 integrin seems to be a specific effect stemming 
from very early glycosylation events within the ER. Whereas CD9, which also 
influences glycosylation of α3β1 integrin, exerts its influence at the later stages of the 
glycosylation pathway (Section 3.3).  
2) CD151’s influence on the glycosylation of α3β1 integrin is only realised by 
maintaining several diverse but interdependent characteristics, namely, 
glycosylation, palmitoylation and tight association with the integrin. CD9, on the 
other hand, is able to influence glycosylation of the integrin through secondary 
association. Furthermore, a difference in the glyco-profile of CD9 or CD81 associated 
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α3β1 integrin indicates the presence of CD151/α3β1 in different type of TERMs 
(Sections 3.1 and 3.2). 
3) CD151 appears to preferentially form tight association with α3β1 over α6β1/β4 
integrins in MDA-231 cells. This observation may explain why CD151 did not alter 
the glycosylation profile of α6β1/β4 integrins, as tight association is one of the 
required criteria for glyco-modification of α3β1 integrin (Section 3.1).  
4) CD151 recruited α3β1 integrin into the light fractions of Brij 96 SDG as part of a 
TERM, as well as a separate entity, highlighting the presence of multiple types of 
CD151/α3β1 associated microdomains (Section 3.2). 
5) CD151 and CD9 were observed to have opposing effects on their ability to induce 
α6 integrin subunit cleavage, which results in α6p variant production (Section 3.1). 
6)  Analysis of glycans on various tetraspanins revealed the glycosylated CD9 to be 
phospho-mannosylated. Based on their resistance to PNGaseF cleavage and their 
localisation to late endosome and lysosomal compartments, CD63 and CD82 may 
also be phospho-mannosylated (Section 3.5). 
7)  Inhibition of glucosidase I/II by castanospermine treatment reduced the levels of 
CD151 as well as α3β1, α6β1/β4 and α2β1 integrins making this compound a 
possible candidate for clinical therapy (Section 3.5).       
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 These observations suggest a fundamental role played by CD151 in cellular 
function which will certainly have some implication in vivo. Most of CD151’s 
influence on α3β1 integrin seems have its roots in the early stages of it biosynthesis 
within the ER. Firstly, even before the association occurs, a selective pressure ensures 
that CD151 preferentially associates with α3β1 and not the α6β1/β4 integrins in 
MDA-231 cell line. This begs the question, what facilitates the facilitators? Are there 
other components within the ER that determine this preferential association? Does 
the tertiary folded structure of the integrin molecule determine this event? Does the 
association with OST complex result in an enrichment of a structurally favourable 
environment which selects for CD151-α3β1 association over α6β1/β4? Or is it simply 
due to abundance of the α3 subunit within the ER in our model system?  
 Interestingly, preferential association between αIIbβ3 integrin and the non-
glycosylated fraction of CD151 has been reported in human platelets when 
immunoprecipitation of the integrin was performed under Triton X-100 condition 
(Lau et al.,  2004). The significance of these selective associations has yet to be 
properly addressed. However, in this study, I found that glycosylation of CD151 is 
pivotal for the molecule to influence the glycosylation of α3β1 integrin (Section 3.2). 
CD151 (GLY) mutant MDA-231 cells showed similar glycosylation profile for α3β1 
integrin as CD151 depleted cells. In this study, I also found that depletion of CD151 
effected how tumour cells interact with HUVEC (Section 3.4). It would have been 
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interesting to determine the role played by α3β1 and α6β1/β4 integrin as well as the 
glycosylation of α3β1 during the tumour cells interaction with HUVEC. This could 
have been achieved by testing the integrin knock down and CD151 reconstituted cell 
lines under the same settings. Unfortunately, this study was terminated at this 
juncture. However, by drawing parallels between the two studies, the preferential 
association between non-glycosylated CD151 and αIIbβ3 may imply that a specific 
glycoform of αIIbβ3 is being generated to dictate which molecules/cells it can interact 
with in vivo. However, this model relies on the whether CD151 or glycosylation of 
CD151 has a role in glycosylation of αIIbβ3 integrin which we did not establish in 
this study. While the significance of this selective pairing between CD151 and 
various laminin binding integrins in vivo is still unknown, Sonnenberg’s group (Sterk 
et al, 2002) reported that Ts151r reactive epitope of CD151 (which requires the QRD 
epitope / unligated CD151 molecule for recognition) was increased in the glomeruli 
of HIV positive patients. Based on their observation, the authors suggested a 
pathophysiological relevance to the expression of paired and unpaired CD151 
molecules. This hypothesis is currently being explored in various cancers.  
 The Brij 96 SDG assay showed that both the QRD mutant of CD151 (which is 
capable of forming TERM) and the palmitoylation deficient of CD151 (which is not 
capable of doing so), are able to recruit α3β1 integrin into the light fractions. 
However, even though both CD151 (QRD) and CD151 (PLM) are capable of 
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recruiting α3β1 integrin and α6β1/β4 integrins (supplementary data) into the light 
fractions of the Brij96 SDG, various studies have shown that they respond differently 
to TGFβ1 stimulation (Sadej et al.,  2010) and in adhesion and migration assays 
(Zevian et al., 2011). This is probably due to the difference in their lateral interaction 
formation whereby each CD151 mutant may be recruiting overlapping as well as 
unique sets of cytoskeletal and signalling molecules. Consequently, different 
signalling pathways will be activated upon stimulation resulting in diverse cellular 
responses. For example, MDA-231 cell lines expressing CD151 (QRD) and CD151 
(PLM) respond differently to TGFβ1 stimulation despite the fact that both mutants 
retain their ability to recruit α3β1 and α6β1/β4 integrins to light fractions (Sadej et al., 
2010). This result may also indicate that only a certain population of CD151 in the cell 
(in this case, the population belonging to the fraction that forms tight association 
with CD151) is involved in the TGFβ1 response.  Similarly, the CD151 QRD mutant 
of HB2 was unable to emulate the organised acini-like structures of the wild type 
HB2 cells when grown in matrigel; indicating TERM containing tightly associated 
CD151 and α3β1 integrin is a prerequisite for this role. Depletion of α3β1 integrin 
resulted in severe growth retardation; while α6β1/β4 depleted cells displayed a 
similar phenotype to wild type HB2 (Novitskaya et al., 2010). It will be interesting to 
know if α3β1 preferentially associates with CD151 over α6β1/β4 in this cell line as 
well. 
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 In contrast, migration and adhesion of the A431 cell on Lm332 was reduced in 
CD151 silenced and CD151 palmitoylation deficient cell lines, but not in QRD mutant 
CD151 (Zevian et al., 2011). The authors also reported that while α3β1 is required for 
initial attachment, α6β4 integrin is important for subsequent stable attachment and 
this process does not require palmitoylation of CD151. Interestingly, my result shows 
that despite not forming tight association with CD151, α6 integrins are recruited into 
the light fractions of Brij 96 SDG by CD151 (PLM). This result may as well indicate a 
completely different relationship between CD151 and α6 integrins compared to α3β1 
integrin. It will be interesting to discover the factors attributing to CD151’s 
association with the α6 integrins.   
 While the exact nature and composition of the CD151-associated 
microdomains was not addressed in this study, data generated during this study as 
well as other published work seem to indicate the presence of heterogeneous CD151 
containing microdomains. During the course of my study, it became clear that CD151 
recruits α3β1 integrin into the light fractions as part of the TERM as well as a 
‘separate entity’. The exact nature of the ‘separate entity’ remains to be established. It 
is tempting to speculate that this entity is a lipid raft component. Lipid rafts (LR) are 
a dynamic liquid-ordered phase of plasma membrane consisting of tightly packed 
saturated phospholipids, enriched in cholesterol and sphingolipid. Consequently, 
they are resistant to disruption by Triton X-100 at 40C, but are disrupted following 
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cholesterol depletion. LR components include GPI anchored proteins attached to the 
outer leaflet, signalling molecules (i.e. Src and Ras) attached to the inner leaflet as 
well as transmembrane proteins (Simons and van, 1988; Brown and London, 2000; 
London and Brown, 2000).  
 In agreement with previous reports, I found that CD151 was incapable of 
recruiting α3β1 into the light fractions when SDG was performed under Triton X-100 
conditions. This should effectively eliminate lipid raft’s involvement in this process. 
However, the existence of more than one type of cholesterol rich domains has been 
suggested previously (Claas et al., 2001) and this view was augmented by the 
observation that CD9-CD81 interaction was disrupted upon cholesterol depletion 
with saponin, but not with methyl-β-cyclodextrin (MβCD) treatment (Charrin et al.,  
2003c). Furthermore, Brij97 SDG performed at 40C and 370C showed that in the 
presence of CD151, α3β1 accumulated in the light fractions while cholesterol 
depletion with MβCD redistributed α3β1 into the high density fraction (Charrin et 
al., 2003b). Whether cholesterol depletion specifically affects cholesterol enriched 
microdomains or the general stability of plasma membrane is unclear. While 
recruitment of α3β1 integrin into the light fractions at 370C may suggest a non-LR 
component, this result may also indicate the presence of two distinct types of 
microdomains. In this study, Western blot comparison of CD9- and CD81- associated 
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pools of α3β1 integrin showed a difference in their glycosylation profiles possibly 
indicating distinct microdomains.  
 Heterogeneity of LRs and their components, and the need to address LRs in a 
wider rather than its traditional definition has been proposed in order for it to have a 
functional relevance (Pike, 2004). To this end, various models describing 
transmembrane proteins that tether at the periphery of LR and form protein-protein 
interaction with LR components have been presented. The possible existence of such 
interactions may explain how α3β1/CD151 complexes might coalesce with LR to 
form distinctive domains which buoy into the light fractions of Brij 96 SDG, but are 
lost under Triton X-100 conditions. Glycosylation which predominantly occurs in the 
ER, and Golgi apparatus precedes cholesterol enrichment and LR formation which 
occurs in the trans Golgi network (TGN) (Klemm et al.,  2009). It will be interesting to 
determine if the clustering that occurs in the earlier stages of ER-Golgi transit 
contributes to the heterogeneity of LRs. 
 The role of tetraspanins in modulating the post-translational modification of 
their integrin partners is perhaps not surprising considering their capacity to recruit 
various components into their microdomain. As shown in this study, ‘facilitation’ 
starts at a very early stage in the ER. In the presence of CD151, the CD151/α3β1 
complex seems to prefer an early exit from ER into the Golgi while in the absence of 
CD151, the integrin is trimmed within the ER prior to exit. From an evolutionary 
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point of view, N-linked glycosylation in yeast, which involves a simple mannose 
trimming step by MnsI prior to exit from ER, is replaced in the higher organism by a 
more complex system involving multiple α-mannosidases localised in the ER and the 
Golgi apparatus (Jelinek-Kelly and Herscovics, 1988; Puccia et al.,  1993; Weng and 
Spiro, 1993b; Weng and Spiro, 1996). Parallel to this event, emergence of integrins 
and tetraspanins in metazoans may reflect how the higher organisms adapted to 
fully benefit from this evolutionary explosion. For example, the presence of CD151 
seems to facilitate the early exit of the α3β1 integrin from the ER. While in yeast, the 
untrimmed Man9NAc2 high mannose precursor exiting ER is more susceptible to 
degradation compared to a Man8NAc2 structure (Jakob et al.,  1998a), in higher 
organisms, evolutionary adaptation seems to not only rescue these molecules, but 
also confers them with functionally relevant glycan diversity. Additionally, the 
selective association between αIIbβ3 and non-glycosylated CD151 populations may 
also suggest an evolutionary adaptation.  
 Why is the glyco-modification important? In a multicellular organism, cell fate 
is determined from its response to stimulation from extracellular matrix (ECM) and 
ECM associated growth factors. This includes maintenance of stem cell niches, tissue 
patterning and differentiation during development, immunological and 
inflammatory response as well as cancer and other diseases. The ECM proteins are 
large and complex molecules consisting of multiple and distinct conserved domains 
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capable of simultaneous interaction with various cell surface receptors and soluble 
molecules. The fate or response of a cell to its environment is determined by the sum 
effect of the ECM-receptor interaction. R.O. Hynes beautifully compared the effect of 
this multifaceted interaction to music played as ‘chords’ and ‘melodies’, rather than 
‘single notes’ (Hynes, 2009). One such family of receptors which interacts with the 
ECM is the ubiquitous integrin family. Glyco-modification on both the ECM and 
integrins have been suggested to be involved in exposing cryptic binding sites 
simultaneously changing the affinity of their interaction (Bellis, 2004). 
 Inhibition of glucosidase I/II (GI/GII) with castanospermine (CST) reduced the 
expression level of CD151 as well as the levels of α2β1, α3β1 and α6β1/β4 integrins. 
While the glycosylation of tetraspanins CD9, CD63, CD82 and α5β1 integrin was 
altered upon CST treatment, their levels remained relatively unchanged. Presence of 
GI/GII inhibitors has previously been shown to prevent lectin-glycoprotein 
interaction, in some cases resulting in proteosomal degradation of the affected 
glycoprotein (Peterson et al.,  1995; Keller et al., 1998). A possible explanation for the 
differences in molecular response to castanospermine treatment may be due to the 
type and strength of the interaction that exist between the glycoprotein and 
CNX/CRT. It has previously been shown that the ER lectins are capable of associating 
with both oligosaccharide and polypeptide segments of nascent proteins (Danilczyk 
and Williams, 2001). This variation in lectin interaction may explain the differences in 
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CST’s effect on various tetraspanins and integrins. However, the difference in the fate 
of the affected glycoproteins upon CST treatment remains to be determined. 
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5. APPENDICES 
 
Appendix 1 - Flow cytometry analysis of MDA-231 cells 
 
mAb epitope 
MDA-231 
151(+) 50% 
CONFLUENCE 
MDA-231 
151(+) 90% 
CONFLUENCE 
MDA-231 
151(-) 50% 
CONFLUENCE 
MDA-231 
151(-) 90% 
CONFLUENCE 
VIIC6 α 3 subunit 55.3 54.8 52.6 51.9 
IVA5 α 2 subunit 35.1 32.7 42.1 41.8 
A6 ELE α 6 subunit 7.52 7.7 9.64 9.57 
TS 2/16 β 1 subunit 79.2 75.4 81.2 89.2 
C9BB CD9 14.2 15.6 13.8 14.4 
6H1 CD63 7.2 7.2 7.5 7.63 
M38 CD81 22.9 23.1 21 20 
M104 CD82 7.86 8.51 6.69 7.01 
5C11 CD151 22.2 21.9 0.698 0.698 
 
MDA-231 cells were plated at 50% and 90% confluence and analysed for cell surface 
expression of various membrane proteins by flow cytometry analysis. (The values 
represent mean fluorescence intensity).  
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Appendix - 2 Flow cytometry analysis of lectin binding property  
(Values represent mean fluorescent intensity) 
EXPERIMENT 1 
      
LECTIN   PARENTAL CD151(-) CD9(-) CD63(-) CD81(-) 
Aleuria aurantia Lectin  AAL 40.6 36.1 36.5 49.8 46.8 
Concanavalin A  CON-A 14.9 12 13.6 13.8 10.4 
Dolichos biflorus agglutinin  DBA 0.394 0.348 0.494 0.338 0.305 
Peanut Agglutinin  PNA 6.15 5.66 5.75 16 5.28 
Phaseolus vulgaris Erythroagglutinin  PHA-E 87.5 82.7 76.1 89.9 90.8 
Phaseolus vulgaris Leucoagglutinin  PHA-L 90.7 88.6 66.5 99.7 92.3 
Ricinus communis agglutinin  RCA 127.6 125.1 124.4 171.8 132.7 
Sambucus nigra agglutinin  SNA 0.799 0.798 1.72 1.5 1.55 
Soybean Agglutinin  SBA 2.41 1.43 1.71 3.8 2.41 
Ulex europaeus Agglutinin  UEA 3.65 1.85 2.63 7.46 8.94 
Wheat Germ Agglutinin  WGA 372 367.5 371.5 419.4 334 
       EXPERIMENT 2 
      LECTIN   PARENTAL CD151(-) CD9(-) CD63(-) CD81(-) 
Aleuria aurantia Lectin  AAL 40.2 37.6 43.3 60.2 50.1 
Concanavalin A  CON-A 17 13.8 17.9 17.9 14.9 
Dolichos biflorus agglutinin  DBA 0.447 0.491 0.637 0.682 0.549 
Peanut Agglutinin  PNA 9.28 8.22 7.38 20.4 8.34 
Phaseolus vulgaris Erythroagglutinin  PHA-E 108.8 110.2 115.3 142.8 116.2 
Phaseolus vulgaris Leucoagglutinin  PHA-L 96.4 114.4 101.2 149 112.5 
Ricinus communis agglutinin  RCA 120.6 107.2 127.3 190.2 107.6 
Sambucus nigra agglutinin  SNA 1.73 1.7 3.63 2.85 2.04 
Soybean Agglutinin  SBA 3.8 2.12 3.56 5.96 2.87 
Ulex europaeus Agglutinin  UEA 5.5 2.63 4.37 14.1 10.6 
Wheat Germ Agglutinin  WGA 207.5 230 244.3 359.9 244.2 
    
 
  
   EXPERIMENT 3   
     LECTIN   PARENTAL CD151(-) CD9(-) CD63(-) CD81(-) 
Aleuria aurantia Lectin  AAL 76.5 71.8 69.6 95.6 78.5 
Concanavalin A  CON-A 40 37.2 42.6 42.6 35.5 
Dolichos biflorus agglutinin  DBA 1.93 2.24 2.6 2.09 0.922 
Peanut Agglutinin  PNA 23.8 19.6 16.8 33.6 13.7 
Phaseolus vulgaris Erythroagglutinin  PHA-E 333.7 310.1 265.1 318.1 250.7 
Phaseolus vulgaris Leucoagglutinin  PHA-L 195.5 185.9 134.8 188.9 145.7 
Ricinus communis agglutinin  RCA 327.6 241.3 294.3 400.9 242 
Sambucus nigra agglutinin  SNA 6.07 5.43 11 7.03 5.67 
Soybean Agglutinin  SBA 7.43 4.13 5.25 10.2 4.32 
Ulex europaeus Agglutinin  UEA 10.4 4.67 6.38 14.2 14.5 
Wheat Germ Agglutinin  WGA 611 554.7 551.2 621.9 476.9 
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Appendix 3 - Migration assay of MDA-231 cells towards Lm332 after antibody 
blocking 
 
 
EXPERIMENT 1 
    ANTIBODY INSERT NUMBER OF MIGRATED CELLS PER FIELD 
PKC 1 206 144 165 209 
  2 97 132 181 122 
X8 1 71 59 60 59 
  2 83 68 83 73 
GOH3 1 124 108 72 89 
  2 199 78 170 101 
IVA5 1 26 23 21 29 
  2 24 22 19 20 
IVA5+GOH3 1 4 4 3 3 
  2 4 1 2 1 
      EXPERIMENT 2 
    ANTIBODY INSERT NUMBER OF MIGRATED CELLS PER FIELD 
PKC 1 155 203 146 198 
  2 230 112 131 174 
X8 1 95 140 98 100 
  2 94 84 86 73 
GOH3 1 87 108 42 55 
  2 69 68 70 92 
IVA5 1 13 12 12 4 
  2 20 29 33 6 
IVA5+GOH3 1 3 2 2 6 
  2 16 8 11 6 
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Appendix 4 - Migration of various MDA-231 derived cells towards Lm332 
EXPERIMENT 1  
    
 
 
    CELL LINE INSERT  NUMBER OF MIGRATED CELL PER FIELD 
CD151(+) 
 
1 236 343 203 210 
2 336 286 216 230 
3 393 344 348 295 
CD151(-) 
 
1 23 29 23 26 
2 26 17 13 35 
3 25 16 36 38 
CD151 recon 
 
1 114 111 77 90 
2 163 151 130 176 
3 232 134 273 151 
CD151 glyco 
 
1 25 16 15 16 
2 41 35 64 45 
3 87 68 100 92 
CD151 sh alpha3 
 
1 57 66 48 58 
2 35 44 54 38 
3 28 40 55 53 
 
 
    EXPERIMENT 2  
    
 
 
    CELL LINE  INSERT NUMBER OF MIGRATED CELL PER FIELD 
CD151(+) 
 
1 216 270 364 379 
2 265 348 283 290 
3 304 401 402 331 
CD151(-) 
 
1 46 52 46 54 
2 77 95 66 59 
3 58 21 9 30 
CD151 recon 
 
1 169 196 52 54 
2 61 58 65 60 
3 73 54 62 58 
CD151 glyco 
 
1 99 151 63 57 
2 88 124 101 190 
3 99 67 148 86 
CD151 sh alpha3 
 
1 70 72 53 75 
2 32 40 26 57 
3 37 37 33 48 
 
 
227 
 
 
Appendix 5 - Migration assay of MDA-231 CD151(+) and CD151 (-) cells towards 
fibronectin 
 
 
 
 
Data presented represents number of migrated cells per field averaged from 7 fields 
per insert. 
  
AVERAGE NUMBER OF MIGRATED CELL PER FIELD PER 
INSERT 
CELL 
LINE EXP  INSERT 1 INSERT 2 INSERT 3 INSERT 4 
CD151 (+) 1 166 179 166 157 
  2 197 181.5 163.5 133.5 
CD151 (-) 1 140.5 101.5 86 122 
  2 162 155.5 197 197 
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Appendix 6 - Adhesion assay of MDA-231 CD151(+) and CD151(-) cells on Lm332 
and fibronectin 
 
 
Data presented represents percentage of cells that remained attached to the matrices 
after washing during a 30 min adhesion assay. 
EXPERIMENT 1 
    
 
Percentage of adhereing cells after 30min at 37oC 
  Laminin 332 Fibronectin BSA 
  1µg/ml 2µg/ml 10µg/ml 10mg/ml 
MDA 151+ 52 65 63 4 
MDA151- 46 71 60 5 
     EXPERIMENT 2 
    
 
Percentage of adhereing cells after 30min at 37oC 
  Laminin 332 Fibronectin BSA 
  1µg/ml 2µg/ml 10µg/ml 10mg/ml 
MDA 151+ 66 74 70 8 
MDA151- 59 69 78 9 
     EXPERIMENT 3 
    
 
Percentage of adhereing cells after 30min at 37oC 
  Laminin 332 Fibronectin BSA 
  1µg/ml 2µg/ml 10µg/ml 10mg/ml 
MDA 151+ 59 69.5 66.5 6 
MDA151- 52.5 70 69 7 
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Appendix 7 - Endothelial attachment assay 
Data represents percentage of MDA-231 CD151(+) / (-) cells that remained attached to 
TNF stimulated HUVEC after 1 minute. The experiment was performed in 
duplicate (2 µ slides each) using HUVECs purified from 4 different cords. No 
attachment was observed for this time point when non stimulated HUVEC was used.  
 
 
 
µ slide 1 
    
 
CORD 1 CORD 2 CORD 3 CORD 4 
MDA 151+ 78 10 76 34 
MDA 151 - 13 54 8 30 
     
     
     µ slide 2 
    µ slide2 CORD 1 CORD 2 CORD 3 CORD 4 
MDA 151+ 70 9 92 28 
MDA 151 - 9 48 8 25 
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Appendix 8 - Transendothelial migration assay of MDA-231 CD151 (+)/(-) cells 
across a monolayer of HBMEC at various time points 
 
 
4hrs Migration Number of migrated cells per field 
INSERT 1 2 3 
MDA 151(+) 48 55 51 60 55 49 55 61 60 
MDA 151(-) 54 49 59 52 49 45 51 53 50 
          
          6hrs Migration Number of migrated cells per field 
INSERT 1 2 3 
MDA 151(+) 160 153 148 170 155 173 190 132 164 
MDA 151(-) 176 149 151 148 180 165 149 150 141 
          
          8hrs Migration Number of migrated cells per field 
INSERT 1 2 3 
MDA 151(+) 201 190 182 222 186 179 194 194 186 
MDA 151(-) 197 184 207 188 169 188 181 199 201 
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6. SUPPLEMENTARY DATA 
Western blot analysis of sucrose density gradient fraction of MDA-231 (PLM)- and 
(QRD)- cell lines  performed under 1% Brij 96 conditions, detected for CD151, α3 
integrin light chain fragment and α6 integrin light chain fragment. 
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